Ryman Healthcare Limited logo

Ryman Healthcare Limited – Annual Report 2022

Annual Report16 June 2022RYMHealthcare

Ryman Healthcare
ANNUAL REPORT 2022

RYMAN HEALTHCARE

As a vertically-integrated retirement village and
aged-care operator, our purpose-driven care model

is woven into every stage of a Ryman village. From

the construction site to welcoming residents in to

their beautiful new homes, care is what drives us

every step of the way.

ANNUAL REPORT 2022

About this report
This is our fifth annual report prepared according to the guiding principles of the

International Integrated Reporting <IR> Framework. The <IR> Framework encourages

businesses to report against issues most material to their stakeholders, as well as

providing insight into how their business creates value and how this value contributes

to sustainable returns for stakeholders over the long term.

Pictured on the front cover is Joyce, a 92-year-old resident at our Logan Campbell Village

in Auckland. Joyce is well known in the village for enjoying daily walks around the beautiful

gardens, often seeking out the support of Caregiver Ramon Martir.

On the inside front cover are Fit-out Site Manager Jason Q Zhao and Site Administrator

Matakeu Timms at our Miriam Corban Village in Auckland. Once complete, the village

will provide residents with exceptional independent and serviced apartment living, plus

resthome, hospital and specialist dementia care.

2

RYMAN HEALTHCARE

04
85

151

182

190

Building for the future

04 At a glance

06 Chair and Group Chief Executive report

16 Our story

19 Who we are and how we create value

27 Listening and responding to our stakeholders

31 Providing sustainable returns to our shareholders

39 An unwavering commitment to care

47 Raising the bar on our resident experience

55 Building a solid platform to grow

65 Caring for our environment

75 Investing in our people

Our financials

87 6-year summary

90 Consolidated financial statements

95 Notes to the consolidated financial statements

146 Independent auditor’s report

Corporate governance

152 Our directors

154 Our senior executives

156 Statement of corporate governance

Thank you to our team of Rymanians

Village locations and directory

ANNUAL REPORT 2022

3

45 operational
villages

16

sites under construction

$783.0m

invested in new villages

6,700+

team members

96.0%

care occupancy

$1.40bn

cash receipts from

residents

1.4%

of total units available

for resale

43.0%

debt to debt-plus-equity

gearing

4,239

care beds

8,538

retirement village units

22.4c

dividend per share

interim 8.8c

final 13.6c

13,200+

residents

$255.0m

underlying profit*

reported

profit

$692.9m

63.8%

13.6%

18.7%

$10.97bn

total assets

19.6%

At a glance

* Refer to page 87 for a definition of underlying profit.

RYMAN HEALTHCARE

4

961
unit refurbishments

completed

$455.9m

new sales

Commenced construction

on 4 new sites

$500,000+

donated to charitable

partnerships

4 new sites

added to the land bank

$623.9m

resales

$1.87bn

resale bank of

future earnings

3

new villages opened

$1.42bn

work in progress

8.99 million care

hours provided

8x voted

Reader’s Digest

Most Trusted Brand

ANNUAL REPORT 2022

5

Chair and
Group Chief Executive report

Image: Greg and Richard inside a new apartment at our Kevin Hickman Village in Christchurch.

RYMAN HEALTHCARE

6

Our success as a
business is what

enables us to take our

exceptional Ryman

model to more and

more people, and

that’s a good thing.”

Richard Umbers, Group Chief Executive


7

ANNUAL REPORT 2022

We are pleased to report a strong result delivered during this period
of considerable disruption. The resilience, commitment and

professionalism of our Ryman team played a key role in helping us

adapt quickly and respond decisively to the changing circumstances.

Quite simply, their efforts have been magnificent.

Our vertically-integrated business model proved particularly

advantageous in maintaining the momentum of the business, allowing

us to reallocate resources to the areas of most need. As a result,

we have been able to keep our residents and team safe as well as

build for the future, acquiring land, constructing new villages, selling

completed and refurbished units and setting new benchmarks in

clinical care.

These outcomes have served to enhance our reputation in the market

and cement our position as a market leader in the retirement sector.

We remain committed to maintaining our leadership position, as well

as generating increased returns to our shareholders and positioning

Ryman for further growth in the years ahead.

Providing care that in the words of our co-founder has got to be

“good enough for Mum or Dad” is key to us achieving this. This ethos

captures something truly unique in the spirit of Ryman and is what

motivates our people every day.

Our low resale stock, combined with mature care occupancy of

96 percent, demonstrates that our villages continue to be in

strong demand.

In a year when we faced increased operating costs and could not

trade or build for a significant amount of time, we are pleased with

what the team has achieved.

Kia ora koutou

As a business that cares

for older people, the last

2 years have certainly

presented us with

challenges, testing all

aspects of our operation

as never before.

RYMAN HEALTHCARE

8

A strong result in a tough year
Strong demand for our continuum of care model,

which delivers both peace of mind and security,

helped to underpin our strong result this year.

The 63.8 percent increase in our reported

IFRS profit to $692.9 million was also driven by

movements in the wider property market and

the payback on our investment in higher-value

locations over recent years.

Underlying profit for the year rose 13.6 percent

to $255.0 million. This included $20.9 million

of COVID-incurred costs related to resident

welfare, staffing, security and personal

protective equipment.

The full-year dividend of 22.4 cents per share

was in line with the prior year and reflects a

payout ratio of 43.9 percent. This is within the

new flexible dividend policy range adopted by

the board of 30 to 50 percent of underlying profit.

Total booked sales rose 8.1 percent to a

record 1,543 units for the year and was a great

achievement given the restrictions in our two

biggest markets, Victoria and Auckland, during

2021 followed by the arrival of Omicron later

that year.

In Victoria, the sales uptick in the wake of the

Omicron peak has been strong. The number of

transacted sales in the last quarter of our financial

year were double what we achieved in the first half.

This is an outstanding turnaround off the back

of a pandemic and further highlights the strong

demand for what we do.

Across New Zealand and Australia, this saw us

end the year with only 120 units or 1.4 percent of

our retirement village portfolio available for resale.

Strengthening the resilience of our

balance sheet

We have continued to diversify our debt and have

executed four separate debt capital market

transactions since December 2020. This has

resulted in $1.13 billion of diversification across

three

geographies, including the NZ$290.0 million

United States Private Placement (USPP), which

closed in April 2022.

We ended the year with total facilities of $3.36 billion

and $737.0 million of headroom. This positions

us well to continue to invest wisely in the

business to meet the demands of our rapidly

ageing population.

Over the year, our debt to debt-plus-equity gearing

has improved to 43 percent reflecting the benefit

of our investment in higher-value villages. The

benefit of this is also evident in the value of our

new sales, the resale bank we have accumulated

and the strong lift in our cash receipts and total

assets during the year.

The value of our new sales lifted 15.4 percent

to $455.9 million. The embedded value of our

portfolio, which includes the resale bank of

$1.87 billion, accrued management fees and

resident loans, is now $2.45 billion. The realisation

of this embedded value, and potential after-tax

earnings, over the next 6 to7 years will support

our growth aspirations as the baby-boomer

generation start entering our villages.

Despite the challenging conditions, cash receipts

from residents rose 18.7 percent to $1.40 billion for

the year. Total assets lifted to $10.97 billion, and

we invested $783.0 million in the portfolio.


We’ve kept our residents and teams safe as well as

building for the future.”

Greg Campbell, Chair

ANNUAL REPORT 2022

9

An unwavering commitment to care
A highlight of the year was the recognition we received for our

COVID response. In Victoria, we were recognised for the many

ways we used innovation and industry-leading initiatives to

encourage COVID-safe practices. Our team was also named

Team of the Year at the 2021 Excellence in Age Services Awards.

Our overall COVID response has been a marathon effort, and

we are incredibly proud of the extraordinary dedication

demonstrated by the Ryman team. A particular highlight was

our vaccination programme, which reached over 13,000 residents

and 6,700 team members throughout the course of the year.

Our commitment to providing exceptional care never wavered.

This was evident in the results of our certification audits where the

number of New Zealand villages to achieve 4-year certification

(the 'gold standard' in care) increased to 91 percent. In Australia,

our villages continue to achieve excellent results and meet the

Aged Care Quality Standards.

We will continue to advocate strongly for improved residential

care resourcing for the sector. However, our emphasis remains on

business improvement and innovation to strengthen care earnings

and ensure the ongoing quality of our care offering. Looking

forward, we expect the rapidly developing critical shortage of care

beds to drive decision making about retirement options. In that

context, Ryman’s investment in our continuum of care means future

residents can choose our villages with confidence.

Demand for our continuum of care model continues to increase,

and we remain focused on exceeding the ever-changing expectations

of our residents.

of our New Zealand villages

have 4-year certification,

the ‘gold standard’ in care

91%

RYMAN HEALTHCARE

10

Enhancing our resident experience
year on year

As a care business, we are steadfast in enhancing

our resident experience. It’s one of the reasons

why we have been named Reader’s Digest

Most Trusted Brand in the aged care and retirement

village sector in New Zealand for the eighth time.

During lockdowns, we adapted our activity and

entertainment line-up into a digital format,

ensuring

that our residents could remain connected

. We

created a speaker series featuring various

celebrities as well as wellness workshops on

sleep, meditation, exercise and movement to

name just a few.

We’re constantly trialling new events and

activities, the highlight this year being our

Olympics@RYMAN tournament. The use of

advanced technology enabled residents at all

of our villages in New Zealand and Australia to

compete against one another for prized gold

medals. The tournament created the perfect

opportunity for connection, camaraderie and fun.

It also encouraged residents to venture out again

after numerous lockdowns and to incorporate

physical activity back into their daily routines.

In the face of challenges, we kept

momentum going

Our growth opportunity is driven by a rapidly

ageing population. Although COVID halted or

slowed construction across several of our villages

for periods of time during the year, we were still

able to welcome residents into their new homes

at three new villages – Raelene Boyle in Melbourne,

Kevin Hickman in Christchurch and Keith Park

in Auckland.

We also commenced construction on four new

villages – Highett and Ringwood East in Melbourne,

Takapuna in Auckland, and Northwood in

Christchurch. These villages will be home to more

than 1,000 residents when completed.

Within our growth plan, we have included a

stronger focus on building more energy-efficient

homes and reducing the embodied carbon in our

villages. We are already seeing this focus come to

life at our Kevin Hickman Village in Christchurch.

Here, we are replacing some structural elements

previously made from steel and concrete with

cross-laminated timber. In doing so, we will be able

to significantly reduce the embodied carbon of

the structure.

ANNUAL REPORT 2022

11

Making great strides in our high-value expansion plans
Our focus on acquiring and developing sites for new communities

in

premium locations has made great strides this year with the

purchase

of four new sites. The sites at Rolleston in Canterbury and

Mulgrave and Kealba in Melbourne are well suited to townhouse-style

developments. The fourth site in Coburg North, Melbourne, will be

an apartment-style village.

We also purchased additional land adjacent to our fast-selling

Deborah Cheetham Village in Ocean Grove as well as a small

retirement village next to our Essendon site in Melbourne.

The value creation that will come from what we are currently building

and what we are primed to build with our land bank is significant.


Our persistent

drive for

improvement

would not be

possible without

the commitment

and dedication

of our teams.”

We’re well prepared for the challenges to come

The supply-chain constraints, material availability and construction

cost inflation challenges facing the construction sector over the

last 12 months are likely to linger for some time after the clinical

emergency of COVID has abated.

We have been very focused on how we face in to these challenges.

We enjoy strong partnerships with our supplier base, many of

whom have grown alongside us over the years. As one of the largest

builders in our sector, we have strong purchasing power, and our

ability to purchase cross-Tasman helps to offset shortages or

delays in either market.

Richard Umbers,

Group Chief Executive

RYMAN HEALTHCARE

12

Our people: our inspiration, our most
precious resource

We continue to invest in growing and developing

our team of committed Rymanians who safeguard

our culture of kindness and excellence but also

deliver strong commercial outcomes.

Our persistent drive for improvement would

not be possible without the commitment and

dedication of our teams. It’s our people who are

the inspiration and driving force behind every

improvement we make.

That’s why investing in the training and

development of our people is paramount. We will

continue to make Ryman a fulfilling place to work,

recognising talent that can be further developed

and encouraging our people to grow their careers

with us.

Leadership that will inspire generations

of Rymanians

In May 2022, Dr David Kerr let us know that he

was stepping down as a director of Ryman. David

has served on Ryman’s board since 1994 and held

the position of chair from 1999 until January 2022.

He participated in Ryman’s listing on the NZX

in 1999 and has been instrumental in Ryman’s

subsequent growth.

David’s legacy as chair is defined by his unwavering

dedication to care, clinical excellence and

outstanding commercial leadership through many

years of extraordinary growth. David has also

formed deep connections with many residents

and has been a sounding board for leaders

across Ryman.

This includes former Group Chief Executive

Gordon MacLeod who we farewelled in October 2021

after 15 years of dedicated service to Ryman.

David’s wisdom will not be lost entirely. We are

delighted that he has agreed to take up a role as

an advisor to our Clinical Governance Committee.

On behalf of everyone, we offer both David and

Gordon a sincere vote of thanks for everything

they have done.

ANNUAL REPORT 2022

13

A strong focus on the future
Our vertically-integrated model and continuum of care offering have

proven to be robust through the global pandemic and will underpin

our success as we continue to face in to the challenges ahead.

We are committed to achieving our corporate ambition of 15 percent

per annum per share growth in underlying profit.

The work our development and construction teams undertake

ensures that we have a good blend of village styles in our land bank

and a strong pipeline of consented sites.


To our Ryman

teams, your

actions personify

what it means

to be a Rymanian,

and we extend

our sincere

thanks to each

and every one

of you.”

A heroic team performance

As chair and group chief executive, we are immensely proud of our

team’s performance over the last year, and we are excited about

Ryman’s journey ahead.

To our Ryman teams, your incredible efforts have kept residents

safe, connected, entertained, informed, cherished and loved. The

flow-on effects of these actions have been felt well beyond the

boundary of our village gates. Your actions personify what it means

to be a Rymanian, and we extend our sincere thanks to each and

every one of you.

Greg Campbell

CHAIR,

RYMAN HEALTHCARE

Richard Umbers

GROUP CHIEF EXECUTIVE,

RYMAN HEALTHCARE

Greg Campbell,

Chair

RYMAN HEALTHCARE

14

Greg Campbell joined the board as director in March 2021 and was
appointed deputy chair in July the same year. Greg’s transition into

the role as chair from January 2022 has been a smooth one, and he

feels very fortunate to be surrounded by the depth of experience

within our board and within the management team.

Greg brings a wealth of experience to the table through his many

years as chief executive and board director across a number of

leading organisations. Greg is a firm believer in striking a balance

between care and commerciality and is passionate that success in

both can be achieved simultaneously and in a sustainable way.

Richard Umbers is an internationally experienced chief executive

with a background leading large organisations in many industry

sectors. He joined us as group chief executive in October 2021

and lives in Christchurch. Richard is a strong believer in fostering a

strong sense of purpose within the team and investing in people to

drive a culture of high performance.

What Richard admires most about Ryman is the unique culture

of genuine care that exists within the business, and his strong

commercial background makes him a natural fit to lead us through

this next period of growth.

Image: Greg and Richard at the construction site at our Kevin Hickman Village

in Christchurch.

ANNUAL REPORT 2022

15

Our story
Bringing their purpose-driven business to life

They soon found a block of 14 two-bedroom flats, which they would

convert into their first resthome.

They renamed the resthome Riverside, the cash flow started to

come in and they were soon in the market for a second property.

With that, Ryman – formed from combining Ryder and Hickman

– was born.

The pair were on the look-out for a business opportunity.

“The perfect business,” Kevin says, “had to combine residential

property – because it’s a good long-term investment and the

banks always like to lend on property – and a strong cash flow.’’

In 1983, when investigating a fire-damaged resthome, Kevin didn’t

like the standard of care he saw. With multiple people to a room and

shared toilets, preserving the dignity of residents didn’t appear to

be a priority.

That experience got Kevin thinking about what the standard should

be. “I thought, what would I want for Mum? I’d want a private room

for a start.”

Kevin had discovered the missing piece to the pair’s perfect

business opportunity – a genuine purpose anchored in care.

It would be a business that would improve the way older people lived

and how they were cared for. A business they could feel good about,

believe in completely, and one that would inspire teams who worked

there for generations to come.

Former police officer

Kevin Hickman and

accountant John Ryder

began working together

in the early 1980s.

RYMAN HEALTHCARE

16

Right from the start, purpose and commerciality shone
A motel complex became their next development. Kevin lived

on site while they rebuilt and, as he says, “we needed to squeeze

every drop of cash flow out of it while we were rebuilding”.

While those early days were challenging, they remained true to their

ambition of making retirement the best period of older people’s

lives. “For some of our residents, it was the first time they’d lived in a

new house.”

They were now witnessing the difference that their exceptional care

model was making. However, Kevin and John were also acutely

aware that they needed to be commercially successful to maintain

that standard and to bring their model to a wider audience.

They believed in reinvesting to grow the company. Profits were

reinvested to lay the foundations for future earnings so that the

value of the investment was always compounding.

The Ryman model was to buy the right site in a well-established

suburb, use working capital to build the first stage of the village,

sell that and use the capital to fund the next stage. They’d then

build a care wing, which would be operated by our team who put

into practice every day what it means to be “good enough for Mum

or Dad”.

After almost 4 decades and 45 villages in total, that model has

become the benchmark in the retirement industry.

However, as Kevin would often say, “If you think you’ve made it,

you’ve had it.” So, with each new retirement generation that

chooses to call a Ryman village home, we continue to adapt and

innovate so we can maintain our exceptional standards. At our

core, we will always remain true to our purpose, as it’s the key to our

commercial success.


I thought, what

would I want

for Mum?”

Kevin Hickman,

Co-founder Ryman Healthcare

ANNUAL REPORT 2022

17

Artist’s impression of our Kevin Hickman Village in Christchurch.
Named in honour of our Co-founder, Kevin Hickman, we welcomed

our first residents to this village during the year.

18

RYMAN HEALTHCARE

18

Who we are
and how

we create value

19

ANNUAL REPORT 2022

19

We are a vertically-integrated
retirement living and

aged-care developer, owner

and operator. We create

beautiful homes and

supportive communities

and provide exceptional

care for older people.

Who we are

Nearly 40 years ago, our founders looked at the industry and

knew instantly that it could and should be better. This became

the purpose that would drive them to create the Ryman model

that is now seen as the benchmark in retirement living and

aged care today.

Ryman has grown to become the largest retirement village

operator in New Zealand with a 15 percent share of the retirement

village and aged-care market. We own and operate 38 villages

across New Zealand and 7 in Victoria, Australia. We have a further

17 villages in the pipeline.

We continue to establish a strong presence in Victoria, Australia, and

the growth opportunities ahead for us in this market are immense.

We provide a comprehensive range of retirement living options,

including independent apartments and townhouses, assisted living

in serviced apartments as well as resthome, hospital and

dementia care.

Our focus on innovation and improving people’s wellbeing as they

grow older has helped underpin our success.

How we create value

We build high-quality retirement village communities. Once

completed, these villages not only generate ongoing returns for our

shareholders, they provide meaningful careers for our people, they

act as supportive hubs to their surrounding communities and they

provide critical healthcare infrastructure.

Ryman village communities are places where older people can

choose to live in beautiful homes with access to superb amenities,

all while enjoying the support of a community of friends, neighbours

and a team of dedicated Rymanians.

Our villages are places where residents can relax knowing that

if their needs change, we can continue to care for them. Families

know their loved ones have the comfort, security and dignity that

comes with the highest standards in clinical care.

RYMAN HEALTHCARE

20

How we create value
K

i

n

d

n

e

s

s

a

n

d

c

a

r

e

R

e

s

i

l

i

e

n

c

e

a

n

d

c

o

m

p

o

s

u

r

e

C

o

m

m

u

n

i

c

a

t

i

o

n

S

t

r

i

v

e

f

o

r

e

x

c

e

l

l

e

n

c

e

S

t

r

o

n

g

t

e

a

m

s

L

e

a

d

a

n

d

e

m

p

o

w

e

r

V

e

r

t

i

c

a

l

i

n

t

e

g

r

a

t

i

o

n

B

u

i

l

d

S

e

l

l

O

p

e

r

a

t

e

C

o

n

t

i

n

u

u

m

o

f

c

a

r

e

m

o

d

e

l

It’s got

to be good

enough for

Mum or

Dad

o

f

c

a

r

e

f

o

r

a

g

e

i

n

g

w

e

l

l

O

ff

e

r

t

h

e

b

e

s

t

c

o

n

t

i

n

u

u

m

h

i

g

h

-

v

a

l

u

e

s

i

t

e

s

E

x

p

a

n

s

i

o

n

t

a

r

g

e

t

i

n

g

D

e

l

i

v

e

r

a

n

u

n

p

a

r

a

l

l

e

l

e

d

r

e

s

i

d

e

n

t

e

x

p

e

r

i

e

n

c

e

L

e

a

d

e

r

s

h

i

p

f

o

r

s

u

s

t

a

i

n

a

b

l

e

p

e

r

f

o

r

m

a

n

c

e

Our resources

Value created

Our

people

Our

relationships

Our

expertise

Our

environment

Our

communities

Our financial

strength

Developing

our

people

Strengthening

our

relationships

Enhancing

our

expertise

Protecting

our

environment

Growing

our

communities

Building

our financial

strength

ANNUAL REPORT 2022

21

Our business model draws
on six capitals to create value.

Our people

Our expertise

Our communities

Our relationships

Our environment

Our financial strength

Our culture of providing care that has got to

be “good enough for Mum or Dad” has shaped

our business model and powers our success.

We are committed to nurturing and protecting

this culture, and that starts with developing our

own people.

We have incredibly talented people within our

team. It is these people who drive our innovation

and allow us to deliver exceptional care, an

unparalleled resident experience and strong

financial returns. That’s why investing in the

training and development of our people

is paramount.

We strive to create an environment where people

feel included and empowered. In doing so, we

see improvements to overall wellbeing, enabling

our people to continue to thrive.

Our people

Our most precious resource is our team.

Ensuring we understand, value and celebrate

what each individual contributes is very

important to us. So is their health, safety and

wellbeing. We want them to love the experience

of working at Ryman, and we want to do

everything we can to help them develop and

build long-term careers with us.

Developing our people

RYMAN HEALTHCARE

22

Our villages are unique. The way they are
designed, the way they are built, how they feel

– it’s all uniquely Ryman.

Our in-house expertise in identifying sites,

designing, consenting, building, selling and

operating world-class retirement villages has

grown tremendously over our 38 years of

operation.

It plays a critical role in our ability to build

high-quality villages that meet the needs of our

residents and the provision of industry-leading

care and the associated clinical outcomes.

We listen to our residents, their families and

our team. This improved understanding means

we can continue to support our team to deliver

exceptional care and an unparalleled resident

experience while rapidly growing the number

of Ryman villages to meet demand.

The communities we build provide our

residents

with security, companionship, social

connectedness and environments that challenge

the conventions of ageing. They are people’s

homes and are in well-established areas

where people have lived and worked and want

to retire.

Our villages help to meet the demands of a

rapidly ageing population, take pressure off the

public health system, provide employment for

local communities and become an economic

driver for local businesses.

Each village we build represents a long-term

investment in care for the communities we

operate in, and each village creates a new

economic engine to support our future growth.

Our expertise

Over the past 38 years, we have built a wealth

of knowledge in how to build, sell and operate

communities where people thrive in retirement

and receive exceptional care. The collective

wisdom and experience of our team and the

systems we have developed over this time are

huge assets that are difficult to replicate.

We are well positioned to rapidly respond to

any changes in the operating and regulatory

environment, and we use our voice to educate

and lobby on behalf of the sector.

Our communities

The communities we serve have a common

social issue – the growing demand for the

care of older people and a scarcity of supply

and skill. Each of our 45 retirement villages

provides critical healthcare infrastructure.

Our new villages are built in areas where there

is unmet need, and they quickly become an

important asset to the wider community. They

also become a social hub for the communities

they serve.

Enhancing our expertise Growing our communities

ANNUAL REPORT 2022

23

Our environment
We want to make sure all decisions are made

with sustainability in mind so that we leave

the environment in a better condition for

generations to come. We are committed to a

zero-carbon future, we are actively pursuing

ways to cut our greenhouse gas emissions

and we are driven to ensure the growth of

our villages is sustainable within the broader

local, national and global contexts in which

we operate. Our aim is to lead by example,

so we encourage all our team and the people

who supply us to think the same way.

Sustainable growth means looking after the

environmental capital we use, including reducing

our carbon footprint and minimising the impact

of our operations on the environment.

We remediate and improve carefully selected

sites so they can be developed into integrated

retirement villages.

Our villages are an efficient way of providing

high-quality homes with minimum impact on

the environment.

The villages we build become homes for thousands

of residents, freeing up homes in existing

communities for new families to move into.

The homes vacated will be close to local amenities

including bus stops, libraries and schools. They

are immediately available, reducing the need for

further urban spread.

Our relationships

We value strong relationships across all

areas of our business – between residents,

their families, our teams, our suppliers and

contractors and our local communities.

We enjoy and invest in these relationships,

many of which are long term and are a key

part of our success.

Trust is the foundation of any great relationship,

and we are deeply aware of the many people

and organisations that put their trust in us.

Residents trust us to care for them into old age.

Their families trust us to care for their loved

ones. Our team trusts us to provide them with

a meaningful, reliable and safe place to work.

Our suppliers trust us to pay on time and our

shareholders trust us to continue providing

strong commercial returns on their investment.

This is a huge responsibility and one we never

take for granted. Trust begins with getting the

basics right – treating everyone with respect

and kindness and communicating in simple and

clear language.

The trust we have developed has contributed

to our achieving market-leading brand

awareness of 92 percent in New Zealand and

our continued growth of brand awareness in

Australia. This has led to strong waitlists, low

levels of stock available for resale and the ability

to pre-sell independent units off plan.

Strengthening our relationshipsProtecting our environment

RYMAN HEALTHCARE

24

Our financial strength
The interest-free source of funds we receive

from occupancy advances and refundable

accommodation deposits is a tremendous value

creator for the business. Our long-term success

and the financial strength it has created allows

us to reinvest to create even more value as well

as generate returns for shareholders to reward

them for investing in us. Our view is always

long term.

Our financial success underpins our ability to

invest in future villages, in innovation, in lifting

the experience of our residents and in the

development of our people.

We create value by building our own operating

assets and generating cash to invest in new

villages. Since listing in 1999, we have grown our

total assets from $103.0 million to $10.97 billion.

Alongside the growth in our total assets, we have

also grown our gross occupancy advances to

$4.86 billion. The value of these advances has

doubled over the last 5 years and reflects the

development of new villages, many of which have

been built in higher-value areas and generate

significant value for the company.

These gross occupancy advances or interest-free

capital sums are a key value creator for the

business. They fund the development of new

villages, and as units resell, these occupancy

advances are repriced and the deferred

management fee that we collect increases,

creating significant value for our shareholders.


The interest-free

source of funds

we receive from

occupancy

advances and

refundable

accommodation

deposits is a

tremendous

value creator for

the business.”

Building our financial strength

David Bennett,

Group Chief Financial Officer

ANNUAL REPORT 2022

25

Our residents, many of whom are shareholders, are some of our
key stakeholders. Pictured here is Suellen, a resident in our

William Sanders Village in Auckland.

26

RYMAN HEALTHCARE

Listening and
responding to our

stakeholders

27

ANNUAL REPORT 2022

27

Our influence goes beyond our village gates into the healthcare
community, research organisations, the arts and hundreds of

community groups.

We are constantly engaging with our stakeholders. Through regular

survey activities, our dedicated resident relations team keeps

abreast of what matters to residents, what we are doing well and

where we can improve.

We connect with our teams through multiple forums, including

annual staff and contractor surveys, weekly team huddles,

one-on-one catchups and focus groups, to ensure we stay on top

of what matters most to our team members and contractors.

Our community relations managers proactively engage with

members of the local community involving them in important

conversations from the start, including village naming and blessing

ceremonies. Our dedicated investor relations and corporate affairs

teams proactively engage with other stakeholders in New Zealand,

Australia and overseas, including investors, banking partners,

regulators and government.

These interactions help strengthen our relationships and identify

what matters most to our stakeholders. We review and collate the

information received and assess its effect on our ability to create

value in the short, medium and long term.

From our discussions, we have identified and grouped the

most-material issues into four areas.

We are responsible to

thousands of stakeholders,

from our residents and

their families, our teams

and our shareholders

through to our contracting

partners, providers of

debt and suppliers in the

communities we operate in.

RYMAN HEALTHCARE

28

Materiality matrix
Significance of impact

Stakeholder importance

Sustainable design

Carbon reduction

Capital management

Resident experience

Communication

Health, safety, wellbeing

Diversity and inclusion

Care quality

Culture

Growing underlying profit

Market dynamics

Staff recruitment, development

Corporate governance, cyber security

Waste and water management

Supply chain

Sponsorship, community engagement

Care and communityPeople

Care quality and continued innovation

Communication

Resident experience, safety and wellbeing

Sponsorship and community engagement

Culture of kindness and care

Diversity and inclusion

Health, safety and wellbeing

Staff recruitment and development

EnvironmentSustainable financial performance

Carbon reduction

Supply chain and material choice

Sustainable design

Waste reduction and water management

Capital management

Corporate governance, cyber security

Growing underlying profit

Market dynamics and regulation

Material issues

ANNUAL REPORT 2022

29

Artist’s impression of our upcoming Takapuna Village in Auckland.
The location of this village is a prime example of a high-value site that

will generate strong returns.

30

RYMAN HEALTHCARE

Providing sustainable
returns to

our shareholders

31

ANNUAL REPORT 2022

If you were to design a
challenge specific to our

sector, COVID would be it.

Like the rest of the world,

we were not immune to

the challenges of the last

2 years and the headwinds

still faced by the sector.

Government restrictions introduced during peak periods of the

pandemic hampered our ability to transact and led to a reduced

workforce on construction sites. This meant our build rate was

slower, delaying our cash collection and pushing out our debt profile.

We have come through this period in a strong position. We’ve

continued to operate, we’ve protected our residents and their families,

we’ve strengthened our brand, we’ve improved our systems and

processes, and demand for our continuum of care offering is stronger

than ever.

Nellie Melba Village Personal Care Worker Joeben Roxas

enjoying a stroll with resident Bernie. Joeben moved

into the village twice during the pandemic to help reduce

the risk of transmission.

RYMAN HEALTHCARE

32

A good business adapts itself to ride the wave of the
challenges it faces.”


A strong result in challenging conditions

We reported a 13.6 percent lift in underlying

profit to $255.0 million in FY22. This growth was

slightly below our stated corporate ambition of

growing underlying profit by 15 percent per annum

per share, reflecting the challenges of COVID

including the additional $20.9 million spent on

keeping residents and staff safe through the year.

Our reported (IFRS) profit of $692.9 million

was up 63.8 percent, driven by a $467.1 million

unrealised fair value movement on investment

property. While these gains are unrealised,

they are based on the pricing we have been able

to achieve over the last 12 months, and it shows

the growth in the value of our portfolio.

Ryman’s total assets grew to nearly $11 billion

during the year driven by our build programme,

investment in higher-value sites and investment

property fair value gains.

The high value nature of our sites means we

anticipate generating $6.80 billion of capital

proceeds from the 29 sites in our land bank

when they are fully occupied and sold down.

To put that into context, our 32 fully sold villages

have currently contributed $3.60 billion of

occupancy advances and refundable

accommodation deposits.

This shows the scale of the momentum we have

been building over recent years, which is well

timed with the demographic boom on our doorstep.

Richard Umbers, Group Chief Executive

To help manage rising construction costs,

we’ve shortened the length of time in which

we commence pre-selling our new stages.

This change means we are able to match

new sale prices to the latest market demand,

improving our ability to offset construction costs.

We spent over $780.0 million building new

villages and investing in our existing portfolio.

This investment ensures our villages remain

in strong demand and we can unlock the

embedded value – currently $2.45 billion

– on our existing portfolio.

The affordability of our units is something we

monitor closely and our residents are freeing

up more capital than ever when they move into

a Ryman village. We are in a strong position to

withstand any market correction with property

prices in Auckland needing to fall 27 percent

before residents stop freeing up capital. For

residents in Melbourne, property prices would

need to fall 47 percent to have the same impact.

We ended the year with $737.0 million of funding

headroom, and combined with our strong

pipeline of consented sites, this means we are

in a strong position to meet the demands of the

rapidly ageing population.

ANNUAL REPORT 2022

33

Demand for our continuum of care model
is unprecedented

Demand for what we do is underpinned by a rapidly ageing population.

In New Zealand, the number of people aged 75 and over is projected

to increase from 365,000 today to 938,000 in 40 years' time.

In Australia, it is a similar situation. The 75 and over age group is

projected to increase from 1.9 million today to 4.4 million in

40 years’ time.

Along with an ageing population, people are also living longer.

However, with increasing longevity comes a sharp increase in the

occurrence of age-related diseases. This could see many individuals

lose their ability to live independently due to a decline in physical or

cognitive functioning.

Our investment in providing exceptional care and support across

a full range of retirement living and aged-care options is an

important differentiator in both the New Zealand and Australian

markets. As a market leader in the retirement sector with a true

continuum of care offering, we are uniquely positioned to benefit

from this changing demographic.

current population in

New Zealand and Australia

aged 75 and over

2.3 million

projected population in

New Zealand and Australia aged

75 and over by 2062

5.3 million

While it has

been a disrupted

period, the

underlying

demand for our

model, and our

ability to deliver

and meet that

demand, is very

much there.”


Cameron Holland,

Chief Executive Officer

– Australia

RYMAN HEALTHCARE

34

Maintaining a sustainable pace
The Ryman ‘flywheel’ of efficiently building, selling and recycling

capital has slowed over recent years as the business has worked

through the challenges that come with building across a greater

number of larger and more-complex sites and increasing

construction costs.

Over this period, we have made significant investment in our people,

systems and processes to increase the growth capacity of the

organisation and to ensure that our ‘flywheel’ can keep turning at

a sustainable pace.

We are already seeing evidence that the enhancements made to our

processes are resulting in tighter capital management. Combined

with strong demand, we are well positioned to achieve our corporate

ambition of growing underlying profit by 15 percent per annum

per share.

Enhancements made over recent years include:

• the introduction of a new organisational structure

• continued strengthening of skills and lifting the capability of

our team

• the adoption of new systems and technologies to further enhance

efficiencies and improve project coordination across the business

• tighter discipline around the staging of capital-intensive sites

and the mix of sites in our land bank

• improved governance oversight across development and

construction through the establishment of a Development, Design

and Construction Committee

• diversification and extending the tenor of our debt.

What gives me

confidence as

to where we are

now and where

we’re going are

the significant

enhancements

we’ve made over

recent years.”


Anthony Leighs,

Director

ANNUAL REPORT 2022

35

Using debt to fund our growth ambitions
Over the year, our debt to debt-plus-equity gearing has improved to

43 percent reflecting the benefit of our investment in higher-value villages

over recent years.

Debt remains a function of our growth plans. We use debt to fund the

purchase of land and the development of a village. This debt is repaid via

the occupancy advances we receive for independent and serviced units

and refundable accommodation deposits for aged-care rooms.

This is a significant value creator for the business. The occupancy advances

and refundable accommodation deposits are effectively interest-free loans

that are repaid with the funds received from the next incoming resident

(less management fees). Any difference in value between the outgoing and

incoming resident is retained by Ryman. This interest-free source of funds

is what has enabled us to create significant value for our shareholders since

listing in 1999.

We aim to recycle capital by the time a village is completed, fully occupied

and sold down. This means that the majority of our debt is productive debt.

The increase we have seen in our debt over the past 4 years reflects the

investments we have been making, including lifting the number of sites we

are building across from four to 16.

At 31 March 2022, we had core debt (systems and other assets and

village capex) of $506.0 million. The remainder of our debt constitutes

undeveloped land, work in progress and new sale debtors.

Use of debt

fiffiffflbn

fiffiffflbn

fiffiffflbn

fiffiffflbn

fiffiffflbn

fiffiffflbn



Mar Mar 

Systems and

other assets

Village capex

New sale

debtors

Development

work in progress

Undeveloped

land

True underlying

value creation

is

a co-equal

fundamental goal

of Ryman. This

takes vision,

commitment,

financial discipline

and excellent

execution. That is

what our founders

were seeking.”


Geoffrey Cumming,

Director

RYMAN HEALTHCARE

36

Our governance committees
Our governance committees have been established

at board and management level, according to key

areas of focus and potential risks to the business.

These committees have evolved over the years

in response to an ever-changing environment in

which we operate. Each of our committees made

invaluable contributions which helped us shape

and navigate our response to COVID.

The structure and support of our committees

ensures we are well positioned to manage

future challenges.

Our new organisational structure generates

additional capacity to deliver strong growth while

enabling the business to respond to local market

conditions. New Zealand and Australian CEOs

lead the regional executive teams, supported by

the shared group structure.

While the New Zealand and Australian markets

are similar in some respects, understanding the

nuances of each market – different legislation,

funding sources, competitor landscape, resident

needs and local councils – is essential to our

ability to grow and deliver great care and profit.

We are already seeing the benefits of the new

structure. Being able to quickly respond to

changing resident needs while building out

long-term projects means we stay relevant and

generate growing returns.

Strengthening the resilience of our

balance sheet

Since 2019, we have been on a journey to improve

the resilience of our balance sheet through the

diversification of our debt in terms of its tenor,

geographic origins and counterparties.

We considered a range of options and ultimately

executed four separate debt capital market

transactions resulting in $1.13 billion of diversification

across three geographies. This includes the

NZ$290.0 million USPP, which closed in April 2022.

Following the closure of our second USPP,

30 percent of our total debt is now fixed with an

average cost of debt of 3.8 percent and tenor of

approximately 6 years.

This work saw us named as a finalist in the

Bloomberg Excellence in Treasury Award for

demonstrating excellence in adaption and

execution of treasury financial management.

The proactive changes we have made to our capital

structure position us well to withstand future

challenges, whether related to the pandemic, rising

geopolitical tensions or an increasingly volatile

capital environment.

During the year, the board also approved a move

to a flexible dividend policy. The new policy

provides the flexibility to pay out 30 to 50 percent

of underlying profit as a dividend (previously fixed

at 50 percent of underlying profit). The change

in policy provides us the option to retain more

cash in the business to meet the extraordinary

growth ahead.

Adapting to changing market conditions

ANNUAL REPORT 2022

37

Rosemary, a resident in our Diana Isaac Village in Christchurch,
enjoys a stroll with Registered Nurse Sandra Hendriks.

38

RYMAN HEALTHCARE

An unwavering
commitment to care

ANNUAL REPORT 2022

39

Since January 2020,
we have invested over

$70 million in keeping our

residents and teams safe

from COVID. The work

we have done has been

greatly valued by our

residents and their families,

and we are very proud

of the resilience our team

has shown through this

challenging period.

Taking control of our COVID vaccination rollout

Key to ensuring the long-term safety of our residents, teams and

communities was the swift rollout of vaccinations. In preparation

for the arrival of the vaccines, we trained our own in-house

vaccination team of 50 nurses. This preparedness meant we were

one of only a few aged-care providers in Victoria to win a tender to

self-vaccinate our team members.

In New Zealand, our strong engagement with district health boards

(DHBs) and the Ministry of Health meant we could help on a

broader scale. When Canterbury DHB asked us to support them

to rapidly vaccinate other aged-care providers in the region,

our vaccination teams and efficiently-run clinics enabled us to

offer assistance.

Through our vaccination programme, we have administered more

than 36,800 vaccination doses to Ryman residents and 17,800 doses

to our team across Australia and New Zealand.

Initiating a vaccination programme of this scale and implementing

the rollout in the shortest timeframe possible was an extraordinary

feat. Our teams demonstrated incredible dedication and commitment

and operated like a well-oiled machine throughout.

The learnings we have garnered through the pandemic have been

well mined and will assist us greatly going forward.

RYMAN HEALTHCARE

40

Award-winning COVID response
in Victoria

With numerous extended lockdowns to contend

with, our villages in Victoria have endured more

than their fair share of COVID-related challenges.

Their marathon efforts were impressive and didn’t

go unrecognised.

Ryman leaders responsible for overseeing our

COVID response were named Team of the Year

for Victoria and Tasmania at the 2021 Excellence

in Age Services Awards.

In 2022, Ryman was named Innovation Award

Winner in the Victorian Chamber of Commerce

COVIDSafe Business Awards. This award was in

recognition of the innovative and industry-leading

steps taken to encourage COVIDSafe practices,

describing Ryman as an expert in how to execute

such a response.

Our response included Ryman team members

moving into villages to reduce the risk of

transmission, the development of a COVID GO

kit that provided our village teams with the

immediate actions they needed to take as soon

as a positive case was detected, the early

introduction of rapid antigen testing for all visitors

and contractors, and the development of our own

COVID digital contact tracing tool, which recorded

all team member and resident interactions.

We shared learnings gathered from our Australian

operations with the aged-care sector in

New Zealand to ensure everyone was well prepared

for the arrival of Omicron.

A fabulous response that was ahead of the curve

in preparedness. There was a clear level of care,

compassion and selflessness in the actions taken and

their efforts and commitment helped save lives.”

Victorian Chamber of Commerce judging panel


Image: Members of our award-winning COVID response

team in Victoria.

ANNUAL REPORT 2022

41

Hazel, Logan Campbell Village resident
It was time for us to give back to the Ryman

team for everything they’ve done, and the

exceptional kindness they’ve shown.”


RYMAN HEALTHCARE

42

While Ryman team members put their home and family
lives on hold to keep residents safe, residents also rallied

around to do their bit to reduce transmission.

Residents inspired

by Ryman team

COVID efforts

At the peak of the pandemic,

some villages faced considerable

staff shortages, with team

members either unwell or

isolating at home.

One of those was Auckland’s

Logan Campbell Village, which

had 30 workers on COVID

leave at one point.

Ryman villages provided the

option for team members to

live on site. For those workers

living in large households, often

alongside other healthcare

workers, it created a unique

opportunity to reduce

transmission even further.

A dozen team members

moved into Logan Campbell

Village, including Village

Manager Rebecca McMillan.

Inspired by their selfless

dedication, residents also

formed a ‘resident crew’ to do

their bit too.

Resident and former nurse

Dawn marvelled at village team

members putting residents

before themselves. She was

only too happy to help with

essential jobs such as folding

laundry and sanitising high-touch

points like lift buttons, banisters

and door handles. Fellow resident

Hazel also helped out by cooking

meals for the team.

Activities Coordinators Gerlie

Navaja and Keefe Martinez

were among the team members

who moved into the village.

Along with going above and

beyond to maintain exceptional

quality of care for their residents,

they also enjoyed participating

in activities with residents.

The collective effort of team

members and residents has

served to enhance the already

strong sense of family that

exists at Ryman villages.

Image: Logan Campbell resident Hazel and Activities Coordinator,

Keefe Martinez.

ANNUAL REPORT 2022

43

Continuing to exceed standards in
clinical excellence

The driving force behind our COVID response

was to keep everyone safe, and in doing so, it

shone a spotlight on the exceptional standard of

care that we simply call day-to-day operations.

We continue to lead the market in the provision

of a high quality of care – 91 percent of our

aged-care centres in New Zealand have now been

awarded 4-year certification, the ‘gold standard’

in care.

Despite the ongoing pressures of COVID,

our villages have not only maintained their

standards in aged care, they have continued

to exceed them.

Our custom-built technology proved

to be invaluable

Our custom-built myRyman Care app provides

nurses and carers access to clinical data and

detailed care tasks required for each care

resident. This award-winning technology ensures

all information is securely recorded – from

critical medical alerts to personal preferences.

The efficiency in which this information is recorded

enables our nurses and carers to spend more

quality time with residents and it makes the transfer

of care between team members seamless.

The app has proven to be an invaluable tool,

enabling us to be agile in responding to the

ever-changing demands of the pandemic. It

enhanced the efficiency of our vaccination rollout

and the management of isolation quarantines.

myRyman Life model of dementia care

Our villages are supportive and caring communities

that work to improve the experience of residents

living with dementia. We provide a safe environment

for residents to enjoy, with a focus on experiences

rather than processes.

We have researched and developed our own model

of dementia care, myRyman Life. The model

aims to challenge perspectives on dementia and

supports people to live in the moment and to feel

kindness, love and security. It promotes spontaneity,

laughter and happiness.

We have continued to enhance our innovative

approach to dementia care through the successful

trial of our Moove and Groove music therapy

programme and our new care companion model.

This model aims to reduce distressed behaviour

through individualised and more-purposeful

engagement and sees team members regularly

partnered with the same residents. These initiatives

will be rolled out to all Ryman dementia care

centres from July 2022.

RYMAN HEALTHCARE

44

myRyman Life awards
2020Winner

Innovation of the Year

– Dementia Care Model

Solution

Asia Pacific Eldercare

Innovation Awards

Refining our care offering

With 3,676 aged-care beds in New Zealand and

a further 563 in Australia, we are an integral part

of the healthcare system, providing a protective

moat around our public hospitals – there are only

12,035 public hospital beds in New Zealand.

We are committed to continuing to meet the

demands of an ageing population while ensuring

sustainable returns for the care that we provide.

In 2020, we introduced refundable accommodation

deposits in New Zealand. This offers our care

residents the choice around how they pay

their weekly room premium. This initiative has

been very popular with our residents, and following

a soft launch in late 2020, we have collected over

$100 million in refundable accommodation deposits.

With resthome care also available in our serviced

apartments, we have been refining the number

of care beds in new villages over recent years

to better align with the number of residents who

transition through to care.

2021Winner

Best Plain English Document

Private Sector

myRyman Life eLearning tool

Plain English Awards

2020Finalist

Best Dementia Care Programme

Asia Pacific Eldercare

Innovation Awards

2022Finalist

Learning and Development

Capability Award

myRyman Life education

HRNZ Awards

ANNUAL REPORT 2022

45

Ryman resident Terry at our Logan Campbell Village in Auckland,
who won an Olympics@RYMAN gold medal in swimming.

RYMAN HEALTHCARE

46

Raising the bar
on our

resident experience

ANNUAL REPORT 2022

47

Feeling connected to a
community that genuinely

cares is one of the highlights

of living in a Ryman village.

Amidst the extraordinary

challenges that COVID

presented, we found ways

to maintain that feeling

of connectedness.

Olympics@RYMAN

In the midst of the pandemic, our residents’ wellbeing was top of our

agenda. With the Tokyo Olympics on the horizon, we dreamt up an

ambitious initiative to enhance the social connection and wellbeing

of our residents: the Olympics@RYMAN.

We invested in innovative technology to make this a hybrid physical

and virtual tournament. Residents gathered to compete using

technology to link events across stadium venues, bowling greens

and village lounges across our villages in New Zealand and Australia.

In every event category – lawn bowls, cycling, swimming, a walking

relay and a ‘quiznastics’ event – our residents competed for the

chance to stand on the podium as an Olympics@RYMAN medallist.

Recognised as the Best Active Ageing Programme and

Innovation of the Year at the Asia Pacific Eldercare Innovation

Awards, our teams did an outstanding job bringing this event to life.

The Olympics@RYMAN provided a great opportunity to test some

very innovative and emerging technologies with our residents and

helped us better understand its potential going forward.

We appreciated the opportunity to

partner with the Olympic Committees

and create a truly unique experience

for our residents.”


Mary-Anne Stone, Chief Strategy Officer

RYMAN HEALTHCARE

48

Poem by Murray S. Lennox
Ryman resident

We yelled, we cried, we gasped and sighed

At victories won and places lost,

Emotions that we couldn’t hide

While they pushed on at what a cost.

That spirit we took up in our own Ryman way,

As residents walked and biked and bowled

While swimmers swam, and quizzers played

And none were left out in the cold.

Technology not seen before

Created a community across the land

While happy bags and food galore

Brought weeks of graft to the final grand!

“Well done” to all who were involved

From stewards to the athletes strong.

We admire your strength and fortitude,

And you all deserve a golden gong!

Robust systems and processes to

enhance our dining experience

When it comes to lasting impressions, enjoyable

dining is an experience that deserves continued

enhancement. Like any good restaurant, we

are constantly refining recipes and improving

systems and processes.

During the year, we introduced an end-to-end

food management system, Saffron.

Saffron gives us better access to nutritional,

allergen and cost data. We use this data to

inform our recipe and menu creation and have

seen significant improvements in resident

experience through the ability to select meals

from a device as well as track allergen

information. The introduction of this system

has also led to cost reductions and better

procurement and contract management.

We also rolled out the Safe Food Pro

digital software to our New Zealand villages,

and we’re implementing it across our

Australian villages. This system improves

our ability to efficiently capture all food

safety records, including refrigeration

and cooking temperatures as well as

food storage temperatures.

Image: Ryman resident Jane from our

Murray Halberg Village in Auckland, and her

support crew during our Olympics@RYMAN

cycling event.

ANNUAL REPORT 2022

49

attendees
103,000

copies of our

Botanical magazine issued

5,000

50

RYMAN HEALTHCARE

Partnering with the Melbourne International Flower and
Garden Show enabled us to be part of a high-profile

event with a wide appeal. It’s a great opportunity to

build brand awareness while also celebrating the lifestyle

and passions that are important to our current and

future residents.

Developing meaningful

partnerships in


our communities

Through our partnership with

the show, we offered a range

of experiences for attendees

to enjoy. This included our

Ryman stand where we offered

refreshing iced tea on tap, our

fully booked workshops with

Australian landscaping expert

Matt Leacy and our inaugural

Ryman Healthcare Balcony

Garden Competition which

sought to provide gardening

inspiration for smaller spaces.

Residents and friends of our

villages enjoyed access to

exclusive ticketing benefits,

and with 103,000 people in

attendance, we were able to

introduce Ryman to a broader

audience and lift our profile in

the Australian market.

Image: Show attendees enjoying the activities at our Ryman stand.

“Giving people the opportunity to

create their own sanctuary in a small

space is important. The benefits to

wellbeing and quality of life are huge.


Sara Correia from Tempest Landscapes, inaugural winner of the

Ryman Healthcare Balcony Garden Competition

ANNUAL REPORT 2022

51

Engaging with our communities
As a care business, building meaningful partnerships and

supporting our communities enables us to make a positive impact

on a larger scale. Through our support of over 400 clubs and

organisations, we have established strong relationships with the

communities outside of our village gates.

Every day we see the positive impact of the arts within our vibrant

village communities, where residents can connect through their

shared appreciation of music, dance and creative hobbies. Our

partnerships with organisations such as the Melba Opera Trust,

the Melbourne Symphony Orchestra, the Royal New Zealand Ballet

and The Court Theatre mean our residents and friends of our

villages benefit from access to wonderful cultural experiences.

Each year, our residents and team members vote to select an

annual charity partner to support. All money raised by them

is matched by Ryman, dollar for dollar. In 2021, we supported

Melanoma New Zealand and the Melanoma Institute Australia,

donating a combined total of $550,000. In New Zealand, these

funds allowed Melanoma New Zealand to buy a Spot Check Van

that has been touring community locations around New Zealand.

Our 2022 charity partners are the Prostate Cancer Foundation NZ

and the Prostate Foundation of Australia.

Our support extends beyond our local communities to causes

that also affect our team and their families abroad. This year, we

sent over 10,000 masks to support Fiji’s COVID relief efforts and

provided essential items, including water, pantry staples and face

masks to Tonga in the wake of the volcanic eruption and tsunami.

We are so grateful

to

Ryman for its

extraordinarily

generous support.

The impact the

van is already

having in the

community has

been significant.”


Andrea Newland,

Melanoma New Zealand

Chief Executive

RYMAN HEALTHCARE

52

Previous winners
2015 Gabi Hollows

(Restoring sight)

2016 Professor Henry Brodaty

(Alzheimers research)

2017 Professor Peter St George-Hyslop

(Neurodegenerative research)

Supporting the wellbeing of older

people globally

The Ryman Prize recognises the world’s best

advancements in the pursuit of enhancing the

quality of life for older people.

As a business that set out to improve the

standards in aged care, our implementation and

sponsorship of the prize has enormous potential

to bring awareness to an often-overlooked sector.

The work of our prizewinners often benefits the

entire aged-care sector, and we feel it’s important

to recognise and reward those who have

dedicated their work to benefit older people.

This year’s winner of the $250,000 prize was

Professor Kenneth Rockwood, a geriatrician,

researcher, academic and anti-ageism campaigner.

Professor Rockwood was selected for his

truly unique contribution to the understanding

of ageing. His Clinical Frailty Scale is used

internationally, and he has made a massive

contribution to scientific literature with hundreds

of peer-reviewed articles and contributions in

the world’s leading medical research journals.

Accepting the award from the Right Honourable

Jacinda Ardern, Prime Minister of New Zealand,

Professor Rockwood said, “This is fantastic

recognition, and the timing could not be better

given COVID. It will give momentum and

recognition to do a whole lot more research and

work for a greater good.’’

2018 Professor Takanori Shibata

(Robotics)

2019 Dr Michael Fehlings

(Degenerative cervical myelopathy research)

2020Miia Kivipelto

(Alzheimers research)

Image: Professor Kenneth Rockwood,

2021 Ryman Prize recipient.

ANNUAL REPORT 2022

53

Ryman Foreman Ian Lee on site at our Miriam Corban Village in Auckland.
Ian was attracted to Ryman’s scale and in-house capabilities.

54

RYMAN HEALTHCARE

Building a solid
platform to grow

55

ANNUAL REPORT 2022

Our villages are designed,
built, sold and operated

by Rymanians. Our ability

to manage every stage

of a village’s life cycle

means that our purpose

of exceptional care is

always at the forefront.

It influences all of our

conversations and drives

the decisions we make.

Design, development and construction under

one roof

The process of building a successful village is more than just buying

a piece of land and constructing buildings on it. Bringing design,

development and construction under one roof enables us to unify

the life cycle of a village. It means our teams work cohesively

throughout each step of the process. This collaboration creates a

better environment for success, with improvements and efficiencies

achieved at each stage.

Led by our chief construction officer, our team has the skills,

breadth of knowledge and capability to deliver at the complexity,

scale and pace required for our portfolio of villages. With expansive

experience in the construction industry and the introduction of new

technologies, systems and processes, we have lifted our approach

in this area and will continue to see the benefits of the changes and

additional rigour put in place.

Ryman is a major player in the construction industry in both

New Zealand and Victoria, Australia.

During the last financial year, we invested over $780.0 million into

building homes for Ryman residents, lifting our investment in

villages and critical healthcare infrastructure to $3.36 billion over

the last 5 years.

We delivered 560 new independent units and serviced apartments,

and 151 care rooms. We also opened three new village centres during

the year.

Despite COVID restrictions and outbreaks, our dedicated team

of 58 sales advisors welcomed over 1,500 new residents into our

independent units and serviced apartments and have booked over

$1 billion of gross occupancy advances.

RYMAN HEALTHCARE

56

Facing in to the construction headwinds
We have been using our scale and long-standing relationships with

suppliers to manage the headwinds currently facing the construction

sector, including supply chain constraints, material availability and

cost inflation.

As we navigate our way through the next 12 to 24 months, it is

critically important that we remain committed to forward planning.

We will continue driving efficiencies in the way we approach our

work for the delivery of each stage of development. We will continue

making the most of our scale and position in the market and we will

make sure we have the right people and resources in place at the

right time.

Lots of little efficiencies create great gains

As a company that provides exceptionally high standards in care,

our drive for continuous improvement never sleeps.

We’ve been developing our technology platforms to ensure we have

the best systems in place to meet the demands associated with

building and operating across an increasing number of sites. This

enhances our capabilities now and in the future.

This year, we will introduce the construction management platform

Procore. This will help streamline our processes at the project level,

leading to improved communication, documentation, accountability

and efficiencies.

The adoption of Salesforce over the coming year will enable us to

harness the advanced capabilities of this world-leading platform

to improve sales analysis and productivity. We will apply workflow

modifications across the business, from sales through to how we

modify and refurbish our units.

There’s plenty

of opportunity

for great gains

to be made by

introducing lots of

little efficiencies.

That is what

we’re focused on

right now.”


Chris Evans,

Chief Construction Officer

ANNUAL REPORT 2022

57

Expanding our growth runway
The population of people aged over 75 in Australia

is over five times larger than in New Zealand and

provides an enormous growth opportunity for

our business.

Having successfully launched in Victoria, we have

proven that our strategy and culture is transportable

to another jurisdiction.

We’ve learned an enormous amount since

we entered the market 10 years ago and have

celebrated a number of successes.

With the adoption of a new organisational structure,

the appointment of our first chief executive of the

Australian business, the opening of our seventh

operational village and a further eight villages

either under way or in the land bank, many of the

challenges we faced entering a new market are

now behind us.

Ryman is a major player in the construction industry

As a developer of retirement living and aged-care facilities,

we are a significant employer across the construction

sector. We have a large in-house team of designers, quantity

surveyors, project managers, health and safety advisors,

quality advisors and support staff.

Construction of our villages sees small communities formed

with upwards of 300 staff and subcontractors on site during

the peak development of any one village.

under construction across

New Zealand and Australia

16 sites

Having a CEO of the Australian business who is

supported by a highly capable local senior leadership

team with a deep understanding of the local market,


has bolstered our capabilities on

the ground

and further enhanced our understanding

of the

Australian market.

The purchase of three new sites in Victoria over

the year has lifted our Australian land bank to nearly

twice that of our current asset base.

With an aim of maintaining the land bank at around

2,800 beds and units, we continue to seek out

sites around the Melbourne metropolitan area.

Having the right mix of sites in the land bank means

we are well positioned to lift both our build rate and

the value we create from this portfolio over the

next 5 years.

We have proven that our strategy and culture

is transportable to another jurisdiction.”


Claire Higgins, Director

RYMAN HEALTHCARE

58

The benefit of higher-value locations
As we have grown, so too has our balance sheet

and our aspirations. This has seen us tilt our

portfolio towards higher-value areas, including

Auckland and Melbourne, over recent years.

While development in these areas can have

higher upfront costs associated with the

purchase of land and the style of village, this is

more than offset by the considerable future

value created.

This value can be seen in the resale bank we have

accumulated. Our resale bank, or the difference

between what our current residents paid and

what the next residents are expected to pay if

we sold that unit at current prices, is $1.87 billion.

This is up more than 146 percent over the last

5 years and in part reflects our push into these

higher-value markets along with wider property

market movements. Our resale bank underpins

our future resale gains, and we expect to realise

this amount over the next 6 to 7 years as the

portfolio turns over.

Even though our build rate has remained relatively

stable over the last 5 years, by focusing on

building villages in higher-value locations, we

have created significant value, and over the long

term the benefits of this will continue to accrue

to shareholders.

The value creation that comes from what we are

currently building and what we are primed to build

with our land bank is also significant. We anticipate

the 29 sites in our land bank will generate capital

proceeds of $6.8 billion when they are completed,

fully occupied and sold down.

A land bank with a great mix of sites

We are focused on ensuring we have the right

mix of sites in our land bank, including the style

of villages we are building. This is important as it

allows us to more effectively manage our working

capital requirements, the consenting process,

the needs of our communities, our build and the

speed at which we recycle capital.

During the year, this mix was enhanced by the

purchase of four new sites – Rolleston in

Canterbury and Mulgrave, Kealba and Coburg

North in Victoria. We also purchased additional

land adjacent to our Deborah Cheetham Village

in Ocean Grove and a small operating retirement

village next to our Essendon site. We now have

a land bank of sites that stretches over half a

decade in front of us.

While COVID has seen construction on some of

our sites halted at times during the year, it has also

presented opportunities. We have been able to

drive forward on the consenting process, and

57 percent of our pipeline is currently consented.

We believe that our focus on higher-value

locations will support the delivery of superior

long-term returns for investors through greater

upfront selling prices, which result in a higher

recurring earnings stream through management

fees collected and resale earnings.

This increase in profitability also allows us to

continue to invest in our people and our systems

and technologies, enabling us to enhance the

resident experience and ultimately bring Ryman

to more communities.

ANNUAL REPORT 2022

59

Auckland
DesignConsentingConstructionVillage

open

Final

stages

Council

approval

Targeted

village

completion

Our development pipeline

Rest of

New Zealand

2023

2023

2024

2025

2026

TBC

TBC

TBC

TBC

TBC

2024

2025

2026

2024

TBC

TBC

Linda Jones

James Wattie

Kevin Hickman

Northwood

Park Terrace

Cambridge

Karori

Newtown

Rolleston

William Sanders

Miriam Corban

Keith Park

Murray Halberg

Takapuna

Kohimarama

Karaka

Targeted village completion is a calendar year date. It is based on current estimates and may vary from the

final completion date.

RYMAN HEALTHCARE

60

DesignConsentingConstructionVillage
open

Final

stages

Council

approval

Targeted

village

completion

Australia

2022

2022

2022

2024

2024

2024

TBC

2026

TBC

TBC

TBC

TBC

TBC

Charles Brownlow

John Flynn

Raelene Boyle

Nellie Melba

Deborah Cheetham

Highett

Ringwood East

Mt Eliza

Mt Martha

Essendon

Mulgrave

Kealba

Coburg North

ANNUAL REPORT 2022

61

RYMAN HEALTHCARE
62

Having lived and breathed construction her whole life,
Senior Quantity Surveyor Liz De Villiers was looking for

an exciting new challenge – and Ryman fit the bill.

A great team that

values diversity

The opportunity to work

within a company where the

developer, contractor and

operator were all under one

roof is what initially attracted

Liz to Ryman.

A big drawcard was the ability

to regularly brainstorm and

problem solve with different areas

of the business. For Liz, that’s

where innovation flourishes.

Liz also loves the caring

aspect and says, “Ryman has

a reputation for looking after

its people and being a big

supporter of work-life balance.”

Ryman’s flexible working policy

enables mums like Liz to

structure work responsibilities

around home life.

Flexible options such as the

ability to work from home or

vary her working schedule

make a big difference to Liz and

her family.

Working both on site and in

the office, Liz enjoys the diverse

and resilient teams she works

with and has noticed the number

of women in construction

has grown.

“How great is that? Construction

is about teamwork. Having a

diverse team with different life

experiences and construction

backgrounds across residential,

commercial and civil projects

has been brilliant.”

“Ryman has a reputation for

looking after its people.

Liz De Villiers, Senior Quantity Surveyor


Image: Liz enjoying the on-site aspect of her role at our Kevin Hickman

Village in Christchurch.

ANNUAL REPORT 2022

63

Artist’s impression of our Raelene Boyle Village in Aberfeldie,
Melbourne which includes a host of sustainable design features

such as rain gardens and a solar energy generation system.

64

RYMAN HEALTHCARE

Caring for our
environment

65

ANNUAL REPORT 2022

As the science around
understanding climate

change and climate risk

has developed globally,

we have elevated our

activity on sustainability.

We’ve brought on

additional internal and

external expertise to

enhance our capabilities

and formalise our

approach in this area.

Our principles of sustainable design

Our 11 principles of sustainable design guide our approach to

designing villages. Each village is treated as unique, and homes are

designed utilising modern technologies that consider environmental

and social impacts and harness natural resources where possible

– all with the goal of improving the health and happiness of our residents.

Measuring our emissions

The care of our residents is our number one priority. We use a

large amount of electricity to keep our residents comfortable and

to ensure our safety systems are continuously operating. This

means electricity is the largest contributor to our operational

emissions footprint.

Despite our absolute emissions for the year to 31 March 2021

rising by 1.9 percent, we have achieved a 22 percent reduction

in our carbon mandatory scope 1, 2 and 3 emissions per $m of

turnover from 2017 to 2021. We are focused on meeting our

30 percent reduction target by 2023.

GHG operational emissions by source (year to 31 March 2021)

Electricity

fiNZffi fffl

Electricity

fiVICffi fffl

Natural gas

fiffifffl

Air travel

fiffifffl

fiffifffl

Waste

fiffifffl

Fuel

RYMAN HEALTHCARE

66

Total gross GHG emissions
(tCO

2

e)

fiffiffffff

fiffiffffff

fiffiffflflfl

fiffiffflflfl





Base)













Total gross emissions (LHS)

Number of residents (RHS)

Total gross GHG emissions per $m turnover

(tCO

2

e)

The unprecedented operating environment under

COVID resulted in a 74 percent decline in our air

travel-related emissions when

compared to 2020.

This offset a large proportion

of emissions related

to the opening of a new village.

Like all businesses, we have adapted to a new

approach in developing new ways of doing

business, and we expect to see a continuation

of the behaviours that enabled a reduction in

air travel-related emissions in the years ahead.

This year, we have extended our scope 3 emissions

inventory to include additional emissions related

to the disposal of waste and recycling, including

glass and composting.

In the coming year, we will carry out a materiality

assessment of the emissions associated with

our supply chain. Where supply chain emissions

are material relative to the total of our direct and

indirect emissions, we will look to report on these

and publish associated reduction plans.

Planning for the future

As we explore further opportunities to reduce our

impact on the environment, we have turned our

attention to the embodied carbon in our buildings.

Across the building sector, emissions associated

with the use of steel and concrete are significant

contributors to the sector’s carbon footprint.

The work we have been doing over the past

2 years will see us embark on our first

development using a cross-laminated timber

structure at our new Kevin Hickman Village

in Christchurch. The expected reduction in

embodied carbon in the cross-laminated structure

is approximately 80 percent.













(Base)



ANNUAL REPORT 2022

67

reduction in embodied
carbon for the CLT structure

80%

reduction in

build time

10%

reduction in heavy

vehicle movements

65%

RYMAN HEALTHCARE

68

We have committed to constructing our first mass
timber structure at our new Kevin Hickman Village using

cross-laminated timber in place of some structural

elements previously made from steel and concrete.

Detailed design is under way, with the construction of the

apartments due to commence in September 2022.

Reducing our

embodied carbon

Cross-laminated timber (CLT)

is one of the products produced

through mass timber construction.

This is where multiple layers

of timber are glued together to

form structural panels that can

be used for the floors and walls

of buildings.

Cross-laminated timber has

two significant advantages

over steel and concrete. Being

a natural product, its carbon

content is extremely low. It’s

also a carbon-positive material

– when trees are replanted,

their growth reduces carbon,

and oxygen is released into

the atmosphere.

By substituting concrete and

steel for cross-laminated

timber, we have also addressed

some high-risk health and

safety considerations, including

reducing heavy vehicle

movement

for on-site deliveries

by 65 percent.

We are now looking at future

opportunities for its use in

other new builds as well as

additional ways to reduce

the embodied carbon in our

buildings such as low-carbon

concrete. We are also pursuing

ways in which we can continue

to improve our waste and

recycling from construction sites.

Image: Artist’s impression of our Kevin Hickman Village apartment buildings.

ANNUAL REPORT 2022

69

Step by step we can make a difference
One of many sustainability initiatives being

undertaken across the business is our partnership

with City to Farm. Since 2019, in partnership with

City to Farm, our Evelyn Page Village in Auckland

has been diverting food scraps away from landfill.

The food scraps are composted on local farms

and used to transform heavy, infertile clay into rich

soil that can support food production, in this case,

banana palms.

50 tonnes of food scraps have now been

diverted from landfill, removing the possibility

that this waste could have emitted 138 tonnes of

greenhouse gases into the environment.

The building of predator traps by our residents

for the Department of Conservation and Predator

Free New Zealand has gathered a huge amount

of momentum over the past year.

Our residents have partnered with charity

Doubtless Conservation and have been busy

building predator traps to protect some of our

most precious species in the South Island high

country. All materials are supplied by Ryman, and

our fantastic residents provide the muscle and

know-how.

The recycling and diverting of construction waste

from landfill at our Auckland and Melbourne

sites continued to improve over the year. We are

currently recycling 87 percent of construction

waste from these sites. We have seen a consistent

improvement in this trend since we began

collecting data in 2019.

Image: Ryman-made predator traps being transported

to the Doubtful Valley.

RYMAN HEALTHCARE

70

Strengthening our expertise
Along with a lift in individual initiatives happening around the group,

we are maturing our understanding around sustainability. This is

reflected in the additional internal and external expertise we have

incorporated into our structure.

During the year, we appointed a dedicated sustainability manager.

In addressing our climate-related risks, we have begun a

programme of work that will ensure we are taking the necessary

steps to address climate change risks while taking advantage of

any opportunities that will arise.

Our board has acknowledged its responsibility for identifying and

managing our climate-related risks and opportunities, and our

disclosure responsibilities have been assigned to a member of the

senior executive team with extensive expertise in sustainability.

The next step in our journey

As part of this programme of work, we have completed a climate

change maturity assessment of our structures, policies and

processes against international standards. We have developed

a roadmap of priority actions to improve our climate-related

risk management policies and processes across the areas of

governance, strategy, risk management, and metrics and targets.

This comprehensive roadmap will be actioned over the next 3 years

as we work to build organisational resilience and capture value

associated with the net-zero transition.

We have engaged the expertise of KPMG to identify the impact of

a range of climate scenarios on our operations, now and in the

future, and to develop adaptive measures to manage the identified

risks and opportunities. A 3-year action plan has been developed to

ensure we meet our climate-related disclosure requirements, which

are expected to be confirmed by the External Reporting Board in

late 2022.

This body of work positions us well to meet these disclosure

requirements, which will be included in our 31 March 2024

annual report.

We want to

leave our planet

in good shape

for generations

to come.

Our residents,

our team and

our investors all

share this goal.”


Greg Campbell,

Chair

ANNUAL REPORT 2022

71

Area
Governance

Establish governance

processes and update

policies

to incorporate

climate change risks.

Assign climate change

responsibilities to key

oversight groups at both

senior executive team

and board level.

Provide climate risk training

to our senior leaders.

Consider the appropriateness

of establishing a technical

advisory committee.

Assess climate change

skills gap across board and

senior executive team on

an ongoing basis.

Enhance governance skills

and performance across board

and senior executive team

on an ongoing basis,

including

integrating climate

change

issues with governance

performance reviews/audits.

Year 1

activities

Year 2

activities

Year 3

activities

Our 3-year action plan

Roadmap to addressing

climate-related risks

This comprehensive roadmap of

priority actions will be carried out

over the next 3 years.

RYMAN HEALTHCARE

72

Strategy
Carry out a risk and

opportunity assessment

using scenario analysis.

Develop a strategy to

address our material

climate change risks

and opportunities.

Establish an action plan

to address our material

climate-related risks

and opportunities.

Carry out a capacity

assessment for

effective climate-related

decision making.

Integrate climate change

considerations into our

business, strategy and

financial planning.

Execute a second iteration

of our climate risk and

opportunity assessment.

Develop a process for

systematically identifying and

analysing

climate-related risks.

Develop a plan to manage

climate-related risks.

Document the extent to

which our climate-related

targets have been informed by

external parameters (such as

science-based targets).

Integrate climate change

risk management processes

into our operations.

Select climate change

metrics based on a

materiality and/

or risk and

opportunity assessment.

Document target setting

objectives and establish targets

for capital deployment and

climate-related opportunities.

Broaden metrics to include

our other climate-related

impacts and risks including

supply chain.

Enhance measurement

processes of our overall

climate-change risk

management progress by

establishing targets to

encompass the delivery of

our climate-related strategies,

plans and policies.

Risk managementMetrics and targets

ANNUAL REPORT 2022

73

Clinical Manager Madelyn Premacio (far right) with her care team at
our Charles Upham Village in Canterbury, whose outstanding daily

efforts demonstrate what it means to be a Rymanian.

74

RYMAN HEALTHCARE

74

Investing in our
people

ANNUAL REPORT 2022

75

Our greatest asset is the
people who work here,

and our culture remains

one of our most unique

differentiators.

Our team is the backbone

of our business, and they

have been outstanding

throughout the past

2 years in what can only

be described as a very

challenging period for

the business.

Our people have worked tirelessly to keep themselves and our

residents safe through the extended lockdowns in New Zealand and

Australia. This has included wearing N95 masks and face shields

through the hot summer period, moving to 12-hour shifts during the

height of the Omicron outbreak, undergoing regular testing and, in

some cases, moving out of their homes and into villages to reduce

their potential exposure to COVID.

Our teams are incredibly supportive of each other, and our

culture of kindness and excellence has been invaluable through

the pandemic. Like many other businesses, our workforce was

impacted by the need for people to self-isolate, and our office and

sales teams stepped up to help on site at our villages. Their support

meant that we were able to cover over 400 shifts during this period

and maintain the quality of our resident care at critical times.

We continued to support our people behind the scenes. We’ve been

focused on how we can improve life for our team members and how

we can show appreciation for the incredible work being done to

keep our residents safe.

Culture is not invented. It is

constantly evolving, which is

why it must be nurtured.”


applications to join our team

54,741

hours of facilitated

leadership development

5 ,70 8

Greg Campbell, Chair

RYMAN HEALTHCARE

76

Andrew Roberts, Regional Facilities Manager in Victoria,
was one of hundreds of team members who chipped in

at villages to lend a hand during the pandemic and keep

operations running smoothly.

ANNUAL REPORT 2022

77

Investing in the health and wellbeing of our people
We have been very conscious of not only the physical stress

that COVID has had on our teams but also the impact on their

overall wellbeing.

Given the wide range of roles our teams perform every day, they

have faced vastly different experiences.

Some of our people have been working from home for extended

periods of time, some have moved out of home and into our villages,

many are working long hours in face masks and face shields and

everyone has had to deal with the stress of keeping themselves

and our residents safe from an invisible disease.

Strengthening the health and wellbeing of our people is a priority.

With input from the New Zealand Institute of Wellbeing and Resilience,

we have continued to develop our health and wellbeing plan and have

conducted a series of resilience workshops facilitated by renowned

expert Dr Lucy Hone.

The response to these workshops was overwhelming, and as a

result, we commenced a programme of online masterclasses

designed to promote and support wellbeing, resilience and mental

health across our broader team.

As part of our mental health awareness campaign to help

destigmatise mental illness and encourage conversations, we shared

video stories from members of the wider Ryman team. These videos

were viewed over 1,000 times, and our teams were provided access

to health and wellbeing resources through our dedicated wellbeing

channel, accessible by all 6,700 team members.

I have complete

admiration for

our team. Many

had to wear full

PPE for hours

on end. It’s just

amazing, they’ve

been incredible.”


Paula Jeffs,

Director

hours of special leave provided

to team members since the

beginning of COVID

110,000

meals a day provided to village

teams during lockdown

3,000

RYMAN HEALTHCARE

78

Supporting our teams through COVID
Maintaining our villages as safe havens meant

asking our team members to stay home if they

or anyone in their household was feeling unwell.

It was important to us that our teams were not

financially impacted when needing to stay

away so we put in place uncapped special leave

through this period. To date, we have provided

over 110,000 hours of this special leave to our

team members.

As further recognition of the role our teams

played in providing essential services during

Level 4 lockdown, we paid our New Zealand

village team members an additional $2 per hour.

In Australia, we made an application on behalf of

all village team members for the essential worker

retention bonus, which was subsequently granted

and paid to our teams.

We also provided our village teams with meals

during these periods, which saw us serving an

additional 3,000 meals a day. We established

hydration stations with electrolyte drinks and

nibbles to ensure our team members working

in face shields and masks were taking micro

breaks every hour and staying hydrated.

To date, more than 1,000 Ryman team

members have tested positive for Omicron.

Our People and Culture team continue to make

wellness calls to check on how those team

members are feeling and whether they need any

assistance, and to encourage them to rest and

take the time they need to recover. As a gesture

from their Ryman family, we are also sending

recovery packs to their homes that include treats

and essentials such as paracetamol, throat

lozenges, tissues, soup and other goodies as well

as a useful guide on how to aid their recovery.

Celebrating our people

The annual Ryman Awards is a time for our

teams to come together and celebrate their

achievements over the year. COVID restrictions

meant that for the second year running our awards

night was hosted virtually with Rymanians and their

families beaming in from around the world.

This year’s awards, hosted by New Zealand

TV personalities Hillary Barry and Laura Daniels,

were watched by over 2,500 people. Throughout

the night, team members took to their keyboards

to send messages of congratulations to their fellow

team winners with over 650 messages posted.

ANNUAL REPORT 2022

79

Recruitment, development
and happiness

We say it a lot, but for good reason – our people

are our most precious resource.

We spend quality time recruiting our team members.

Our culture of caring is unique, and it’s something

that we work hard to nurture and protect.

Qualifications, experience and intelligence are

of course very important. However, as a care

business, we hold care, kindness, integrity and

the ability to be a team player in very high regard.

These are the defining qualities of a Rymanian.

Our Ryman characteristics empower our people

to act with kindness and excellence, and we

have developed our own bespoke training and

leadership development programmes to reinforce

these values across the organisation. These

learning activities equip our teams with the tools

and skills necessary to meet our high standards.

Journeying into care

Our nurses, care team and wider village teams are

the front line of our organisation. Every interaction

with a resident or family member, no matter how

small, contributes to our purpose of caring. It takes

a special kind of person to demonstrate this level

of care each and every day.

Our nurses perform a very special role in our

villages and we have invested in ways to nurture

their careers with us. We visit nursing students

and attend career fairs accompanied by a Ryman

nurse to tell our story, providing an open and

supportive forum where nursing students can ask

questions and learn more about nursing in aged care.

Kindness and care

Kindness is in our DNA;

it underpins everything

we do.

Strong teams

We build positive,

trusting teams who

work together as one.

Resilience and

composure

We keep going despite

the bumps in the road.

Strive for

excellence

We innovate and

work hard to earn

our success.

Core characteristics

Communication

We use simple, clear

language that gets

straight to the point.

Lead and empower

We lead others with

kindness, clarity

and support.

Leadership characteristic

RYMAN HEALTHCARE

80

Supporting nurses through their graduate training
Launched in 2019, Ryman’s nurse graduate programme, also known

as Nursing Entry to Practice (NETP), provides support and ongoing

education for graduate nurses as they take their first steps into

the profession. Each NETP graduate is assigned an experienced

clinician who mentors them throughout the year. They are also

supported by the clinical leadership team at their dedicated Ryman

village and our NETP support team.

The majority of our NETP graduate nurse applications are a result

of our presentations to nursing students and attendance at career

fairs. The programme began with two graduates in 2019 and has

grown to nine graduates in 2022. Our aim is to grow this number

each year.

Helping our teams pursue their dreams

We are huge believers in the power of education to change lives,

and we offer several scholarships each year.

The Cashin Scholarship, set up in memory of former Ryman Director

Mike Cashin, is open to all Ryman team members and their immediate

family, including spouses, children and grandchildren. Each year,

members of the Cashin family help to select the winner.

The Graeme Rabbits scholarship is open to all of our team members,

contractors and suppliers. Graeme’s family choose one deserving

person every year to receive 3 years of funding and support to pursue

their choice of education or a community project.

We also offer scholarships to nursing students as a way of supporting

graduates during their final year of study. The scholarship provides

a $6,000 lump sum for graduates to use at their discretion. Since

2020, we have awarded four nursing scholarships – three in

New Zealand and one in Australia.

In total, we offer over $40,000 in scholarships every year to deserving

people both inside and outside of Ryman.

We have nine

graduates in

our nursing

programme.

Our aim is

to grow this

number

each year.”


Cheyne Chalmers,

Chief Executive Officer

– New Zealand

ANNUAL REPORT 2022

81

Shanlee Barnes-Webber, Serviced Apartment Coordinator
Working for Ryman under

their values and support is truly

a blessing.”


RYMAN HEALTHCARE

82

After becoming the inaugural recipient of the Ryman
Nursing Scholarship, Shanlee Barnes-Webber has

become a real Ryman success story.

From Ryman

scholarship to


unit coordinator

Shanlee’s career has moved

in leaps and bounds since she

was first awarded the $6,000

scholarship in 2017, an award

specifically aimed at third-year

nursing undergraduates.

It was the perfect segue into

Ryman’s NETP programme,

which gives new graduate

nurses the support and

supervision they need during

their first year in the profession.

Shanlee worked as a registered

nurse in the hospital at our

Diana Isaac Village in

Christchurch for a further

6 months after the NETP

programme. During this time,

she made a point of grabbing

every opportunity that came

her way.

“I put my hand up to do any

training and extra tasks I could.

“I was part of the COVID

vaccination team,

PCR testing,

catheterisation and I am trained

to do mask fit testing too.”

Then in February 2022, the

serviced apartment unit

coordinator role came up.

“I was unsure if I was going to

apply, but I had a lot of support

and encouragement from my

co-workers, and it’s the best job

I’ve ever had.”

Shanlee’s story is a recurring

theme at Ryman, and the

happiness she enjoys in her

role is one of the many reasons

why investing in our people is

so important.

Image: Shanlee enjoying a regular visit with serviced-apartment residents

June and Jack – the trio share a special bond.

ANNUAL REPORT 2022

83

Artist’s impression of our upcoming Highett Village located in the sought-after
suburb of Bayside in Melbourne – a prime example of a high-value site that will

generate strong returns.

84

RYMAN HEALTHCARE

Our
financials

85

ANNUAL REPORT 2022

Our history of strong
financial performance

and development pipeline

of 29 new villages sets

us up for sustainable

future growth.

86

RYMAN HEALTHCARE

6-year summary
FOR THE YEAR ENDED 31 MARCH 2022

20222021202020192018

2017

Financial

Underlying profit (non-GAAP)$m255.0224.4242.02 27.0203.5178.3

Reported net profit after tax$m692.9423.1264.7326.0388.2356.7

Net operating cash flows$m586.0413.1449.8401.4349.3322.8

Net assets$m3,434.52,829.22,301.02 ,170.11,940.51,652 .1

Interest-bearing debt to interest-

bearing debt-plus-equity ratio%43%44%42%38%35%34%

Dividend per sharecents22 .422 .424.222 .720.41 7. 8

Villages

New sales of occupation rightsno.560503513414458600

Resales of occupation rightsno.983925923824825718

Total sales of occupation rightsno.1,5431,4281,4361,2381,2831,318

Land bank (to be developed)

1,2

no.6,3066,1466,5956,5935,9525,554

Portfolio:

Aged-care bedsno.4,2394,0873,9113,6603,3673,281

Retirement-village unitsno.8,5387, 9 8 37,4 2 36,8786,4145,968

Total units and bedsno.12,77712,07011,33410,5389,7819,249

1 Includes retirement-village units and aged-care beds.

2 Of the 6,306 units and beds in the land bank, 2,581 are subject to resource and building consent.

20222021202020192018

2017

Underlying profit (non-GAAP)$m255.0224.4242.02 27.0203.5178.3

Plus unrealised fair-value movement

on retirement-village units$m4 67.1201.2(70.9)102.4185.3184.7

Plus deferred tax movement

$m

(29.2)12 .693.6(3.4)(0.6)(6.3)

Less impairment – loss on disposal

$m

-(15.1)----

Reported net profit after tax$m692.9423.1264.7326.0388.2356.7

Underlying profit is a non-GAAP* measure and differs from NZ IFRS profit for the year. Underlying profit does not have a standardised

meaning prescribed by GAAP and so may not be comparable to similar financial information presented by other entities.

The Group uses underlying profit, with other measures, to measure performance. Underlying profit is a measure that the Group

uses consistently across reporting periods.

Underlying profit includes realised movement on investment property for units in which a right to occupy has been sold during the period

and for which a legally binding contract is in place at the reporting date. The occupancy advance for these units may have

been received or be included within the trade receivables balance at reporting date.

Underlying profit excludes deferred taxation, taxation expense, unrealised movement on investment properties, and impairment losses

on non-trading assets because these items do not reflect the trading performance of the Company. Underlying profit determines the

dividend payout to shareholders.

* Generally Accepted Accounting Principles.

ANNUAL REPORT 2022

87

88
RYMAN HEALTHCARE

Financial statementsFinancial statements
Consolidated financial statements

90 Consolidated income statement

91 Consolidated statement of comprehensive income

92 Consolidated statement of changes in equity

93 Consolidated balance sheet

94 Consolidated statement of cash flows

Notes to the consolidated financial statements

95 Statement of compliance

95 Basis of preparation

96 Measurement base

96 Critical judgements in applying accounting policies

96 Adopting new and amended standards and interpretations

96 Standards and Interpretations on issue but not yet adopted

97 COVID-19

97 Summary of significant accounting policies

108 Other notes

108 Operating expenses

109 Depreciation and amortisation expense

109 Finance costs

110 Income tax

112 Trade and other receivables

113 Property, plant and equipment

116 Investment properties

118 Intangible assets

118 Cash and cash equivalents

118 Trade and other payables

119 Employee entitlements

119 Interest-bearing loans and borrowings

122 Lease liabilities

123 Occupancy advances (non-interest bearing)

124 Share capital

124 Reserves

126 Dividends

126 Related-party transactions

127 Key management personnel compensation

128 Financial instruments

139 Commitments

139 Contingent liabilities

139 Reconciliation of net profit after tax with net cash flow from operating activities

140 Subsidiary companies

141 Segment information

143 Employee share schemes

145 Subsequent events

145 Authorisation

Independent auditor’s report

146

90

95

ANNUAL REPORT 2022

89

The accompanying notes form part of these financial statements.
Consolidated income statement

FOR THE YEAR ENDED 31 MARCH 2022

Notes20222021

$000

$000

Care fees398,206359,241

Management fees105,55293,170

Interest received41103

Other income4,9983,280

Total revenue508,797455,794

Fair-value movement of investment properties7745,885416,847

Total income1,254,682872,641

Operating expenses1(466,238)(395,306)

Depreciation and amortisation expense2(35,698)(32,368)

Finance costs3(30,664)(19,365)

Loss on disposal6-(15,102)

Total expenses(532,600)(4 6 2 ,1 4 1 )

Profit before income tax722,082410,500

Income tax (expense)/credit4(29,209)12,561

Profit for the year692,873423,061

Earnings per share

Basic and diluted (cents per share) 15138.684.6

RYMAN HEALTHCARE

90

Consolidated statement of comprehensive income
FOR THE YEAR ENDED 31 MARCH 2022

Notes20222021

$000$000

Profit for the year692,873423,061

Items that will not be later reclassified to profit or loss

Revaluation of property, plant and equipment (unrealised)6, 16a-195,793

-195,793

Items that may be later reclassified to profit or loss

Fair-value movement and reclassification of cash-flow hedge reserve16b38,4107,0 57

Deferred tax movement recognised in cash-flow hedge reserve16b(10,857)(1,976)

Movement in cost of hedging reserve16c1,3193,753

Deferred tax movement in cost of hedging reserve16c(369)(1,051)

Gain/(Loss) on hedge of foreign-owned subsidiary net assets16d690(4,414)

(Loss)/Gain on translation of foreign operations16d(1,977)16,546

27, 2 1 619,915

Other comprehensive income2 7, 2 1 6215,708

Total comprehensive income720,089638,769

All profit and total comprehensive income is attributable to parent company shareholders and is derived from continuing operations.

The accompanying notes form part of these financial statements.

ANNUAL REPORT 2022

91

The accompanying notes form part of these financial statements.
Consolidated statement of changes in equity

FOR THE YEAR ENDED 31 MARCH 2022

Notes

Issued

capital

Asset

revaluation

reserve

Cash-

flow

hedge

reserve

Cost of

hedging

reserve

Foreign-

currency

translation

reserve

Treasury

stock

Retained

earnings

Total

equity

$000$000$000$000$000$000$000$000

Balance at

1 April 202033,2902 5 7,7 7 5(1 7,1 4 3 )-(10,345)(32,359)2,069,7592,300,977

Profit for the year16------423,061423,061

Other comprehensive

income for the year

16

-195,7935,0812 ,70212,132--215,708

Total comprehensive

income for the year

16

-195,7935,0812 ,70212,132-423,061638,769

Treasury stock

movement

16

-----(3,030)-(3,030)

Dividends paid to

shareholders

17

------(107,500)(107,500)

Balance at

31 March 202133,290453,568(12,062)2 ,70 21,7 87(35,389)2,385,3202,829,216

Balance at

1 April 202133,290453,568(12,062)2 ,70 21,7 87(35,389)2,385,3202,829,216

Profit for the year16------692,873692,873

Other comprehensive

income for the year

16

--27,553950(1,287)--27, 2 1 6

Total comprehensive

income for the year

16

--27,553950(1,287)-692,873720,089

Treasury stock

movement

16

-----(2 ,785)-(2 ,785)

Dividends paid to

shareholders

17

------(112,000)(112,000)

Balance at

31 March 202233,290453,56815,4913,652500(38,174)2,966,1933,434,520

RYMAN HEALTHCARE

92

The accompanying notes form part of these financial statements.
Consolidated balance sheet

AT 31 MARCH 2022

Notes20222021

$000

$000

Assets

Cash and cash equivalents928,30920,171

Trade and other receivables5671,463542,798

Inventory26,31226,738

Advances to employees2615,41511,141

Property, plant and equipment62,091,0011,658,583

Investment properties78,027,2676, 8 3 7, 278

Intangible assets851,68442,444

Derivative financial instruments201 9,574-

Deferred tax asset 435,05732,456

Total assets10,966,0829,171,609

Equity

Issued capital1533,29033,290

Reserves16435,037410,606

Retained earnings16f2,966,1932,385,320

Total equity3,434,5202,829,216

Liabilities

Trade and other payables10264,254106,072

Employee entitlements1139,81232,034

Revenue in advance81,25171,817

Derivative financial instruments2027, 2 9 128,611

Refundable accommodation deposits199,783113,666

Interest-bearing loans and borrowings122 ,576,7372,274,093

Occupancy advances (non-interest bearing) 144,286,4593,702,215

Lease liabilities1313,49413,885

Deferred tax liability 442 ,481-

Total liabilities 7,531,5626,342,393

Total equity and liabilities10,966,0829,171,609

Net tangible assets

Basic and diluted (cents per share)15676.65 57.4

ANNUAL REPORT 2022

93

The accompanying notes form part of these financial statements.
Consolidated statement of cash flows

FOR THE YEAR ENDED 31 MARCH 2022

Notes20222021

$000

$000

Operating activities

Receipts from residents231,396,1551,176,401

Interest received266229

Payments to suppliers and employees(4 35,170)(421,135)

Payments to residents(346,030)(323,810)

Interest paid(29,243)(18,566)

Net operating cash flows23585,978413,119

Investing activities

Purchase of property, plant and equipment(284,288)(219,416)

Purchase of intangible assets(14,346)(9,462)

Purchase of investment properties(434,395)(577,504)

Capitalised interest paid(50,006)(37,179)

Advances to employees(4, 275)(917)

Net investing cash flows(787,310)(844,478)

Financing activities

Drawdown/(repayment) of bank loans (net)57,6 74(36,712)

Proceeds from the Institutional Term Loan269,243-

Proceeds from the issue of retail bonds-150,000

Proceeds from US Private Placement notes-416,874

Dividends paid(112,000)(107,500)

Purchase of treasury stock (net)(2 ,785)(3,030)

Repayment of lease liabilities (2,662)(2 ,476)

Net financing cash flows209,470417,156

Net increase/(decrease) in cash and cash equivalents8,138(14,203)

Cash and cash equivalents at the beginning of the year20,17134,374

Cash and cash equivalents at the end of the year28,3092 0,1 7 1

RYMAN HEALTHCARE

94

Notes to the consolidated financial statements
FOR THE YEAR ENDED 31 MARCH 2022

The notes to the financial statements include information which is considered relevant and

material to assist the reader in understanding changes in the Group’s financial position

and performance. Information is considered relevant and material if:

• the amount is significant because of its size or nature

• it is important for understanding the results of the Group

• it helps explain changes in the Group’s business

• it relates to an aspect of the Group’s operations that is important to future performance.

STATEMENT OF COMPLIANCE

The financial statements presented are those of Ryman Healthcare Limited (the Company),

and its subsidiaries (the Group). Ryman Healthcare Limited is a profit-oriented entity

incorporated in New Zealand that develops, owns, and operates integrated retirement

villages, resthomes, and hospitals for the elderly within New Zealand and Australia.

Ryman Healthcare Limited is a Financial Markets Conduct reporting entity under the Financial

Reporting Act 2013 and the Financial Markets Conduct Act 2013. Its financial statements

comply with these Acts.

The consolidated financial statements have been prepared in line with Generally Accepted

Accounting Principles in New Zealand (NZ GAAP). The statements comply with New Zealand

equivalents to International Financial Reporting Standards (NZ IFRS) and other applicable

financial reporting standards.

The consolidated financial statements also comply with International Financial Reporting

Standards (IFRS).

BASIS OF PREPARATION

Accounting policies are selected and applied in a way that ensures the resulting financial

information satisfies the concepts of relevance and reliability, and the substance of the

underlying transactions or other events is reported.

The accounting policies set out below have been consistently applied in preparing the financial

statements for the year ended 31 March 2022. These policies have also been applied to the

comparative information presented for the year ended 31 March 2021.

The information is presented in thousands of New Zealand dollars (NZD).

All reference to AUD refers to Australian dollars.

All reference to USD refers to US dollars.

ANNUAL REPORT 2022

95

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

MEASUREMENT BASE

The Group follows the accounting principles recognised as appropriate for measuring and

reporting financial performance and financial position on a historical-cost basis, except when:

•certain property, plant and equipment is subject to revaluation (note 6)

•investment property is measured at fair value (note 7)

•certain financial assets and liabilities are measured at fair value (note 20).

CRITICAL JUDGEMENTS IN APPLYING ACCOUNTING POLICIES

In applying the Group’s accounting policies, management must make judgements, estimates,

and assumptions about the carrying value of assets and liabilities that are not readily apparent

from direct sources.

The estimates and associated assumptions are based on historical experience and various

other factors that are reasonable under the circumstances. The results form the basis of

making the judgements. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to

accounting estimates are recognised in the period in which the estimate is revised, if the

revision affects only that period. Revisions to accounting estimates are recognised in the

period of the revision and future periods, if the revision affects both current and future periods.

The following accounting policies and notes contain information about significant areas of

estimation uncertainty and critical judgements in applying accounting policies that have the

most significant effect on the amounts recognised in the financial statements.


Valuation of property, plant and equipment – policy (d) and note 6


V

aluation of investment property – policy (f) and note 7.

ADOPTING NEW AND AMENDED STANDARDS AND INTERPRETATIONS

In the current year, the Group adopted all mandatory new and amended standards

and interpretations.

STANDARDS AND INTERPRETATIONS ON ISSUE BUT NOT YET ADOPTED

We are not aware of any NZ IFRS Standards or Interpretations that have recently been issued

or amended that have not yet been adopted by the Group that would materially impact the

Group for the annual report period ending 31 March 2022.

RYMAN HEALTHCARE

96

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

COVID-19

The outbreak of COVID-19, declared by the World Health Organization as a global pandemic

on 11 March 2020, resulted in some uncertainty in both global and local markets in the years

following. New Zealand and Australia responded to the virus with strong public health

measures and a range of economic stimulus packages. Increased vaccination rates and a

move from an elimination to a minimisation strategy with the Omicron variant continues to

reduce the severity of the impact of the pandemic.

The Group continues to adapt its policies and procedures to operate in the conditions created

by COVID-19. Operating within the COVID-19 environment is now considered part of our

business-as-usual environment. The Group has assessed the impact of COVID-19 on the

financial statements. Key accounting judgements in respect of property, plant, and equipment

and investment property no longer have material uncertainties in respect of COVID.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following significant accounting policies have been adopted to prepare and present

the financial statements of the Group.

a. Basis of consolidation – acquisition method

The consolidated financial statements are prepared by combining the financial statements

of all the entities that comprise the Group, being the Company (the parent entity) and

its subsidiaries as defined in NZ IFRS 10 – Consolidated Financial Statements. A list of

subsidiaries appears in note 24 to the financial statements.

Consistent accounting policies are used to prepare and present the consolidated financial

statements. All significant inter-company transactions and balances are eliminated in full

on consolidation.

The financial statements of subsidiaries are prepared for the same reporting period as the

parent company, using consistent accounting policies.

Income and expenses for each subsidiary whose functional currency is not New Zealand

dollars are translated at exchange rates that approximate the rates at the actual dates of the

transactions. Assets and liabilities of such subsidiaries are translated at exchange rates at

balance date.

All resulting exchange differences are recognised in the foreign-currency translation reserve,

which is a separate component of equity.

ANNUAL REPORT 2022

97

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

b. Revenue recognition

The Group recognises revenue and income from the following major sources.

• Care fees

• Management fees

• Interest received.

Revenue and income are recognised as follows.

Care fees

Care facility and retirement-village service fees are linked to providing service on a specific

day (service date). Revenue from care and retirement-village service fees are recognised

on completion of the service date.

Management

fees

Residents of the Group’s independent-living units and serviced apartments pay a management

fee for the right to share in the use of the village centre and other common facilities. The

management fee is calculated as a percentage of the occupation-right agreement amount.

The fee accrues monthly, for a set period, based on the terms of individual contracts.

Management fees are recognised on a straight-line basis over the period of service.

The period is determined as being the greater of the expected period of tenure, or the

contractual right to management fees.

The expected periods of tenure, based on historical experience across our villages,

are estimated to be 7 years for independent units and 3 to 4 years for serviced units.

The estimated expected periods of tenure are unchanged from last year.

The timing of when management fees are recognised is an accounting estimate.

Historical experience across all villages is used in determining periods of tenure.

Interest

received

Interest income is recognised in the income statement as it accrues, using the effective

interest method.

c. Borrowing costs

Borrowing costs directly attributable to the acquisition, construction, or production of

qualifying assets (assets that take a substantial period of time to get ready for their intended

use) are added to the cost of those assets until the assets are substantially ready for use.

All other borrowing costs are recognised in profit and loss in the period in which they are incurred.

RYMAN HEALTHCARE

98

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

d. Property, plant and equipment

Property, plant and equipment comprises completed care facilities, corporate assets and land

(including long-term leases of land), and care facilities under development.

All property, plant and equipment is initially recorded at cost. Typically, these costs include the

cost of land, materials, wages, and interest incurred during the period required to complete

and prepare the asset for its intended use.

Following initial recognition at cost, completed care-facility land and buildings are carried at

a revalued amount, which is the fair value at the date of the revaluation, less any subsequent

accumulated depreciation on buildings and accumulated impairment losses.

Independent valuations are performed with sufficient regularity to ensure that the carrying

amount does not differ materially from the asset’s fair value at the balance-sheet date.

Any revaluation surplus is recorded in other comprehensive income and credited to the

asset revaluation reserve included in the equity section of the balance sheet, unless it reverses

a revaluation decrease of the same asset previously recognised in the income statement.

In this case, the increase is credited to the income statement to the extent of the decrease

previously charged.

Any revaluation deficit is recognised in the income statement unless it directly offsets

a previous surplus of the same asset in the asset revaluation reserve, in which case the

revaluation deficit is recorded in other comprehensive income.

In addition, any accumulated depreciation at the revaluation date is eliminated against the

gross carrying amount of the asset, and the net amount is restated to the revalued amount

of the asset.

On disposal, any revaluation reserve relating to the particular asset being sold is transferred

to retained earnings.

An item of property, plant and equipment is derecognised on disposal or when no future

economic benefits are expected to arise from the continued use of the asset.

Any gain or loss arising on disposal of the asset (calculated as the difference between the net

disposal proceeds and the carrying amount of the item) is included in the income statement

in the period the item is derecognised.

ANNUAL REPORT 2022

99

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

f. Investment properties

Investment properties include land and buildings (including long-term leases of land),

equipment and furnishings relating to retirement-village units and community facilities,

including units and facilities under development. They are intended to be held for the long

term to earn rental income and for capital appreciation.

Retirement-village units and community facilities are revalued on a semi-annual basis and

restated to fair value as determined by the Directors having taken into consideration the

valuation report produced by the independent registered valuer and the requirement of


NZ IFRS 13 – Fair Value Measurement to assume that market participants act in their economic

b

est interest. Any change in fair value is taken to the income statement. The fair value is

determined using discounted cash-flow methodology.

Rental income from investment properties, being the management fee and retirement-village

service fees, is accounted for in line with accounting policy (b).

e.Depreciation

Depreciation is provided on all property, plant and equipment, other than freehold land,

at straight-line (SL) rates calculated to allocate the asset’s cost or valuation, less estimated

residual value, over their estimated useful lives, starting from the time the assets are ready

for use, as follows.


Buildings 2% SL

•Plant and equipment 10–20% SL

•Furniture and fittings20% SL


Motor vehicles20% SL

The estimated useful lives, residual value and depreciation method are reviewed at the

end of each reporting period, with the effect of any changes in estimate accounted for on

a prospective basis.

No depreciation is provided for investment properties.

Right-of-use assets relating to leases are depreciated on a straight-line basis over the term

of the lease.

RYMAN HEALTHCARE

100

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

g. Intangible assets

Expenditure on research activities is recognised as an expense in the period in which

it is incurred.

An internally generated intangible software asset arising from development (or from the

development phase of an internal project) is only recognised if all the following criteria have

been demonstrated.

• It is technically feasible to complete the intangible asset so that it is available for use or sale.

• The Group intends to complete the intangible asset and use or sell it.

• The intangible asset can be used or sold.

• Probable future economic benefits of the intangible asset can be generated.

• Adequate technical, financial, and other resources are available to complete the

development and use or sell the intangible asset.

• The expenditure attributable to the intangible asset can be measured during its development.

The amount initially recognised for internally generated intangible assets is the sum of the

expenditure incurred from the date when the intangible asset first meets the recognition

criteria listed above. Where no internally generated intangible asset can be recognised,

development expenditure is recognised in profit or loss in the period in which it is incurred.

After initial recognition, internally generated intangible assets are reported at cost less

accumulated amortisation and accumulated impairment losses, on the same basis as

intangible assets that are acquired separately.

Internally generated intangible assets are amortised using the straight-line method at a rate

of 10 percent from the point at which the asset is ready for use. Amortisation is recognised in

profit or loss.

ANNUAL REPORT 2022

101

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

i. Leases

Group as

a lessee

Apart from short-term or low-value assets, leases are included on the balance sheet through the

recognition of right-of-use assets and associated lease liabilities. Right-of-use assets related to

buildings and plant and equipment are presented within property, plant and equipment. Long-

term leases of land are recognised within property, plant and equipment and investment property.

At inception of the lease a lease liability is calculated based on the present value of the

remaining cash flows, discounted using the Group’s incremental borrowing rate. Subsequently,

the lease liability is adjusted for interest and lease payments, as well as the impact of lease

modifications. The right-of-use asset is initially measured at the value of the initial lease

liability, and subsequently measured at cost less accumulated depreciation, adjusted for

any remeasurement of the lease liability.

Where a lease contract contains both lease and non-lease components (for example, tower

cranes), the Group does not separate non-lease components from lease components, and

instead accounts for the whole contract as a lease.

h. Impairment of assets

At each interim and annual balance-sheet date, the Group reviews the carrying amounts of

its assets to determine whether there is any indication that those assets have suffered an

impairment loss. If such an indication exists, the recoverable amount of the asset is estimated

to determine the extent of any impairment loss.

Where the asset does not generate cash flows that are independent from other assets,

the Group estimates the recoverable amount of the cash-generating unit to which the

asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing

value in use, the estimated future cash flows are discounted to their present value. The Group

uses a discount rate that reflects current market assessments of the time value of money

and the risks specific to the asset, for which the estimates of future cash flows have not

been adjusted.

If the recoverable amount of an asset (cash-generating unit) is estimated to be less than its

carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its

recoverable amount.

An impairment loss is immediately recognised as an expense, unless the asset is carried

at fair value. In this case, the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset

(cash-generating unit) is increased to the revised estimate of its recoverable amount.

However, this is only to the extent that the increased carrying amount does not exceed

the carrying amount that would have been determined had no impairment loss been

recognised for the asset (cash-generating unit) in prior years.

A reversal of an impairment loss is immediately recognised as income, unless the asset

is carried at fair value. In this case, the reversal of the impairment loss is treated as a

revaluation increase.

RYMAN HEALTHCARE

102

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

Cash and cash

equivalents

Group as

a lessor

The Group acts as a lessor under occupation right agreements with village residents.

The assets leased by the Group as a lessor are classified as investment properties and are

accounted for in line with accounting policy (f). Lease income on occupation right agreements

is generated in the form of deferred management fees and is accounted for in line with

accounting policy (b).

Cash and cash equivalents comprise cash on hand, cash in banks and on-demand deposits,

and other short-term, highly liquid investments readily convertible to a known amount of cash

and subject to an insignificant risk of changes in value. This includes all call borrowing, such as

bank overdrafts, used by the Group as part of its day-to-day cash management.

Financial

assets at

amortised

costs

Trade receivables are held to collect contractual cash flows. The cash flows are the payment

of principal and interest.

Trade receivables are measured at amortised cost, less any impairment. This is equivalent

to fair value, being the receivable face (or nominal) value, less appropriate allowances for

estimated irrecoverable amounts.

The allowance recognised is the lifetime expected credit losses based on an assessment of

each individual debtor. It is estimated based on the Group’s historical credit loss experience

and general economic conditions. Expected credit loss represents the expected credit losses

that will result from all possible default events over the expected life of the debtor.

Trade receivables are written off when there is no realistic chance of recovery.

j. Revenue in advance

Revenue in advance represents those amounts by which the management fees over the

contractual period exceed recognition of the management fee based on expected tenure.

k. Financial instruments

Financial assets and financial liabilities are recognised on the Group’s balance sheet when the

Group becomes party to the contractual provisions of the instrument.

The Group calculates its incremental borrowing rate with reference to the external

borrowing facilities available to the Group. The incremental borrowing rate is used to

measure lease liabilities.

Depreciation and finance costs associated with right-of-use assets and lease liabilities

associated with equipment used in the construction of assets are capitalised as a cost of

constructing the asset.

The lease payment for short-term leases and leases of low-value assets is recognised

in the profit and loss over the lease term.

ANNUAL REPORT 2022

103

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

Trade and

other payables

Trade and other payables are measured at amortised cost. This is equivalent to the face

(or nominal) value of payables, which is assumed to approximate their fair value.

Interest-bearing

loans and


borrowings

Bank loans and borrowings are initially recorded at fair value, less directly attributable

transaction costs. After initial recognition, loans and borrowings are measured at amortised

cost. Any differences between the initial amount recognised and the redemption value is

recognised in profit and loss using the effective interest-rate method.

Fair value

estimation

The fair value of financial assets and financial liabilities must be estimated for recognition

and measurement, or for disclosure purposes.

The face (or nominal) value less estimated credit adjustments of trade receivables and

payables is assumed to approximate their fair values.

Occupancy

advances

Occupation agreements confer to residents the right of occupancy of the retirement-village

unit for life, or until the resident terminates the agreement.

Amounts payable under occupation agreements (occupancy advances) are non-interest

bearing and recorded as a liability in the balance sheet, net of management fees and resident

loans receivable. The resident-occupancy advance is initially recognised at fair value and later

at amortised cost.

As the resident may terminate their occupancy with limited notice, and the occupancy

advance is non-interest bearing, the occupancy advance has demand features and so is

carried at face value, which is the original advance received.

The advance, net of management fee, is repayable following both the termination of the

occupation agreement and the settlement of a new occupancy advance for the same

retirement-village unit.

Refundable

accommodation

deposits

Refundable accommodation deposits relate to deposits held on behalf of residents who

reside in rooms in the care centres in Australia and New Zealand. Refundable accommodation

deposits confer to residents the right of occupancy of the room for life, or until the resident

terminates the agreement.

Amounts payable under refundable accommodation deposits are non-interest bearing and

recorded as a liability in the balance sheet.

As the resident may terminate their occupancy with limited notice, and the refundable

accommodation deposit is non-interest bearing, the refundable accommodation deposit

has demand features and so is carried at face value, which is the original deposit received.

The deposit is repayable following the termination of the right to occupy.

RYMAN HEALTHCARE

104

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

Hedges of a net investment in a foreign operation, including a hedge of a monetary item that

is accounted for as part of the net investment, are accounted for in two ways. Gains or losses

relating to the effective portion of the hedge are recognised in other comprehensive income.


Any gains or losses relating to the ineffective portion of the hedge are recognised in profit or loss.

Hedge

accounting

The Group designates certain derivatives as hedging instruments. At the start of the hedge

relationship, the Group documents the relationship between the hedging instrument and the

hedged item. Risk management objectives and strategies for undertaking hedge transactions

are documented. The Group also documents at the start and on an ongoing basis whether

the hedging instrument is expected to be effective. Hedge accounting is discontinued when

the hedge instrument expires or is sold, terminated, exercised or no longer qualifies for

hedge accounting.

Derivative

financial

instruments

The Group uses derivative financial instruments to manage cash flow, interest rate and foreign

currency risk.

Interest-rate swaps and cross-currency interest-rate swaps (CCIRS) are initially recognised

at fair value on the date a contract is entered into and remeasured to their fair value at each

reporting date.

When Group’s swap arrangements meet the requirements of cash flow hedge accounting,

changes in the fair value of the swaps are recognised in other comprehensive income and

accumulated as a separate component of equity. Amounts deferred in equity are recycled

in profit or loss in the periods when the hedged item is recognised in profit.

When Group’s swap arrangements meet the requirements of fair value hedge accounting,

changes in the fair value of the swaps are taken directly to the income statement for the year,

to offset the change in fair value of the hedged item also recorded in the income statement.

Changes in the fair value of the cost to convert foreign currency to New Zealand dollars (NZD)

of cross-currency interest-rate swaps are separately accounted for as a cost of hedging and

recognised within a new reserve within equity (cost of hedging reserve).

l. Employee entitlements

A liability for benefits accruing to employees for wages and salaries, annual leave, and

long-service leave is accrued and recognised in the balance sheet when it is probable that

settlement will be required, and the liabilities are capable of being measured reliably. The

liability is equal to the present value of the estimated future cash outflows as a result of

employee services provided at balance date.

m. Taxation

Income tax on the profit or loss for the year comprises current and deferred tax. Income tax

is recognised in the income statement except when it relates to items recognised in other

comprehensive income or directly in equity. In this case, it is recognised in other comprehensive

income or in equity.

Hedges

of a net

investment

ANNUAL REPORT 2022

105

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

n. Treasury stock

Shares purchased on market under the leadership share scheme are treated as treasury stock

on acquisition at cost. On vesting to the employee, treasury stock shares are credited to equity

and an employee advance is recorded initially at fair value and later at amortised cost.

Any loss on disposal by the Company (for example, when the employee elects not to take full

responsibility for the loan or leaves before the end of the 3-year restrictive period) accrues to

the Company and is taken directly against equity.

o. GST

Revenues, expenses, assets, and liabilities are recognised net of the amount of Goods and

Services Tax (GST) except when:

• the GST incurred on a purchase of goods and services is not recoverable from the

taxation authority

• receivables and payables are stated with the amount of GST included.

Deferred tax

Deferred tax is provided using the comprehensive balance-sheet liability method. This method

provides for temporary differences between the carrying amount of assets and liabilities for

financial reporting purposes and the amounts used for taxation. Deferred tax is not provided

for on:

• non-depreciating assets (land) included within property, plant and equipment, and

investment properties; and

• temporary differences arising from the initial recognition of assets or liabilities that affects

neither accounting profit nor taxable profit, and does not give rise to equal taxable and

deductible temporary differences.

The amount of deferred tax provided is based on the way the carrying amount of assets and

liabilities are expected to be realised and settled. The tax rates used are those expected to

apply in the period of settlement, based on tax rates enacted or substantively enacted.

A deferred tax asset is recognised only when it is probable that future taxable profits will be

available, and against which the asset can be used. Deferred tax assets are reduced if it is no

longer probable that the related tax benefit will be realised.

Deferred tax assets and liabilities are offset when they relate to income taxes levied by the

same taxation authority and the Group intends to settle current tax assets and liabilities on

a net basis.

Current tax

Current tax is the expected tax payable on the taxable income for the year, using tax rates

enacted or substantively enacted at the balance-sheet date, and any adjustment to tax

payable for previous years. Current tax for current and prior periods is recognised as a liability

(or asset) if it is unpaid (or refundable).

RYMAN HEALTHCARE

106

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

p.Statement of cash flows

The statement of cash flows is prepared exclusive of GST. This is consistent with the method

used in the income statement.

Cash and cash equivalents comprise:

• cash on hand and demand deposits


other short-term, highly liquid investments.

Short-term, highly liquid investments are investments that are readily convertible to a known

amount of cash and are subject to an insignificant risk of changes in value. These investments

include all call borrowing such as bank overdrafts used by the Group as part of its day-to-day

cash management.

Operating activities represent all transactions and other events that are not investing or

financing activities and includes receipts and repayments of occupancy advances.

Investing activities are those activities relating to the acquisition and disposal of investments

and any other property, plant and equipment, or investment properties.

Financing activities are those activities relating to changes in the equity and debt capital

structure

of the Group and those activities relating to the cost of servicing the Company’s equity capital.

q. Foreign-currency translation

Functional and

presentation

currency

Both the functional and presentation currency of Ryman Healthcare Limited and its

New Zealand subsidiaries is New Zealand dollars ($). The functional currency for its Australian

subsidiaries is Australian dollars (AUD).

Transactions

and balances

Transactions in foreign currencies are initially recorded in the functional currency by applying the

exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated

in foreign currencies are retranslated at the rate of exchange ruling at the balance-sheet date.

All exchange differences relating to the following two items are recognised in other

comprehensive income and accumulated in reserves.


The effective portion of a hedge of a net investment in foreign operations

• Differences arising on translation of a foreign operation.

Non-monetary items that are measured at historical cost in a foreign currency are translated

using the exchange rate as at the date of the initial transaction. Non-monetary items carried at

fair value that are denominated in foreign currencies are retranslated at the rates at the date

when the fair value was determined.

The net amount of GST recoverable from, or payable to, the taxation authority is included

as part of the receivables or payables in the balance sheet.

Commitments and contingencies are disclosed net of the amount of GST recoverable from,

or payable to, the taxation authority.

ANNUAL REPORT 2022

107

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

1. OPERATING EXPENSES

20222021

$000

$000

Employee costs (see below)305,759264,400

Property-related expenses64,04454,911

Other operating costs (see below)96,43575,995

Total operating expenses466,238395,306

Employee costs and other operating costs include:

Post-employment benefits (KiwiSaver/Superannuation)10,3338,842

Auditor’s remuneration to Deloitte Limited comprises:

• Audit of financial statements452358

• Australia aged-care reporting87

Directors’ fees (note 19)1,3651,094

Donations^517433

^ No donations have been made to any political party (2021: $Nil).

RYMAN HEALTHCARE

108

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

2. DEPRECIATION AND AMORTISATION EXPENSE

20222021

$000

$000

Depreciation (note 6)

• Buildings9,1668,353

• Plant and equipment12,84910,598

• Furniture and fittings4,4754,391

• Motor vehicles1,4401,413

• Right-of-use assets2,6622 ,476

30,59227, 2 3 1

Amortisation (note 8)

• Software5,1065,137

5,1065,137

Total35,69832,368

3. FINANCE COSTS

20222021

$000

$000

Total interest paid on loans and borrowings (including related fees)59,94550,816

Release of cash-flow hedge reserve (note 16)20,5235,354

Amount of interest capitalised (note 6 and note 8)(50,006)(37,179)

Net interest expense on borrowings30,46218,991

Interest on lease liabilities (note 13)2023 74

Total finance costs30,66419,365

ANNUAL REPORT 2022

109

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

4. INCOME TAX

a. Income tax recognised in income statement

20222021

$000

$000

Tax expense comprises:

Current tax expense--

Deferred tax expense/(credit)29,209(12,561)

Total income tax expense/(credit)29,209(12,561)

The income tax expense on pre-tax accounting profit from operations reconciles to the income tax expense

in the financial statements as follows.

2022202220212021

$000%$000

%

Profit before income tax expense 722,082410,500

Income tax expense calculated at 28%202,18328.0%114,94028.0%

Tax effect of:

Non-taxable income(208,894)(28.9)%(116,717)(28.4)%

Property temporary differences69,5979.3%15,5023.8%

Tax losses recognised(59,636)(8.0)%(45,122)(11.0)%

Other25,9593.5%18,8364.6%

Total tax expense/(credit)29,2093.9%(12,561)(3.0)%

The tax rate used in the above reconciliation is the corporate tax rate of 28 percent (2021: 28 percent)

payable by New Zealand corporate entities on taxable profits under New Zealand tax law. The corporate

tax rate in Australia is 30 percent (2021: 30 percent).

Non-taxable income arises principally from the fair value movement of investment property.

During the period, the Group revised its approach for calculating deferred tax on investment properties

and its estimate of the useful life of buildings included within investment properties and property, plant

and equipment. As a result of this change in accounting estimate, the Group recognised an additional

deferred tax expense and deferred tax liability of $45.3 million.

Total Group tax losses available in New Zealand and Australia amounted to $567.6 million

(2021: $410.7 million) and AU$156.0 million (2021: AU$105.8 million), respectively. Recognition

of the deferred tax asset is based on expected taxable earnings in future periods. There are no

unrecognised tax losses in New Zealand (2021: $Nil) and Australia (2021: AU$Nil).

RYMAN HEALTHCARE

110

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

4.INCOME TAX (CONTINUED)

b.Deferred tax asset/liability

Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance

$000$000$000

$000

2022

Property, plant and equipment(43,226)(16,706)(26)(59,958)

Investment properties(15,563)(52,891)455(67,999)

Deferred management fee (68,892)(20,619)(30)(89,541)

Derivative financial instruments3,640-(11,315)( 7,675 )

Other6,9521,371-8,323

Tax loss carry-forwards recognised149,54559,636245209,426

Total deferred tax asset/(liability)32,456(29,209)(10,671)(7,424)

Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance

$000$000$000

$000

2021

Property, plant and equipment

(34,894)(8,292)(40)(43,226)

Investment properties(7,845)(7,210)(508)(15,563)

Deferred management fee(49,623)(18,868)(401)(68,892)

Derivative financial instruments6,667-(3,027)3,640

Other5,1321,809116,952

Tax loss carry-forwards recognised103,01845,1221,405149,545

Total deferred tax asset/(liability)22,45512,561(2,560)32,456

Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation

authority and the Group intends to settle current tax assets and liabilities on a net basis.

The net deferred tax liability of $7.4 million as at 31 March 2022 is reflected in the statement of financial

position as deferred tax asset of $35.1 million and deferred tax liability of $42.5 million. The deferred

tax asset relates to the Australian subsidiaries and the deferred tax liability relates to the New Zealand

group companies.

ANNUAL REPORT 2022

111

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

4. INCOME TAX (CONTINUED)

c. Imputation credit memorandum account

20222021

$000

$000

Closing balance87494

Imputation credits available directly and indirectly

to shareholders of the parent company, through:

• parent company870-

• subsidiaries494

Closing balance87494

5. TRADE AND OTHER RECEIVABLES

20222021

$000

$000

Trade debtors 654,769498,695

Other receivables16,69444,103

Total trade and other receivables671,463542,798

Debtors are non-interest bearing, although the Group has the right to charge interest on overdue settlements of

occupancy advances or overdue care fees. Debtors principally comprise amounts due for occupancy advances

and care fees.

Occupancy advances are payable by residents on occupation of a retirement-village unit. The receivable for

the occupancy advance is recognised when a legally binding contract with the resident is in place. At the same

time as recognising the occupancy advance receivable the Group recognises the corresponding occupancy

advance liability.

Care fees are received from residents (payable 4-weekly in advance) and various government agencies.

Government-agency payment terms vary but are typically paid fortnightly in arrears for care services provided

to residents.

There is no significant concentration of credit risk as trade debtors are either individual residents or government

agencies. No changes have been made in the techniques or significant assumptions used in determining expected

credit losses during the reporting period.

RYMAN HEALTHCARE

112

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

6. PROPERTY, PLANT AND EQUIPMENT

Freehold

land at

valuation

Buildings

at

valuation

Property

under

development

at cost

Plant and

equipment

at cost

Furniture

and fittings

at cost

Motor

vehicles

at cost

Right-of-

use

assetsTotal

$000$000$000$000$000$000$000$000

2022

Gross carrying amount

Balance at 1 April 2021540,259415,577599,746126,58156,34514,95428,2841,781,746

Additions1,0476,251435,34913,5821,7521,8618,193468,035

Net foreign-currency

exchange difference(938)(390)(2 ,445)(56)(45)(15)(50)(3,939)

Transfer from property

under development24,95081,472(115,117)4,3534,342---

Transfer (to)/from

investment property--4,816----4,816

Disposals--------

Balance at 31 March 2022565,318502,910922,349144,46062,39416,80036,4272,250,658

Accumulated depreciation

Balance at 1 April 2021-(1,079)-(50,080)(47,6 2 6 )(9,714)(14,664)(123,163)

Depreciation-(9,166)-(12,849)(4,475)(1,440)(2,662)(30,592)

Depreciation capitalised

to property under

development------(5,902)(5,902)

Balance at 31 March 2022-(10,245)-(62,929)(52,101)(11,154)(23,228)(159,657)

Total book value565,318492,665922,34981,53110,2935,64613,1992,091,001

ANNUAL REPORT 2022

113

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

6. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Freehold

land at

valuation

Buildings

at

valuation

Property

under

development

at cost

Plant and

equipment

at cost

Furniture

and fittings

at cost

Motor

vehicles

at cost

Right-of-

use

assetsTotal

$000$000$000$000$000$000$000$000

2021

Gross carrying amount

Balance at 1 April 2020328,972391,336584,810100,85252,03813,84920,6011,492,458

Additions1497,906117,09122,9611,2321,0587,4 1 1157,808

Net foreign-currency

exchange difference2 ,6112,27516,7051901464727222,246

Transfer from property

under development12,73431,118(49,359)2,5782,929---

Transfer (to)/from

investment property--(31,429)----(31,429)

Disposals--(38,072)----(38,072)

Revaluation195,793(17,058)-----178,735

Balance at 31 March 2021540,259415,577599,746126,58156,34514,95428,2841,7 8 1,74 6

Accumulated depreciation

Balance at 1 April 2020-(9,784)-(39,482)(43,235)(8,301)(5,584)(106,386)

Depreciation-(8,353)-(10,598)(4,391)(1,413)(2 ,476)(27, 2 3 1 )

Depreciation capitalised

to property under

development------(6,604)(6,604)

Revaluation-17,058-----17,058

Balance at 31 March 2021-(1,079)-(50,080)(47,6 2 6 )(9,7 1 4 )(14,664)(123,163)

Total book value540,259414,498599,74676,5018,7195,24013,6201,658,583

All completed resthomes and hospitals included within the definition of freehold land and buildings were

revalued to fair value based on an independent valuation report prepared by registered valuers, CBRE Limited,

at 31 March 2021, in line with NZ IFRS 13 – Fair Value Measurement. These revaluations are undertaken every

2 years, unless there is sustained market evidence of a significant change in fair value.

The valuers used multiple valuation techniques to estimate and determine fair value. The valuer made key

assumptions that include capitalisation of earnings (using capitalisation rates ranging from 11.0 percent to

15.0 percent), together with observed transactional evidence of the market value per care bed (ranging from

$70,000 to $230,000 per care bed).

As the fair value of land and buildings is determined using inputs that are unobservable, the Group has

categorised property, plant and equipment as Level 3 under the fair-value hierarchy in line with NZ IFRS 13

– Fair Value Measurement.

The significant unobservable inputs used in the fair-value measurement of the Group’s freehold land and

buildings are the capitalisation rate and the market value per care bed.

RYMAN HEALTHCARE

114

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

6. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

As the valuer uses several valuation techniques, a significant decrease in the capitalisation rate could but may

not necessarily result in a significantly higher fair-value measurement. Conversely, a significant increase in the

capitalisation rate could but may not necessarily result in a significantly lower fair-value measurement.

A significant increase in the market value per care bed could but may not necessarily result in a significantly

higher fair-value measurement. Conversely, a significant decrease in the market value per care bed could but

may not necessarily result in a significantly lower fair-value measurement.

Property under development includes land held pending the development of a retirement village amounting

to $636.4 million (2021: $343.4 million) and is valued at cost.

Interest for the Group of $49.0 million (2021: $36.4 million) has been capitalised during the period of construction

in the current year. The weighted-average capitalisation rate on funds borrowed is 3.45 percent per annum

(2021: 2.72 percent per annum).

The assets shown at cost are care-facility assets under development, plant and equipment, furniture and fittings,

and motor vehicles, plus additions since the last valuation.

The carrying amount at which each revalued class of property, plant and equipment would have been carried

had the assets been measured under historical cost is shown below.

Freehold landBuildingsTotal

$000$000

$000

Carrying amount (at cost)

Carrying amount at 31 March 2022128,789491,357620,146

Carrying amount (at cost)

Carrying amount at 31 March 2021103,730414,268517,998

The completed resthomes and hospitals were last valued at 31 March 2021. The Group has considered the fair

value of these assets and determined that there is no indication that the carrying value of the assets is materially

different from fair value at 31 March 2022. In reaching this conclusion, the Group has considered capitalisation

rates, market evidence of comparable sales, market demand, occupancy and earnings per bed.

Right-of-use assets

Included within property, plant and equipment are the right-of-use assets relating to leases.

Buildings

Plant and

equipmentTotal

$000$000

$000

Balance at 1 April 2021

10,5213,09913,620

Additions6587,5358,193

Net foreign-currency exchange difference(50)-(50)

Depreciation(2,662)-(2,662)

Depreciation capitalised to property under development(158)( 5,74 4 )(5,902)

Balance at 31 March 20228,3094,89013,199

ANNUAL REPORT 2022

115

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

6.PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Disposal of land

No land was disposed of in 2022. During 2021, the Group sold the land in Coburg, Melbourne. The sale led to a loss

on disposal of $15.1 million, which was recognised in the income statement.

7.INVESTMENT PROPERTIES

20222021

$000

$000

At fair value

Balance at beginning of financial year6, 8 3 7, 2785,760,060

Additions452,068624,926

Fair-value movement:

Realised fair-value movement:


new retirement-village units110,681108,377

• existing retirement-village units168,071107,317

278,752215,694

Unrealised fair-value movement4 67,1 3 3201,153

745,885416,847

Net foreign-currency exchange differences(7,964)35,445

Net movement for the year1,189,9891 ,07 7, 2 1 8

Balance at end of financial year8,027,2676 , 8 3 7, 2 7 8

The realised fair-value movement arises from the sale and resale of rights to occupy to residents. Investment

properties are not depreciated and are fair valued. As the fair value of investment property is determined using

inputs that are unobservable, the Group has categorised investment property as Level 3 under the fair-value

hierarchy in line with NZ IFRS 13 – Fair Value Measurement. NZ IFRS 13 requires that the inputs are consistent with

the characteristics of the asset that a market participant would take into account in a transaction for the asset.

The carrying value of completed investment property is the fair value as determined by the Directors having taken

into consideration the valuation report produced by the independent registered valuer, CBRE Limited, at 31 March

2022. This report combines discounted future cash flows and occupancy advances received from residents for

retirement-village units that are complete, or nearing completion, for which there is an agreement to occupy. From

time-to-time the Directors obtain additional independent valuations for consideration in their determination of

investment property carrying value.

Key assumptions used in determining the fair value and the sensitivity of the valuation to these assumptions are

detailed below.

The carrying amount of completed investment properties as determined by the Directors is based on the

independent valuers report and also includes occupancy advances received from residents, adjusted for accrued

deferred management fees and revenue in advance.

RYMAN HEALTHCARE

116

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

7.INVESTMENT PROPERTIES (CONTINUED)

Total investment property carrying value included in the balance sheet also includes, at cost, investment property

work in progress and retirement-village units that are complete or nearing completion for which there is no

agreement to occupy in place.

Key assumptions

The valuer used significant assumptions that include growth rate (ranging from 0.50 percent to 4.24 percent

nominal) (2021: 0.50 percent to 4.20 percent) and discount rate (ranging from 12.00 percent to 16.00 percent)

(2021: 12.00 percent to 16.50 percent).

Sensitivity

A 0.5 percent decrease in the 5-year plus growth rate would result in a $194.7 million lower fair-value

measurement. Conversely, a 0.5 percent increase in the 5-year plus growth rate would result in a

$214.9 million higher fair-value measurement.

A 0.5 percent decrease in the discount rate would result in a $125.7 million higher fair-value measurement.

Conversely, a 0.5 percent increase in the discount rate would result in a $115.8 million lower fair-value

measurement.

Other inputs used in the fair-value measurement of the Group’s investment property portfolio include the average

age of residents and the occupancy period. A significant increase in the average age of entry of residents or

a decrease in the occupancy period would result in a significantly higher fair-value measurement. Conversely,

a significant decrease in the average age of entry of residents or increase in the occupancy period would result

in a significantly lower fair-value measurement.

Work in progress

Investment property includes investment property work in progress of $494.7 million (2021: $653.0 million),

which has been valued at cost. The Directors have determined that for work in progress cost represents fair

value. No independent valuation of investment property work in progress is obtained.

Operating expenses

Direct operating expenses arising from investment property that generated income from management fees

during the period amounted to $13.1 million (2021: $7.9 million). All investment property generated income from

management fees during the period for the Group, except for investment property work in progress.

Security

Residents make interest-free advances (occupancy advances) to the retirement villages in exchange for the right

to occupy retirement-village units. Under the terms of the occupancy agreement, the resident receives a unit title

for life and a first mortgage over the residual interest for security purposes, or a first mortgage is held over the

individual title by the statutory supervisor.

ANNUAL REPORT 2022

117

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

8. INTANGIBLE ASSETS

20222021

$000

$000

Gross carrying amount

Opening balance55,31845,856

Additions14,3469,462

Closing balance69,66455,318

Accumulated amortisation

Opening balance(12,874)(7,737)

Amortisation (note 2)(5,106)(5,137)

Closing balance(17,980)(12,874)

Total book value51,68442,444

All intangible assets relate solely to internally generated software.

Interest for the Group of $1.0 million (2021: $0.8 million) has been capitalised to intangible assets during

the current year. The weighted-average capitalisation rate on funds borrowed is 3.45 percent per annum

(2021: 2.72 percent per annum).

9. CASH AND CASH EQUIVALENTS

The Group has an arrangement with ANZ that on a nightly basis a sweep is performed across all transactional

bank accounts. This consolidates all transactional bank accounts into a single account.

There is a right to offset cash balances against bank debt documented in the Group’s facility agreement.

The Group has access to an overdraft facility. The bank overdraft facilities are secured by a general security

agreement and mortgages over the freehold land and buildings of the Group in the same manner as the bank

loans (note 12). Interest would be payable at the 3-month BKBM rate, plus a specified margin. The interest rate

on all overdraft facilities at 31 March 2022 was 9.65 percent (2021: 8.90 percent).

10. TRADE AND OTHER PAYABLES

20222021

$000

$000

Trade payables78,94672,366

Other payables185,30833,706

Total trade and other payables264,254106,072

Trade payables are typically paid within 30 days of the invoice date or on the 20th of the month following the

invoice date. Other payables at 31 March 2022 includes $174.4 million for the purchase of land (2021: $26.0 million).

RYMAN HEALTHCARE

118

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

11. EMPLOYEE ENTITLEMENTS

20222021

$000

$000

Holiday-pay accrual and other benefits39,81232,034

12. INTEREST-BEARING LOANS AND BORROWINGS

Interest-bearing loans and borrowings include secured bank loans, institutional term loan, unsubordinated

fixed-rate retail bonds and USPP notes.

20222021

$000$000

Bank loans12a1,780,6191,728,018

Institutional term loan (ITL)12b269,658-

Retail bonds – RYM01012c150,000150,000

USPP notes - using contracted fixed USD FX rate12d416,557416,874

2,616,8342,294,892

FX movement of USD USPP notes12d14,61511,862

Total loans and borrowings at face value2,631,4492,306,754

Issue costs for the ITL capitalised12b(876)-

Issue costs for the retail bond capitalised12c(2,605)(3,139)

Issue costs for the USPP capitalised12d(2,170)(2,049)

Total loans and borrowings at amortised cost2,625,7982,301,566

Revaluation of ITL debt in fair-value hedge relationship12b(5,690)-

Revaluation of USPP debt in fair-value hedge relationship12d(43,371)(27,473 )

Total loans and borrowings2 ,576,7 3 72,274,093

a. Bank loans (secured)

20222021

$000

$000

Bank loans (secured) – NZD1 , 2 74 ,74 01,162,000

Bank loans (secured) – AUD in NZD505,879566,018

Total bank loans (secured) 1,780,6191,728,018

Less cash and cash equivalents (note 9)(28,309)(20,171)

Net bank loans1,752,3101,707,847

Less than 1 year-25,000

Within 1–5 years1,780,6191,703,018

Total bank loans (secured)1,780,6191,728,018

Average interest rates for bank loans – NZD3.94%2 .71%

Average interest rates for bank loans – AUD2.37%1.86%

The bank loan facilities have varying maturity dates through to May 2027 (2021: April 2025). The average

interest rates disclosed above exclude the impact of interest-rate swap agreements described in note 20.

ANNUAL REPORT 2022

119

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

12.INTEREST-BEARING LOANS AND BORROWINGS (CONTINUED)

b.Institutional Term Loan (secured)

20222021

$000

$000

Institutional Term Loan269,658-

Total ITL at face value 269,658-

Issue costs for the ITL capitalised

Opening balance--

Capitalised during the year(1,000)-

Amortised during the year124-

(876)-

Total ITL at amortised cost268,782-

Revaluation of debt in fair-value hedge relationship(5,690)-

Total Institutional Term Loan263,092-

During the year, the Group entered into an AU$250.0 million 7-year institutional term loan which matures

in May 2028. The average interest rate for the loan is 3.84 percent.

c. Retail bonds (secured)

20222021

$000

$000

Retail bond – RYM010150,000150,000

Total retail bonds at face value 150,000150,000

Issue costs for the retail bond capitalised

Opening balance(3,139)-

Capitalised during the year(22)(3,297)

Amortised during the year556158

(2,605)(3 ,1 3 9 )

Total retail bonds at amortised cost147,395146,861

The Group issued a retail bond for $150.0 million in December 2020. The retail bond has a maturity date

of 18 December 2026 and is listed on the NZX Debt Market (NZDX) with the ID RYM010.

The coupon rate for the retail bond is 2.55 percent.

Retail bond issue expenses, fees and other costs incurred in arranging retail bond finance are capitalised

and amortised over the term of the relevant debt instrument.

RYMAN HEALTHCARE

120

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

12.INTEREST-BEARING LOANS AND BORROWINGS (CONTINUED)

d. USPP notes

20222021

$000

$000

USPP notes416,557416,874

FX movement of USD USPP notes14,61511,862

Total USPP notes at face value 431,172428,736

Issue costs for the USPP notes capitalised

Opening balance(2,049)-

Capitalised during the year(300)(2,070)

Amortised during the year17921

(2,170)(2,049)

Total USPP notes at amortised cost429,002426,687

Revaluation of debt in fair-value hedge relationship(43,371)(27,473 )

Total USPP notes385,631399,214

On 17 February 2021 the Group completed a United States Private Placement (USPP) note issuance,

securing US$300 million of long-term debt. In conjunction with the USPP issuance, the Group entered

into cross-currency interest-rate swaps to formally hedge the exposure to foreign-currency risk over the

term of the notes. The USPP amount received in AUD (equivalent of US$25 million) is not hedged, the

remaining US$275m is hedged with a contracted USD FX rate of 0.7202.

This debt is carried at amortised cost and translated to New Zealand dollars using foreign exchange rates

at balance date.

USPP note expenses, fees and other costs incurred in arranging USPP finance are capitalised and amortised

over the term of the relevant debt instrument.

Security

The bank loans, institutional term loan, retail bonds and USPP notes are secured by a general security

agreement over the parent and subsidiary companies and supported by first mortgages over the freehold

land and buildings (excluding retirement-village unit titles provided as security to residents – note 7).

The subsidiary companies listed at note 24 have all provided guarantees for the Group’s secured loans

as parties to the general security agreement.

Contractual cash outflows are disclosed in note 20.

ANNUAL REPORT 2022

121

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

13. LEASE LIABILITIES

a. Group as a lessee

The Group leases office buildings, sales offices, office equipment (such as photocopiers), and plant and

equipment used in the construction of retirement-village units and aged-care beds.

The right-of-use assets relating to these leases are included within property, plant and equipment (note 6).

Amounts recognised in profit and loss

20222021

$000

$000

Depreciation of right-of-use assets (note 6)2,6622 ,476

Interest expense on lease liabilities (note 3)2023 74

Expenses relating to short-term or low-value leases9251,212

Maturity profile for lease liabilities

The maturity profile for lease liabilities and how the Group manages liquidity risk is included in note 20

– financial instruments.

The Group has lease contracts that include extension options. These options, which have been included to

provide operational flexibility, are exercisable only by the Group and not the lessors. The Group assesses at

lease commencement date whether it is reasonably certain to exercise the extension options. The Group

estimates that the potential future lease payments, should it exercise all the extension options, would result

in an increase in lease liability of $12.0 million (2021: $8.9 million).

At 31 March 2022 the Group is committed to $8.0 million for short-term leases (including short-term

construction equipment leases) (2021: $5.7 million).

b. Group as a lessor

The Group acts as a lessor under occupation right agreements with village residents. The assets leased by

the Group as a lessor are disclosed as investment property and lease income on occupation right agreements

is generated in the form of deferred management fees. The lease term is determined to be the greater of

the expected period of tenure or the contractual right to management fees. The Group uses the portfolio

approach to account for leases of units to village residents and allocates individual leases to different

portfolios depending on the type of unit. The Group does not have any sub-leases.

RYMAN HEALTHCARE

122

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

14.OCCUPANCY ADVANCES (NON-INTEREST BEARING)

20222021

$000

$000

Gross occupancy advances (see below)4,864,7134,205,105

Less management fees and resident loans(578,254)(502,890)

Closing balance4,286,4593,702,215

Movement in gross occupancy advances

20222021

$000

$000

Opening balance4,205,1053,686,813

Plus net increases in occupancy advances:


ne

w retirement-village units455,855395,094


existing retirement-village units. 168,072107,317

Net foreign-currency exchange differences(4,640)21,807

Increase/(decrease) in occupancy advance balances40,321(5,926)

Closing balance4,864,7134,205,105

Gross occupancy advances are non-interest bearing and occupancy advances are not discounted. The fair value

of net occupancy advances is $2,667 million using the relevant discount rate for each village.

The change in occupancy advance balances shows the net movement in occupancy advance that has

resulted from:



units tha

t have been re-sold but the previous resident has yet to be repaid; and


units that have been repaid but the unit remains unsold at balance date.

ANNUAL REPORT 2022

123

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

15. SHARE CAPITAL

Issued and paid-up capital consists of 500,000,000 fully paid ordinary shares (2021: 500,000,000) less

treasury stock of 2,741,246 shares (2021: 2,655,017 shares) (note 26). All shares rank equally in all respects.

Basic and diluted earnings and net tangible assets per share have been calculated on the basis of 500,000,000

ordinary shares (2021: 500,000,000 shares).

Shares purchased on market under the leadership share scheme (note 26) are treated as treasury stock (note 16)

until vesting to the employee.

Basic and diluted earnings per share (EPS)

20222021

Profit for the year ($000)692,873423,061

Weighted average number of shares (in ‘000)500,000500,000

Basic and diluted EPS (cents per share)138.684.6

Net tangible asset (NTA) per share

20222021

NTA ($000)3,382,8362 ,786,7 72

Ordinary shares at the end of period (‘000)500,000500,000

Basic and diluted NTA per share (cents per share)676.65 5 7. 4

NTA is calculated as total assets less intangible assets and less total liabilities.

16. RESERVES

20222021

$000$000

Reserves

Asset revaluation reserve16a453,568453,568

Cash-flow hedge reserve16b15,491(12,062)

Cost of hedging reserve16c3,6522 ,702

Foreign-currency translation reserve16d5001,787

Treasury stock16e, 26(38,174)(35,389)

435,037410,606

RYMAN HEALTHCARE

124

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

16. RESERVES (CONTINUED)

20222021

$000$000

a. Asset revaluation reserve

Opening balance453,5682 57,7 75

Revaluation-195,793

Closing balance453,568453,568

b. Cash-flow hedge reserve

Opening balance(12,062)( 1 7,1 4 3 )

Valuation of interest-rate swap31,8941,116

Valuation of cross-currency interest-rate swap(14,007)587

Released to income statement20,5235,354

Deferred tax movement on cash-flow hedge reserve(10,857)(1,976)

Closing balance15,491(12,062)

c. Cost of hedging reserve

Opening balance2 ,702-

Valuation of cross-currency interest-rate swap1,3193,753

Released to income statement--

Deferred tax movement on cost of hedging reserve(369)(1,051)

Closing balance3,6522 ,70 2

d. Foreign-currency translation reserve

Opening balance1,787(10,345)

Gain/(Loss) on hedge of foreign-owned subsidiary net assets690(4,414)

(Loss)/Gain on translation of foreign operations(1,977)16,546

Closing balance5001,7 87

e. Treasury stock (note 26)

Opening balance(35,389)(32,359)

Acquisitions(15,625)(13,425)

Vesting /forfeiture of shares12,84010,395

Closing balance(38,174)(35,389)

f. Retained earnings

Opening balance2,385,3202,069,759

Net profit attributable to shareholders692,873423,061

Dividends paid(112,000)(107,500)

Closing balance2,966,1932,385,320

The cost of hedging reserve captures changes in the fair value of the cost to convert foreign currency to NZD

of the cross-currency interest-rate swaps on USPP debt.

ANNUAL REPORT 2022

125

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

17.DIVIDENDS

2022202220212021

Cents per shareTotal $000Cents per share

Total $000

Recognised amounts

Final dividend paid – prior year13.6068,00012 .7063,500

Interim dividend paid – current year8.8044,0008.8044,000

112,000107,500

Unrecognised amounts

Final dividend – current year13.6068,00013.6068,000

Full-year dividend – current year22 .40112,00022 .40112,000

18.RELATED-PARTY TRANSACTIONS

Parent company

The parent entity in the Group is Ryman Healthcare Limited.

Equity interests in related parties

Details of the percentage of ordinary shares held in subsidiaries are disclosed in note 24.

Transactions with companies associated with directors

20222021

$000

$000

Rental costs1,72 11,654

Sub-contractor labour and equipment hire19690

Since August 2012 Ryman Healthcare Limited has leased office accommodation from the Airport Business Park

Christchurch Limited (the Airport Business Park).

On 1 December 2019 Warren Bell became an independent director or trustee of the Airport Business Park’s

shareholders. He does not have any personal ownership interest.

The lease of the office accommodation is recognised as a right-of-use asset and associated lease liability.

Rental costs detailed in the table above are the total cash payments made in the current financial year in

respect of the lease agreement.

Anthony Leighs is Managing Director of Leighs Construction Limited, which has supplied sub-contractor labour

and equipment hire to Ryman Healthcare Limited since December 2019. This arrangement ceased during 2021.

Jo Appleyard is a Partner at Chapman Tripp who provide the Group with legal services. George Savvides is a

Director of Insurance Australia Group Limited (IAG) who provide, through their New Zealand subsidiary NZI, the

Group with insurance coverage. Neither Director is involved in the quoting or provision of services to the Group.

Any transactions undertaken with these entities have been entered into on an arm’s-length basis and in the

ordinary course of business.

RYMAN HEALTHCARE

126

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

19. KEY MANAGEMENT PERSONNEL COMPENSATION

20222021

$000

$000

Compensation

Short-term employee benefits (senior executive team)7,4703,971

Directors’ fees1,3651,094

Total key management personnel and directors’ compensation8,8355,065

Key management personnel are the senior executive team of the Group and include the group chief executive and

eight senior executive team members at 31 March 2022 (2021: group chief executive and six senior executive team

members). The composition and number of senior executive team members fluctuated throughout the year.

Short-term employee benefits included in the 2022 financial year include payments to our former CEO who resigned

in May 2021 after 15 years of services. This payment relates to both short term and medium terms incentives and his

willingness to continue in the role until October 2021 while the board conducted a global search for the new CEO.

In addition, NZ IAS 24 - Related Party Disclosures requires directors’ fees to be included within key management

personnel compensation. All directors are non-executive and are not involved in the day-to-day operations of the

Group (2021: all directors).

Directors’ fees relate to the fees paid to nine directors that were in place for the full financial year (2021: eight directors).

Post-employment benefits (KiwiSaver/Superannuation) employer contributions included in short-term employee

benefits (senior executive team) above are $237,259 (2021: $111,769 senior executive team).

In addition, the Company provides certain senior employees with limited recourse loans on an interest-free basis

to support employees’ participation in the leadership share scheme (note 26).

ANNUAL REPORT 2022

127

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS

The financial instruments consist of cash and cash equivalents, trade and other receivables, trade and other

payables, occupancy advances, refundable accommodation deposits, employee advances, loans, overdrafts,

cross-currency interest rate swaps, interest rate swaps and lease liabilities.

Categories of financial instruments

20222021

$000

$000

Financial assets

Cash and cash equivalents (note 9)28,30920,171

Financial assets at amortised cost (loans and receivables)686,878553,939

Derivative instruments in designated hedge accounting

relationships (interest rate swaps)

1 9,574-

7 3 4 ,76 1574,110

Financial liabilities

Amortised cost7,3 27, 2 3 36,196,046

Derivative instruments in designated hedge accounting

relationships (interest rate swaps)5,43117,339

Derivative instruments in designated hedge accounting

relationships (cross-currency interest rate swaps (CCIRS))21,86011,272

Lease liabilities13,49413,885

7,368,0186,238,542

a. Credit risk management

Credit risk is the risk of the failure of a debtor or counterparty to honour its contractual obligation resulting

in financial loss to the Group.

Financial assets, which potentially subject the Group to credit risk, consist principally of cash and cash

equivalents, trade and other receivables, advances to employees, and derivative financial instruments.

The maximum credit risk at 31 March 2022 is the fair value of these assets.

Credit risk relating to cash and cash equivalents and derivative financial instruments is managed by restricting

the amount of cash and marketable securities that can be placed with any one institution. The Group minimises

its credit risk by spreading such exposures across a range of institutions with reference to the credit ratings of

these institutions. The Group’s cash equivalents are placed with high-credit, quality financial institutions. The

Group does not require collateral from its debtors.

RYMAN HEALTHCARE

128

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

The directors consider the Group’s exposure to any concentration of credit risk from trade and other

receivables and advances to employees to be minimal, given that (typically):

• the occupation of a retirement-village unit does not take place until an occupation advance

has been received

• care fees are payable 4-weekly in advance when due from residents

• care fees not due from residents are paid by government agencies

• advances to employees are subject to the terms of the employee share schemes (note 26).

The total credit risk to the Group from trade and other receivables and advances to employees at

31 March 2022 was $686.9 million (2021: $553.9 million) and there were no material overdue debtors

at 31 March 2022 (2021: $Nil). The composition of financial assets is shown in the table below.

20222021

$000

$000

Trade and other receivables (note 5)671,463542,798

Advances to employees (note 26)15,41511,141

686,878553,939

b. Interest-rate risk

Interest rate risk is the risk that fluctuations in interest rates impact the Group’s financial performance,

future cash flows or the fair value of its financial instruments.

The Group’s interest rate risk arises from loans and borrowings. Loans and borrowings issued at variable

interest rates expose the Group to changes in interest rates. Loans and borrowings issued at fixed rates

expose the Group to changes in the fair value of the borrowings.

The Group’s policy is to manage its interest rate exposure using a mix of fixed and variable rate debt and

interest rate derivatives that are accounted for as cash flow hedges or fair value hedges.

The interest rate applicable to the bank overdraft is variable. The interest rates applicable to the bank loans

are reviewed at each 3-monthly rollover. The Group always seeks to obtain the most competitive interest rate.

Cash flow and fair value hedges

Each hedge relationship is formalised in hedge documentation at inception. The Group uses Bancorp

Treasury Services Limited (BTSL), as an independent valuer, to determine the existence of an economic

relationship between the hedging instrument and the hedged item based on the currency, amount and timing

of respective cash flows, interest rates, tenors, repricing dates, maturities and notional amounts. BTSL then

assesses whether the derivative designated in each hedging relationship is expected to be, and has been,

effective in offsetting the changes in cash flows of the hedged item.

ANNUAL REPORT 2022

129

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

The details of the Group’s hedging instruments are as follows. All hedging instruments are recorded under

Derivative Financial Instrument in the statement of financial position.

CurrencyInterest ratesMaturity

Notional amount of

hedging instrument

Fair value

or carrying

amount of

the hedging

instrument:

Asset /

(Liability)

Change in

value used for

calculating

hedge

effectiveness

(years) NZ$000 NZ$000

2022

Cash flow hedges

Interest rate swaps

NZD2.066%–2.825%3–6NZ$402 million14,73014,730

Interest rate swaps

AUD1.463%–1.785%2–5AU$130 million4,8444,844

Fair value hedge

Interest rate swaps

AUDFloating6AU$54 million(5,431)(5,431)

Fair value and

cash flow hedges

Cross-currency interest

rate swaps (CCIRS)

USD:NZDFloating9–14US$275 million(21,860)(21,860)

(7,717)(7,717)

CurrencyInterest ratesMaturity

Notional amount of

hedging instrument

Fair value

or carrying

amount of

the hedging

instrument:

Asset /

(Liability)

Change in

value used for

calculating

hedge

effectiveness

(years) NZ$000 NZ$000

2021

Cash flow hedges

Interest rate swaps

NZD2.750%–2.825%5NZ$250 million(17,339)(17,339)

Fair value and

cash flow hedges

Cross-currency interest

rate swaps (CCIRS)

USD:NZDFloating10–15US$275 million(11,272)(11,272)

(28,611)(28,611)

The fair value of interest rate swaps is determined by discounting the future cash flows using the yield curves

at the end of the reporting period and the credit risk inherent in the contract. The fair value of the CCIRS

has been calculated using the discounted cash flow method, estimated using forward interest and foreign

exchange rates (from observable yield curves and forward exchange rates).

RYMAN HEALTHCARE

130

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

Interest rate swaps as cash flow hedges

The Group has entered into various interest rate swaps to provide an effective cash flow hedge against

floating interest rate variability on a defined portion of core debt.

These interest rate swaps qualify for cash flow hedge accounting. Interest rate swaps are initially recognised

at fair value on the date a contract is entered into and remeasured to their fair value at each reporting date.

The effective portion of the change in the fair value of the swaps is recognised in other comprehensive income

and accumulated as a separate component of equity. The ineffective portion is recognised in the income

statement. The balance of the interest rate swap reserve is expected to be released to the income statement

over the maturity profile of the underlying debt.

The hedge ratio is 1:1. The face value of the interest rate swaps is the same value as the face value of the bank

loans. As the critical terms of the interest rate swap contracts and the hedged item are the same, significant

hedge ineffectiveness is not expected.

At 31 March 2022, the Group had several interest rate swaps in place with total notional principal amount

of approximately NZ$542 million, which is made up of NZ$402 million and AU$130 million (2021: NZ$250

million). These swaps cover terms of up to 7 years (2021: 5 years) and are effective for various periods.

Some of these swaps will become effective at a future date.

20222021

$000

$000

Current321,640250,000

Forward starting220,222-

541,862250,000

These interest rate swaps effectively change the Group’s interest rate exposure on the principal covered

from a floating rate to an average fixed rate ranging between 2.094 percent and 2.335 percent (2021: 2.757

percent). The notional principal amounts covered by these swaps and the average contracted fixed interest

rate for their remaining maturities are shown below.

Average contracted fixed interest rateNotional principal amount covered

2022202120222021

%%$000

$000

Within 1 year2.228%2 .757%461,862250,000

1–2 years2.231%2 .757%481,862250,000

2–3 years2.231%2 .757%481,862200,000

3–4 years2.335%2 .757%450,504150,000

4–5 years2.094%2 .757%275,504150,000

5–6 years2.200%-180,000-

ANNUAL REPORT 2022

131

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

Interest rate swap as a fair value hedge

During the year, the Group entered into an interest rate swap to mitigate its exposure to fair value changes

arising from the fixed rate portion of the institutional term loan. The swap, which has a total notional principal

amount of AU$53.85 million and a term of 7 years, effectively changes the Group’s interest rate exposure

on the principal covered from a fixed to floating rate. The Group has designated AU$53.85 million of its

institutional term loan in a fair value hedge relationship.

Under a fair value hedge, the change in the fair value of the hedged risk is attributed to the carrying value of

the underlying institutional term loan. This debt revaluation is recognised in the income statement to offset

the mark-to-market revaluation of the hedging derivative.

Cross-currency interest rate swaps (CCIRS) as fair value and cash flow hedges

The Group manages its interest rate risk on USPP notes using CCIRS. The CCIRS transform a series of known

fixed interest rate USD cash flows to floating rate NZD cash flows, mitigating exposure to fair value changes

in USPP notes. The USPP amount received in AUD (equivalent of US$25 million) is not hedged.

The details of the CCIRS are as follows.

AmountCurrencyMaturityNote coupon

2022

Fair value

Asset /

(Liability)

2021

Fair value

Asset /

(Liability)

US$000%$000

$000

Swap participants

Bank of New Zealand55,000USD:NZD18/02/20314.06%(3,564)(932)

MUFG45,000USD:NZD18/02/20314.06%(4,07 7)(2,001)

Bank of New Zealand60,000USD:NZD16/02/20334.16%(4,4 47)(2,152)

ANZ Bank New Zealand Ltd40,000USD:NZD16/02/20334.16%(3,309)(1,877)

ANZ Bank New Zealand Ltd75,000USD:NZD16/02/20364.26%(6,463)(4,310)

275,000(21,860)(11,272)

For hedge accounting purposes, the CCIRS are aggregated and designated as both fair value hedges

and cash flow hedges.

The hedge ratio is 1:1. The face value of the CCIRS is the same value as the face value of the USPP notes.

The maturity of the USPP notes and associated CCIRS is matched. As the critical terms of the CCIRS

contracts and the hedged item are the same, significant hedge ineffectiveness is not expected.

The hedge accounting treatment is as described for interest rate swaps above.

The cross-currency basis elements of the CCIRS are excluded from the designation and are separately

recognised in other comprehensive income in a cost of hedging reserve (note 16).

RYMAN HEALTHCARE

132

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

Interest rate sensitivity

The following table demonstrates the Group’s sensitivity to a change in floating interest rates of plus/(minus)

50 basis points, with all other variables held constant, of the Group’s profit and equity.

20222021

$000

$000

Increase in interest rates of 50 basis points

Effect on profit after taxation – increase/(decrease)(2,503)(2 ,671)

Effect on equity after taxation – increase/(decrease)(9,337)(13,526)

Decrease in interest rates of 50 basis points

Effect on profit after taxation – increase/(decrease)2 ,4492,543

Effect on equity after taxation – increase/(decrease)9,86114,202

Managing interest rate benchmark reform

In the prior year, the Group adopted Phase 1 of the International Accounting Standards Board’s amendments

for the benchmark reform. These amendments modify specific hedge accounting requirements to allow

hedge accounting to continue for the affected hedges.

In the current year, the Group adopted Phase 2 of the amendments which became mandatory for adoption

for reporting periods beginning on or after 1 January 2021.

The Group does not have any financial instruments which are directly affected by the interbank offered rates

(“IBOR”) reform.

However, the Group has an indirect exposure to USD LIBOR as the designation of the Group’s CCIRS as fair

value hedges and cash flow hedges for the Group’s USPP notes reference the USD LIBOR. The total notional

principal amount of the CCIRS is USD $275 million.

As at 31 March 2022, the Group’s hedge designation and documentation has not yet been updated to

reference an alternative benchmark rate on the basis that market practice has yet to be established

determining the calculation of the alternate benchmark rate. The Group continues to work with its external

adviser to monitor the relevant market developments and to assess any impact that the transition may have.

The Group expects to amend its hedging documentation to reference the US Secured Overnight Financing

Rate when widespread market practice is established.

ANNUAL REPORT 2022

133

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

c. Foreign-currency risk

Foreign currency risk is the risk that the value of the Group’s assets, liabilities, and financial performance

will fluctuate due to changes in foreign currency rates.

The Group is exposed to currency risk in Australian (AUD) and US dollars (USD).

Exposure to the Australian dollar arises primarily as a result of its subsidiaries in Australia as well as the USPP

borrowings received in AUD. The risk to the Group is that the value of the overseas Australian subsidiaries’

financial position and financial performance will fluctuate in economic terms and, as recorded in the

consolidated accounts, due to changes in the overseas exchange rates.

The Group hedges the currency risk relating to its Australian subsidiaries by holding a portion of its borrowings

(both bank debt and USPP notes) in Australian dollars. Any foreign currency movement in the net assets of the

Australian subsidiary is partially offset by an opposite movement in the Australian dollar debt.

Exposure to the US dollar arises from the USPP borrowings. This exposure has been fully hedged by way of

cross-currency interest rate swaps (CCIRS) hedging both principal and interest. The CCIRS correspond in

amount and maturity to the relevant US dollar borrowings with no residual foreign currency risk exposure.

The CCIRS consist of a fair value hedge component and a cash flow hedge component. The effective

movements of the fair value hedge component are taken to the income statements along with all movements

of the hedged risk on the USPP notes (USD only). The effective movements of the cash flow hedge

components are all taken to the cash flow hedge reserve.

Foreign exchange sensitivity

The following sensitivity analysis is based on the foreign currency risk exposures in existence at the reporting

date. At 31 March 2022, had the New Zealand dollar moved either up or down by 10 percent, with all other

variables held constant, profit and equity would have been affected as follows.

20222021

$000

$000

Increase in value of NZ dollar of 10%

Impact on profit after taxation – increase/(decrease)(9,384)(2,939)

Impact on equity after taxation – increase/(decrease)(39,952)(32,397)

Decrease in value of NZ dollar of 10%

Impact on profit after taxation – increase/(decrease)11,4703,592

Impact on equity after taxation – increase/(decrease)48,83039,596

The net exposure at balance date is representative of what the Group was and is expecting to be exposed

to in the next 12 months from balance date.

RYMAN HEALTHCARE

134

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

d. Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due without

incurring unacceptable losses or risking reputational damage.

The Group manages liquidity to ensure that it has sufficient liquidity to meet its liabilities when due. This

includes under both normal and stressed conditions. Ultimate responsibility for liquidity risk management

rests with the directors, who have built an appropriate liquidity risk management framework for the

management of the Group’s short, medium, and long-term funding and liquidity management requirements.

Occupancy advances and refundable occupation deposits

The Group manages the liquidity risk on occupancy advances through the contractual requirements in the

occupation agreement.

Following termination of the agreement, in New Zealand the occupancy advance is repaid at the earlier of:

• receipt of the new occupancy advance from the incoming resident

• at the end of 3 years.

Following termination of the agreement, in Australia the occupancy advance is repaid at the earlier of:

• 14 days after a new resident takes up residence

• receipt of the new occupancy advance from the incoming resident

• at the end of 6 months.

The repayment obligation for refundable occupation deposits in New Zealand is within 30 working days

of the resident vacating their care room.

The repayment obligation for refundable occupation deposits in Australia is within 14 days of the resident

vacating their care room.

Lines of credit and undrawn facilities

The Group manages liquidity risk by maintaining adequate reserves, banking facilities, and reserve borrowing

facilities, and by regularly monitoring forecast and actual cash flows and the maturity profiles of financial

assets and liabilities.

The Group maintains the following lines of credit.

• Secured overdraft facility of $2.8 million (2021: $2.8 million) (note 9).

• Syndicated NZD and AUD bank loan facilities totalling NZ$1.9 billion (2021: NZ$1.9 billion)

and AU$529.5 million (2021: AU$471.0 million), respectively (note 12(a)).

• Institutional term loan of AU$250 million (note 12(b)).

• Retail bonds of $150.0 million (note 12(c)).

• USPP notes of US$300 million (note 12(d)).

At balance date, the Group had NZ$592.1 million (2021: NZ$647.3 million) and AU$136.5 million

(2021: AU$36.0 million) of undrawn facilities at its disposal to further reduce liquidity risk.

ANNUAL REPORT 2022

135

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

Lease liabilities

The Group does not face a significant liquidity risk with regard to lease liabilities (note 13).

Maturity profile

The following table details the Group’s exposure to liquidity risk (including contractual interest obligations

for interest-bearing loans and borrowings).

Contractual maturity dates

20222021

On

demand

Less

than

1 year1–5 years

Greater

than

5 yearsTotal

On

demand

Less

than

1 year1–5 years

Greater

than

5 yearsTotal

$000$000$000$000$000$000$000$000$000$000

Financial

liabilities

Trade and other

payables

-264,254--264,254-106,072--106,072

Interest rate

swaps

-(125)4,8281,4776,180-17,339--17,339

CCIRS-5,82239,078(33,226)1 1 ,6 74-11,272--11,272

Refundable

accommodation

deposits (non-

interest bearing)

199,783---199,783113,666---113,666

Bank loans

(secured)

--1,072,855712,9561,785,811-26,0351,703,018-1,729,053

Institutional term

loan (secured)

-6,78928,436278,514313,739-----

Retail bond

(secured)

-3,687164,344-168,031-3,68715,300152,869171,856

USPP notes-15,63553,345538,005606,985-16,44158,755518,302593,498

Occupancy

advances (non-

interest bearing)

1

-526,8453,759,614-4,286,459-438,9263,263,289-3,702,215

Lease liabilities-7,6036,817-14,420-6,2558,230-14,485

199,783830,5105,129,3171 , 4 9 7,7 2 67,657,336113,666626,0275,048,592671,1716,459,456

1 The above figures have been calculated on the anticipated level of occupancy advance repayments based on historical

experience. To date, new occupancy advances received have always exceeded repaid occupancy advances (net of

management fees) and represent a positive net operating cash flow to the Group.

RYMAN HEALTHCARE

136

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

Changes in liabilities arising from financing activities

Opening

balance

Financing

cash flow

Foreign

exchange

movement

Net

changes in

fair valuesOther

Closing

balance

$000 $000 $000 $000 $000 $000

2022

Derivatives (net)

28,611--(20,894)-7,7 1 7

Interest-bearing loans

and borrowings

2,274,093326,917(2,222)(21,588)(463)2 ,576,737

Lease liabilities

13,885(2,662)--2,27113,494

Liabilities arising from

financing activities

2,316,589324,255(2,222)(42,482)1,8082,597,948

Opening

balance

Financing

cash flow

Foreign

exchange

movement

Net

changes in

fair valuesOther

Closing

balance

$000 $000 $000 $000 $000 $000

2021

Derivatives (net)

23,809--4,802-28,611

Interest-bearing loans

and borrowings

1,741,613530,16134,980(27,473 )(5,188)2,274,093

Lease liabilities

15,145(2 ,476)--1,21613,885

Liabilities arising from

financing activities

1,780,567527,68534,980(22,671)(3,972)2,316,589

ANNUAL REPORT 2022

137

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

20. FINANCIAL INSTRUMENTS (CONTINUED)

e.Fair values

Apart from the financial instruments noted below, the carrying amounts of financial instruments in the

Group’s balance sheet are the same as their fair value in all material aspects, due to the demand features

of these instruments and/or their interest rate profiles.

2022

Carrying amount

2022

Fair value

2021

Carrying amount

2021

Fair value (Restated)

$000$000$000

$000

Institutional term loan

263,092272,035

--

Retail bond

147,3951 3 7,7 75

146,861149,880

USPP notes

385,631442,017

399,214482,696

The fair value of the fixed rate portion of the institutional term loan has been determined at balance date on

a discounted cash flow basis and applying discount factors to the future AUD interest payment and principal

payment cash flows. The fair value of the floating rate portion is assumed to be the same as its carrying

amount. The fair value of the institutional term loan is categorised as Level 2 under the fair value hierarchy

in accordance with NZ IFRS 13 – Fair Value Measurement.

The fair value of the retail bond is based on the price traded at on the NZX market at 31 March 2022.

The fair value of the retail bond is categorised as Level 1 under the fair value hierarchy in accordance

with NZ IFRS 13 – Fair Value Measurement.

The fair value of the USPP notes has been determined at balance date on a discounted cash flow basis

and applying discount factors to the future USD interest payment and principal payment cash flows.

The fair value of the USPP is categorised as Level 2 under the fair value hierarchy in accordance with

NZ IFRS 13 – Fair Value Measurement.

The fair value of interest rate swaps and CCIRS are derived using inputs supplied by third parties that are

observable, either directly (prices) or indirectly (derived from prices). The fair value of these derivatives is

categorised as Level 2 under the fair value hierarchy contained within NZ IFRS 13 – Fair Value Measurement.

f. Market risk

The Group is primarily exposed to interest rate risk (note 20 (b)) and foreign currency risk (note 20 (c)).

g.Capital management

The Group’s capital includes share capital, reserves, and retained earnings. The objective of the Group’s capital

management is to ensure a strong credit rating to support business growth and maximise shareholder value.

The Group’s capital is managed at the parent company level. The Group is subject to capital requirements

imposed by its bank and the lenders included in the banking syndicate through covenants agreed as part of the

lending facility arrangements, bond holders through covenants in the Master Trust Deed and USPP note holders

through covenants in the Note Purchase Agreement.

The Group has met all externally imposed capital requirements for the 12 months ended 31 March 2022

and 31 March 2021.

The Group’s capital structure is managed, and adjustments are made with board approval to the structure,

considering economic conditions at the time. There were no changes to objectives, policies, or processes

during the year.

RYMAN HEALTHCARE

138

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

21. COMMITMENTS

Capital expenditure commitments

The Group had commitments relating to construction contracts amounting to $361.5 million at 31 March 2022

(2021: $180.6 million).

The Group has an ongoing commitment for maintaining the land and buildings of the integrated retirement

villages, resthomes, and hospitals.

22. CONTINGENT LIABILITIES

The Group had no contingent liabilities at 31 March 2022 (2021: $Nil).

23. RECONCILIATION OF NET PROFIT AFTER TAX WITH NET CASH FLOW FROM

OPERATING ACTIVITIES

20222021

$000

$000

Net profit after tax692,873423,061

Adjusted for:

Movements in balance-sheet items

Occupancy advances659,608518,292

Accrued management fees(73,827)(59,116)

Refundable accommodation deposits8 6 ,47432 ,470

Revenue in advance9,4357,5 1 5

Trade and other payables9,1724,845

Trade and other receivables(129,017)(92,565)

Inventory390(26,738)

Employee entitlements7,7 786,356

Non-cash items:

Depreciation and amortisation33,02629,892

Depreciation of right-of-use assets2 ,6722 ,476

Loss on disposal-15,102

Deferred tax29,209(12,561)

Unrealised foreign-exchange (gain)/loss4,070(19,063)

Adjusted for:

Fair-value movement of investment properties(745,885)(416,847)

Net operating cash flows585,978413,119

Net operating cash flows includes net occupancy advance receipts from retirement-village residents of

$908.1 million (2021: $787.7 million).

Also included in operating cash flows are net receipts from refundable accommodation deposits of $87.4 million

(2021: $27.9 million).

Net operating cash flows also include management fees collected of $50.2 million (2021: $48.0 million).

ANNUAL REPORT 2022

139

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

24. SUBSIDIARY COMPANIES

All trading subsidiaries operate in the aged-care sector in New Zealand and Australia, are 100 percent owned,

and have a balance date of 31 March. The operating subsidiaries are listed below.

• Anthony Wilding Retirement Village Limited

• Bert Sutcliffe Retirement Village Limited

• Bob Owens Retirement Village Limited

• Bob Scott Retirement Village Limited

• Bruce McLaren Retirement Village Limited

• Café Ryman Russley Road Limited

• Charles Brownlow Retirement Village Pty Ltd

• Charles Fleming Retirement Village Limited

• Charles Upham Retirement Village Limited

• Deborah Cheetham Retirement Village Pty Ltd

• Diana Isaac Retirement Village Limited

• Edmund Hillary Retirement Village Limited

• Ernest Rutherford Retirement Village Limited

• Essie Summers Retirement Village Limited

• Evelyn Page Retirement Village Limited

• Frances Hodgkins Retirement Village Limited

• Grace Joel Retirement Village Limited

• Hilda Ross Retirement Village Limited

• James Wattie Retirement Village Limited

• Jane Mander Retirement Village Limited

• Jane Winstone Retirement Village Limited

• Jean Sandel Retirement Village Limited

• John Flynn Retirement Village Pty Ltd

• Julia Wallace Retirement Village Limited

• Keith Park Retirement Village Limited

• Kevin Hickman Retirement Village Limited

• Kiri Te Kanawa Retirement Village Limited

• Linda Jones Retirement Village Limited

• Logan Campbell Retirement Village Limited

• Malvina Major Retirement Village Limited

• Margaret Stoddart Retirement Village Limited

• Miriam Corban Retirement Village Limited

• Murray Halberg Retirement Village Limited

• Nellie Melba Retirement Village Pty Ltd

• Ngaio Marsh Retirement Village Limited

• Possum Bourne Retirement Village Limited

• Raelene Boyle Retirement Village Pty Ltd

• Rita Angus Retirement Village Limited

• Rowena Jackson Retirement Village Limited

• Ryman Aged Care (Australia) Pty Ltd

• Ryman Construction Pty Ltd

• Ryman Healthcare (Australia) Pty Ltd

• Ryman Napier Limited

• Shona McFarlane Retirement Village Limited

• Weary Dunlop Retirement Village Pty Ltd

• William Sanders Retirement Village Limited

• Yvette Williams Retirement Village Limited

RYMAN HEALTHCARE

140

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

25. SEGMENT INFORMATION

Products and services from which reportable segments derive their revenue

The Ryman Group operates in one industry, being the provision of integrated retirement villages for older people

in New Zealand and Australia. The service provision process for each of the villages is similar, and the class of

customer and methods of distribution and regulatory environment are consistent across all the villages.

Segment revenues and results

The accounting policies of the reportable segment are the same as the Group’s accounting policies. The segment

profit represents profit earned for the segment after all costs including all administration costs, directors’ fees,

interest revenue, finance costs, and income-tax expense.

The board makes resource allocation decisions to the segment, based on the expected cash flows and results of

Group operations as a whole. No operations were discontinued during the year. To monitor segment performance

and allocate resources to the segment, the board monitors assets attributable to the segment. All assets are

allocated to the reportable segment.

Information about major customers

Included in total revenue are revenues that arose from sales to the Group’s largest customers.

The Group derives care-fee revenue for eligible government-subsidised, aged-care residents who receive

resthome, hospital, or dementia-level care. The government aged-care subsidies received from the New Zealand

Ministry of Health included in Group care fees amounted to $133.7 million (2021: $122.5 million). There are no other

significant customers.

ANNUAL REPORT 2022

141

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

25. SEGMENT INFORMATION (CONTINUED)

Geographical information

The Group operates in New Zealand and Australia.

In presenting information based on geographical areas, net profit, underlying profit, and revenue are based on the

geographical location of operations. Assets are based on the geographical location of the assets.

New ZealandAustraliaGroup

$000$000

$000

Year ended 31 March 2022

Revenue435,33773,460508,797

Underlying profit (non-GAAP)203,76351,186254,949

Deferred tax credit (note 4)

(50,923)2 1,714(29,209)

Unrealised fair-value movement (note 7)436,80430,3294 67,1 3 3

Profit for the year589,644103,229692,873

Non-current assets8,322,2361,902,34710,224,583

New ZealandAustraliaGroup

$000$000

$000

Year ended 31 March 2021

Revenue405,39650,398455,794

Underlying profit (non-GAAP)192,28632,163224,449

Deferred tax credit (note 4)

5,8616,70012,561

Unrealised fair-value movement (note 7)192,5828,571201,153

Impairment – loss on disposal (note 6)-(15,102)(15,102)

Profit for the year390,72932,332423,061

Non-current assets7,230,2981,340,4638,570,761

Underlying profit is a non-GAAP (Generally Accepted Accounting Principles) measure and differs from NZ IFRS

profit for the year. Underlying profit does not have a standardised meaning prescribed by GAAP and so may not

be comparable to similar financial information presented by other entities. The Group uses underlying profit, with

other measures, to measure performance. Underlying profit is a measure that the Group uses consistently across

reporting periods.

Underlying profit includes realised movement on investment property for units in which a right-to-occupy

has been sold during the period and for which a legally binding contract is in place at the reporting date.

The occupancy advance for these units may have been received or be included within the trade receivables

balance at reporting date (see note 5).

Underlying profit excludes deferred taxation, taxation expense, unrealised movement on investment properties,

and impairment losses on non-trading assets because these items do not reflect the trading performance of the

Company. Underlying profit determines the dividend payout to shareholders.

RYMAN HEALTHCARE

142

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

26. EMPLOYEE SHARE SCHEMES

Leadership share scheme

The Group operates an employee share scheme for certain senior employees, other than non-executive

directors, to purchase ordinary shares in the Company.

The Group provides the employees with limited recourse loans on an interest-free basis to support employees’

participation in the scheme. These shares are treated as treasury stock when purchased on market, due to the

features of the scheme.

The loans are applied to the purchase of shares on market, so the number of shares and the consideration

for each share are determined by the market price at that time. The scheme holds 2,741,246 fully allocated

shares, which represents 0.55 percent of the total shares on issue (2021: 2,655,017 fully allocated shares, which

represented 0.53 percent of the total shares on issue). All net dividends received in respect of the shares must

be applied to repayment of the loans.

Shares purchased under the scheme are held by two directors as custodians, and the shares carry the same

rights as all other ordinary shares. The loan is repayable at the discretion of the employee but is repayable

when the employee leaves the Group. Shares subject to this scheme vest 3 years from the date of purchase.

Due to the features of the scheme, it is accounted for as a share option plan under NZ IFRS 2 – Share-based Payment.

The following table reconciles the shares purchased on market under the scheme at the beginning and end of the

financial year. The weighted average exercise price is calculated based on the share price on purchase date less

any net dividends received since purchase date.

2022202220212021

Number

of shares

Weighted average

exercise price

Number

of shares

Weighted average

exercise price

Balance at beginning of the financial year2,655,01713.122,711,24411.75

Purchased on market during the year1,065,25914.67994,86013.49

Forfeited during the financial year(241,716)13.19(236,003)9.19

Vested during the financial year(737,314)12.54(815,084)8.88

Balance at end of the financial year2,741,24613.722,655,0171 3 .1 2

Represented by:

Shares granted in August 2018--753,06812.64

Shares granted in August 2019804,14312.03915,98313.19

Shares granted in August 2020871,84413.28985,96613.43

Shares granted in August 20211,065,25914.61--

Balance at end of the financial year2,741,24613.722,655,0171 3 .1 2

ANNUAL REPORT 2022

143

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

26. EMPLOYEE SHARE SCHEMES (CONTINUED)

Shares vested in August 2021 were originally purchased at $12.98 per share in 2018 and are now held directly by

employees. The amounts owed by employees in these vested shares are included within advances to employees.

This balance includes $464,130 owing by the senior executive team (as defined in note 19) in the share scheme

(2021: $277,083).

Under NZ IFRS 2, the Group measures the fair value of the services received by reference to the fair value

of the share options granted.

The directors estimate the fair value of the share options granted using the Black-Scholes pricing model.

Due to the on-market purchase and sale features of the scheme, and the scheme agreement arrangements,

the directors consider any such value to be immaterial.

All employee share scheme

In addition, the Group operates a share scheme that is available for all employees.

Participants of this scheme contribute a minimum of $500 (and up to a maximum amount of $10,000) towards

the on-market purchase of Ryman Healthcare Limited shares. To help the employee purchase more shares,

the Group advanced an interest-free loan equal to the employee’s contribution towards the share purchase

(financial assistance).

The loan is repayable at the discretion of the employee but is repayable when the employee leaves the Group.

Shares purchased under the scheme are held in the employee’s name. The financial assistance provided by the

Group is recorded in advances to employees.

RYMAN HEALTHCARE

144

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2022

27. SUBSEQUENT EVENTS

The directors resolved to pay a final dividend of 13.6 cents per share or $68 million, with no imputation

credits attached, to be paid on 17 June 2022.

United States Private Placement (USPP) note issuance

Subsequent to 31 March 2022, the Group completed a United States Private Placement (USPP) notes issuance,

securing US$200m of long-term debt. The USPP issuance is made up of three tranches with maturity dates of 10,

12 and 15 years. In conjunction with the issuance, the Group entered into cross-currency-interest-rate swaps to

formally hedge the exposure to foreign-currency risk over the term of the notes. The proceeds from the issuance

were used to repay bank loans.

28. AUTHORISATION

The directors authorised the issue of these financial statements on 19 May 2022.




Claire Higgins

Non-Executive Director and

Chair of Audit and Financial Risk Committee

Greg Campbell

Chair

ANNUAL REPORT 2022

145

OpinionWe have audited the consolidated financial statements of Ryman Healthcare Limited and its
subsidiaries (the ‘Group’), which comprise the consolidated balance sheet as at 31 March 2022, and

the consolidated income statement, statement of comprehensive income, statement of changes in

equity and statement of cash flows for the year then ended, and notes to the consolidated financial

statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements, on pages 90 to 145, present

fairly, in all material respects, the consolidated financial position of the Group as at 31 March 2022,

and its consolidated financial performance and cash flows for the year then ended in accordance with

New Zealand Equivalents to International Financial Reporting Standards (‘NZ IFRS’) and International

Financial Reporting Standards (‘IFRS’).

Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (‘ISAs’) and

International Standards on Auditing (New Zealand) (‘ISAs (NZ)’). Our responsibilities under those

standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated

Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis

for our opinion.

We are independent of the Group in accordance with Professional and Ethical Standard 1

International Code of Ethics for Assurance Practitioners (including International Independence

Standards) (New Zealand) issued by the New Zealand Auditing and Assurance Standards Board and

the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional

Accountants (including International Independence Standards), and we have fulfilled our other ethical

responsibilities in accordance with these requirements.

Our firm carries out other assurance assignments for the Group relating to Australian aged care.

These services have not impaired our independence as auditor of the Company and Group.

In addition to this, partners and employees of our firm deal with the Company and its subsidiaries

on normal terms within the ordinary course of trading activities of the business of the Company and

its subsidiaries. The firm has no other relationship with, or interest in, the Company or any of

its subsidiaries.

Audit materialityWe consider materiality primarily in terms of the magnitude of misstatement in the financial

statements of the Group that in our judgement would make it probable that the economic decisions

of a reasonably knowledgeable person would be changed or influenced (the ‘quantitative’ materiality).

In addition, we also assess whether other matters that come to our attention during the audit would in

our judgement change or influence the decisions of such a person (the ‘qualitative’ materiality). We use

materiality both in planning the scope of our audit work and in evaluating the results of our work.

We determined materiality for the Group financial statements as a whole to be $22.5m.

Key audit

matters

Key audit matters are those matters that, in our professional judgement, were of most significance

in our audit of the consolidated financial statements of the current period. These matters were

addressed in the context of our audit of the consolidated financial statements as a whole, and in

forming our opinion thereon, and we do not provide a separate opinion on these matters.

Independent Auditor’s Report

TO THE SHAREHOLDERS OF RYMAN HEALTHCARE LIMITED

RYMAN HEALTHCARE

146

Key audit matterHow our audit addressed the key audit matter
Valuation of Investment Property

As explained in policy (f) and note 7 in the consolidated

financial statements, investment properties are carried

at fair value on the consolidated balance sheet. The

fair value of these properties is determined based

on a Directors valuation at 31 March 2022, which is

supported by an independent external valuation.

The valuation is subject to a number of complex

estimates and assumptions.

The valuation model is a discounted cash flow model.

The Directors adjust the value for occupancy advances

received from residents, deferred management fees

and revenue in advance. The valuation relies on various

estimates and underlying assumptions, including

current unit pricing, discount rates, future long term

house price growth rates and the occupancy periods

of residents. A small percentage difference in certain

input assumptions could result in a material change to

the valuation.

These properties were valued at $8,027m

(2021: $6,837m). The revaluation gain recognised

in the consolidated income statement was $746m

(2021: $417m).

We included the valuation of investment properties

as a key audit matter for two reasons:

1. The significance to the financial statements:

The investment properties account for 73% of the

total assets (2021: 75%), making it the most significant

balance on the balance sheet.

2. The complexity of the valuation model that

supports the Directors valuation.

Our procedures focused on:

• The appropriateness of the valuation methodology, including

the appropriateness of assessments made by the Directors

in determining the carrying value of investment property;

• The reasonableness of underlying assumptions in the

valuation model.

Our procedures included, amongst others:

• Evaluating the Group’s processes for determining the

Directors valuation of the investment properties, including

their consideration of the valuations obtained from the

independent valuer;

• Reading the valuation reports for properties within the

group and reviewing the valuation methodology and the

reasonableness of the significant underlying assumptions;

• Discussing with management the nature of key assumptions;

• Assessing the reasonableness of adjustments made by

the Directors;

• Assessing the competence, objectivity, and integrity of

the independent registered valuers. We assessed their

professional qualifications and experience. We also obtained

representation from them about their independence and the

scope of their work and considered restrictions imposed on

the valuation process (if any);

• Meeting with the valuers to understand the valuation process

adopted. The purpose of the meeting was to identify and

challenge the critical judgment areas in the valuation model

and to confirm the valuation approach was in accordance

with NZ IFRS 13 Fair Value Measurement. We critically

challenged the changes made to key assumptions and their

reasonableness relative to the 31 March 2021 valuation;

• Using our in-house valuation specialists to assess the

appropriateness of the valuation methodology;

• Agreeing a sample of sales and resales to contracts,

calculating actual growth rates on resales for the sample

to compare to growth rates applied by the valuer, and

calculating the average tenure of residents based on a

sample of contracts to compare to assumed occupancy

periods applied by the valuer;

• Comparing a sample of current unit market values

determined by the valuer to actual prices received at

comparable units within the village;

• Assessing the discount rates for reasonableness by

comparing the rates to those adopted in the previous year

and the rates adopted by comparable entities; and

• Considering the appropriateness of the disclosures in note 7.

ANNUAL REPORT 2022

147

Key audit matterHow our audit addressed the key audit matter
Valuation of care-facility land and buildings

As explained in policy (d) and note 6 in the financial

statements, care facility land and buildings are

carried at their fair value at the date of revaluation

less any subsequent accumulated depreciation and

impairment losses.

The net book value of care facility land and buildings

as reflected in note 6 is $1,058m (2021: $955m).

The Group obtains independent valuations at least

every 2 years and performs internal assessments in the

intervening years to determine whether there are any

indications that the carrying amount differs materially

from fair value at the balance sheet date.

The last independent valuation was completed as

at 31 March 2021. A revaluation gain of $196m was

recognised in other comprehensive income in 2021.

The valuer used a combination of capitalised earnings

data and comparable market evidence to derive

fair value.

In the current year, the Group has determined that

there are no indications that the fair value of care

facility land and buildings differs materially from their

carrying value. In reaching this assessment the Group

has considered capitalisation rates, market evidence

of comparable sales, market demand, occupancy,

and earnings.

We included the valuation of care facility land and

buildings as a key audit matter in the current year due

to the significant judgement exercised by the Group

in determining that there are no indications that the

carrying value differs materially to the fair value at

31 March 2022.

Our procedures included, amongst others:

• Critically assessing the documentation prepared by the

Group supporting their assessment of whether there have

been any significant changes to the inputs and assumptions

used in the 2021 valuation that would lead to the carrying

value of care facility land and buildings being materially

different to fair value at 31 March 2022;

• Challenging the Group’s analysis of the following inputs and

assumptions used in the Group’s assessment:

- occupancy rates;

- capitalisation rates; and

- market comparative sales;

• Analysing care centre earnings data for the current period

compared to prior period;

• Critically assessing the documentation prepared by the

Group supporting their assessment that there were no

indicators that the fair value of developing villages not subject

to revaluation in 2021 were materially different to their

carrying amount at 31 March 2022;

• Agreeing material additions to supporting documentation;

and

• Considering the appropriateness of the disclosures in note 6.

RYMAN HEALTHCARE

148

Other
information

The directors are responsible on behalf of the Group for the other information. The other information

comprises the information in the Annual Report that accompanies the consolidated financial

statements and the audit report. The Annual Report is expected to be made available to us after the

date of this auditor’s report.

Our opinion on the consolidated financial statements does not cover the other information and we will

not express any form of assurance conclusion thereon.

Our responsibility is to read the other information identified above when it becomes available and

consider whether the other information is materially inconsistent with the consolidated financial

statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the other information in the Annual Report, if we conclude that there is a material

misstatement therin, we are required to communicate the matter to the directors and consider further

appropriate actions.

Directors’

responsibilities

for the

consolidated

financial

statements

The directors are responsible on behalf of the Group for the preparation and fair presentation of the

consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal control

as the directors determine is necessary to enable the preparation of consolidated financial statements

that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible on behalf of the Group

for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters

related to going concern and using the going concern basis of accounting unless the directors either

intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor’s

responsibilities

for the audit of

the consolidated

financial

statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial

statements as a whole are free from material misstatement, whether due to fraud or error, and to issue

an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is

not a guarantee that an audit conducted in accordance with ISAs and ISAs (NZ) will always detect a

material misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if, individually or in the aggregate, they could reasonably be expected to influence the

economic decisions of users taken on the basis of these consolidated financial statements.

A further description of our responsibilities for the audit of the consolidated financial statements is

located on the External Reporting Board’s website at:

https://www.xrb.govt.nz/standards-for-assurance-practitioners/auditors-responsibilities/audit-report-1

This description forms part of our auditor’s report.

Restriction

on use

This report is made solely to the Company’s shareholders, as a body. Our audit has been undertaken

so that we might state to the Company’s shareholders those matters we are required to state to them

in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept

or assume responsibility to anyone other than the Company’s shareholders as a body, for our audit

work, for this report, or for the opinions we have formed.

Mike Hoshek, Partner for

Deloitte Limited

Christchurch, New Zealand

19 May 2022

ANNUAL REPORT 2022

149

Artist’s impression of our upcoming Northwood Village in Christchurch
– a great example of a townhouse-style village that lends itself to an

efficient build process and therefore accelerated returns.

150

RYMAN HEALTHCARE

Corporate
governance

151

ANNUAL REPORT 2022

Greg Campbell (Chair)
MBA (DIST) FNZIM

Greg joined the board in

March 2021 and was appointed

chair in January 2022. He is

an experienced chief executive

and board director with more

than 25 years’ experience in

leading large organisations.

Greg has strong governance

and commercial skills, a deep

operational understanding of

business and a strong interest

in sustainability.

Claire Higgins

BCOM, FCPA, FAICD

Based in Victoria, Claire is a

non-executive director with

experience across a range

of sectors in Australia and

New Zealand. Claire joined

the board in 2014, is chair

of REI Superannuation and

GMHBA and holds director

positions in the medical device

and philanthropic sectors.

Dr David Kerr

CNZM, MBCHB, FRNZCGP

David joined Ryman’s board in

1994 and was chair from 1999

until he stepped down in January

2022. David is a fellow and past

president of the New Zealand

Medical Association and has

been awarded a Fellowship

with Distinction by the Royal

New Zealand College of General

Practitioners. He was made a

Companion of the New Zealand

Order of Merit in 2020. David

has announced his intention

to retire from the board in

July 2022.

Our directors

Image: Warren Bell, Paula Jeffs, Geoffrey Cumming, Dr David Kerr, Jo Appleyard, George Savvides,

Greg Campbell, Claire Higgins, Anthony Leighs.

RYMAN HEALTHCARE

152

George Savvides
AM, BE (HONS), MBA, FAICD

Based in Melbourne, George

joined the board in 2013. He

has extensive experience in

Australia’s healthcare industry,

including 14 years as managing

director of Medibank, Australia’s

largest health insurer. George

is chair of SBS (Broadcasting),

a non-executive director of

IAG (Insurance Australia Group)

and a Fellow of the Australian

Institute of Directors. In 2020,

George was made a Member

of the Order of Australia for

significant service to the

community, charitable groups

and business.

Anthony Leighs

NZCB

Anthony joined the board

in 2018. He is also director

of leading commercial

construction firm Leighs

Construction, which

he founded in 1995 and built

into one of New Zealand’s

leading commercial

construction contractors.

He is a former chairman of

the New Zealand Registered

Master Builders Association.

Paula Jeffs

BA, GRAD DIP (IR), GAICD,

CAHRI

Paula is a Melbourne-based

human resources executive

with experience across the

healthcare, finance and

government sectors and deep

expertise in workforce planning,

organisational capability and

executive coaching. In the early

stages of her working life, Paula

spent several years as a carer

in the aged and disability sector.

Paula joined the board in 2019.

Geoffrey Cumming

BA (HONS), MSC (ECON), LLD

Geoff rejoined the board in

June 2018, having previously

served as a director from 1999

to 2000. Geoff is a Melbourne-

based New Zealand citizen who

is an economist, investor and

philanthropist. He has more

than 30 years’ experience as a

chief executive and company

director and has served on

more than 25 boards. In 2019,

Geoff was inducted into the

Alberta Business Hall of Fame.

Jo Appleyard

LLB (HONS)

Jo joined the board in

2009 and is also a partner

at Chapman Tripp. She is a

skilled advocate and litigator

specialising in commercial,

employment and resource

management law. Jo was a

member of the NZ Markets

Disciplinary Tribunal

between 2011 and 2020.

Warren Bell

MCOM, FCA

Warren joined the board in

2011. He is an experienced

public and private company

director and was previously

an audit partner. Warren is

currently chair of Hallenstein

Glasson and has a long

history in the New Zealand

retail sector. He is also chair

of Christchurch-based

St George’s Hospital and

is a director of several

private companies.

ANNUAL REPORT 2022

153

Richard Umbers
GROUP CHIEF EXECUTIVE

Richard joined Ryman in 2021.

Richard is an internationally

experienced CEO with a

background in leading large

businesses. Richard was

previously divisional director

of buying at Kaufland in

Germany and CEO and

managing director of Myer

Australia. He also held senior

roles at Woolworths in Australia

and was managing director of

Progressive Enterprises Limited

in New Zealand.

Cheyne Chalmers

CHIEF EXECUTIVE

OFFICER – NEW ZEALAND

Cheyne joined Ryman in 2020

as chief operations officer and

was appointed CEO NZ in June

2022. As a registered nurse

with a Master in Management,

Cheyne has held senior public

health roles including executive

director of residential and

support services and chief

nursing and midwifery officer

at Monash Health, Melbourne.

Cheyne is also an adjunct

professor at Deakin University

in Victoria.

David Bennett

GROUP CHIEF

FINANCIAL OFFICER

Dave joined Ryman in 2013

and was promoted to group

chief financial officer in 2017.

He is a board member of the

Retirement Villages Association

of New Zealand and the

New Zealand Aged Care

Association. Dave has a

Bachelor of Commerce

and is a chartered accountant.

Before joining Ryman, he worked

as an accountant and auditor.

Our senior executives

Image: Rick Davies, Andrew Crerar, Cheyne Chalmers, David Bennett, Marsha Cadman, Richard Umbers,

Cameron Holland, Mary-Anne Stone, Chris Evans.

RYMAN HEALTHCARE

154

Cameron Holland
CHIEF EXECUTIVE

OFFICER – AUSTRALIA

Cameron is an experienced

business leader with over

15 years’ experience leading

the commercial and operational

arms of some of Australasia’s

largest and most well-known

brands, including Jetstar and

Lonely Planet. Cameron also

has extensive experience

in the aged care, home care

and retirement living sector

in Australia. Cameron joined

Ryman in 2021.

Rick Davies

CHIEF TECHNOLOGY AND

INNOVATION OFFICER

Rick is an experienced

technology and commercial

leader, having worked

extensively within the

ecommerce sector. Rick has

held a range of senior roles

including leading Trade Me’s

iconic retail marketplace

division. Rick has a Bachelor

of Science and joined Ryman

in 2019.

Marsha Cadman

CHIEF SALES AND

MARKETING OFFICER

Marsha has extensive

experience across both

sales and marketing and

has a Master in Business

Administration. Before joining

Ryman in 2021, she was general

manager strategy, customer

and sustainability at Waste

Management New Zealand.

Marsha also held senior roles

at South East Water in

Melbourne and MyState

Financial in Tasmania.

Chris Evans

CHIEF CONSTRUCTION

OFFICER

Chris joined Ryman in 2021.

He is an experienced

construction leader having

enjoyed more than 25 years

working for John Holland Group

in a range of operational and

senior leadership positions

in Australia. More recently

Chris worked at Sydney Airport,

where he was chief assets

and infrastructure officer.

Andrew Crerar

CHIEF PEOPLE AND

SAFETY OFFICER

Andrew joined Ryman in

2018 as people development

manager. He was promoted

to group people development

manager in 2019 before moving

into his current role in 2020.

Prior to this, Andrew completed

a Master of Arts (Economic

Psychology) and worked in

the public health sector in

the United Kingdom and

in professional services in

New Zealand.

Mary-Anne Stone

CHIEF STRATEGY OFFICER

Mary-Anne has over 25 years’

experience in the healthcare

sector including senior

management roles in primary

health, retirement living and

home and community care.

Mary-Anne has a Master in

Population Health focused

on health systems for ageing

populations and health equity.

Mary-Anne rejoined Ryman

in 2020.

ANNUAL REPORT 2022

155

Ryman believes in the
benefit of good corporate

governance and the

value it provides for our

shareholders, residents,

employees and other

stakeholders.

Ryman’s board of directors is responsible for the company’s

corporate governance. The board undertakes this role with

reference to best practice and takes into consideration the

recommendations outlined in the NZX Corporate Governance

Code (the Code).

The company’s approach to applying the recommendations

outlined in the Code are set out on the following pages.

The section is set out in the order of the principles detailed

in the Code and explains how Ryman is applying the

Code’s recommendations.

Ryman’s policy documents referred to in this section

are available at:

rymanhealthcare.co.nz/about-us/investors/governance

.

BOARD COMPOSITION

At 31 March 2022, we had

nine directors on our board:

Greg Campbell, Dr David Kerr,

Geoff Cumming, George Savvides,

Paula Jeffs, Claire Higgins,

Warren Bell, Jo Appleyard

and Anthony Leighs.

All are non-executive directors,

and seven are independent

for the purposes of the NZX Main

Board Listing Rules. The board

has stated that the appropriate

size of the board is between seven

and nine directors.

8

5

4

9

56

7

2

6

9

S

t

r

a

t

e

g

y

H

u

m

a

n


r

e

s

o

u

r

c

e

s

D

i

g

i

t

a

l


a

n

d


H

e

a

l

t

h

,


c

l

i

n

i

c

a

l


a

n

d


H

e

a

l

t

h


a

n

d


s

a

f

e

t

y

P

r

o

p

e

r

t

y


a

n

d


R

i

s

k


m

a

n

a

g

e

m

e

n

t

F

i

n

a

n

c

e

,


a

c

c

o

u

n

t

i

n

g

E

x

e

c

u

t

i

v

e


l

e

a

d

e

r

s

h

i

p

G

o

v

e

r

n

a

n

c

e


a

n

d


t

a

x

a

t

i

o

n

c

o

n

s

t

r

u

c

t

i

o

n

a

g

e

d


c

a

r

e

t

e

c

h

n

o

l

o

g

y

AREAS OF

EXPERTISE

RYMAN HEALTHCARE

156

* Geoff Cumming is a citizen of both New Zealand and Canada who resides in Melbourne, Australia.
** Attendance in the financial year to 31 March 2022.

2 nationalities

(6 New Zealanders and 3 Australians *)

are independent

78%

are female

33%

Average age

61

BOARD STATS AND FACTS

Board meeting

attendance

100%

BOARD COMMITTEES

Director

members

Director

independence

Director

attendance**

Audit, Finance and Risk

667%94%

People and Safety

683%100%

Clinical Governance

3100%100%

Development, Design

and Construction

580%92%

Governance, Nominations

and Remuneration

475%92%

ANNUAL REPORT 2022

157

Statement of corporate governance
NZX Listing

Rules

The company applies the NZX Main Board Listing Rules (the Listing Rules). At the date of

this report, the current version of the Listing Rules are those dated 10 December 2020.

PRINCIPLE 1 – CODE OF ETHICAL BEHAVIOUR

“Directors should set high standards of ethical behaviour, model this behaviour and hold

management accountable for these standards being followed throughout the organisation.”

Code of

ethics

As part of the board’s commitment to the highest standards of behaviour and accountability,

Ryman has adopted a code of ethics that outlines our position on the things that are most

important in upholding our shared standards.

Our code of ethics sets out the core principles of behaviour that are expected of every

person who works for and with Ryman, regardless of where they are or what they do.

These expectations are the same for everyone, including directors, senior leaders, team

members, consultants, business partners and anyone who works with us.

The code is intended to support decision making that is consistent with Ryman’s

characteristics, business goals and legal and policy obligations rather than to prescribe an

exhaustive list of acceptable behaviour and the things that fall outside of our expectations.

The board approves the code of ethics, which covers:

• who we are – our values and characteristics

• our commitment to health, safety and wellbeing – we do it safely or not at all

• our people – supporting, developing and leading our team members

• environment and community – the work we do to protect our environment and be positive

members of our community

• protecting our assets and property – being good stewards of company information,

property and value

• freedom to speak up – supporting people to raise concerns, including whistleblowing

and protected disclosures, free from reprisal or victimisation

• how we do business – accepting gifts or other benefits, dealing with conflicts of interest

and maintaining confidentiality

• complying with the law and reporting breaches.

Ryman team members are expected to read the code of ethics as part of their induction

and keep it at the core of everything they do. It is also accessible to all team members on the

Ryman intranet and the company website.

Financial

product

trading policy

Ryman supports the integrity of New Zealand’s financial markets. This integrity is maintained,

in part, through the insider trading laws that apply in New Zealand. Ryman’s financial product

trading policy outlines how those laws apply as well as the rules that Ryman has put in place

so that those laws are followed.

RYMAN HEALTHCARE

158

Statement of corporate governance (continued)
PRINCIPLE 2 – BOARD COMPOSITION AND PERFORMANCE

“To ensure an effective board, there should be a balance of independence, skills, knowledge,

experience and perspectives.”

The board of

directors

The directors are responsible for the corporate governance practices of the company.

The practices adopted by the board are prescribed in a charter that sets out the protocols

for how the board operates.

The charter complies with the relevant recommendations in the Code and is reviewed annually.

The board’s primary role is to effectively represent and promote the interests of

shareholders with a view to adding long-term value to the company’s shares.

The board carries out its responsibilities according to the following mandate.

• The board should consist of a majority of non-executive directors.

• At least a third of the directors should be independent of management and free from any

business or other relationship or circumstance that could materially interfere with the

exercise of a director’s independent judgement.

• The board’s chair should be a non-executive director (and not the group chief executive).

• Directors should possess a broad range of skills, qualifications and experience and remain

up to date on how best to perform their duties as directors.

• Management must provide information of sufficient content, quality and timeliness as the

board considers necessary to allow the board to effectively discharge its duties.

• The effectiveness and performance of the board and its individual members should be

re-evaluated annually.

The board consists entirely of non-executive directors. The directors of the company at

31 March 2022 are Greg Campbell (chair), Dr David Kerr, Jo Appleyard, Warren Bell,

Claire Higgins, George Savvides, Geoff Cumming, Anthony Leighs and Paula Jeffs.

The board has determined that Greg Campbell, Dr David Kerr, Jo Appleyard, Claire Higgins,

George Savvides, Anthony Leighs and Paula Jeffs are all independent directors for the

purposes of the Listing Rules.

More information on the directors, including their experience, interests, qualifications, length of

service and shareholdings, is provided in the ‘Director's disclosures’ section of this report and

on the company’s website. A summary of the board’s skill set is detailed in the table below.

Day-to-day management of Ryman is delegated to the group chief executive and the senior

executive team. The group chief executive and senior executive team are delegated the

responsibility for implementing the board’s strategy.

Directors, certain employees and their related parties must seek approval from the company to

trade in the company’s quoted financial products (shares and retail bonds). Trading is limited

to two trading windows between the full-year announcement date and 31 August, and between

the half-year announcement date and 31 January each year.

The directors’ shareholdings and all trading of quoted financial products during the year by the

directors is disclosed in the ‘Director's disclosures’ section of this report. A director or senior

manager is obliged to advise the NZX promptly if they trade in the company’s shares or retail bonds.

ANNUAL REPORT 2022

159

Statement of corporate governance (continued)
Governance

Experience of governance through board

appointments at other organisations or

through former CEO experience.

••••••••

Executive leadership

Former CEO or C-suite executive with

excellent track record of growing value,

leading with purpose, strategy, development

and execution, including investing in people,

leadership of culture and effective delegation.

•••••

Finance, accounting and taxation

Finance and accounting experience of

large companies. May hold a recognised

accounting qualification. The skills to chair

the Audit, Finance and Risk Committee.

••••

Risk management

Risk management experience developed

through either leadership or governance

roles at similar-sized organisations.

•••••••••

Property and construction

Experience successfully leading property

and construction companies or performing

governance roles for companies in the sector.

Skills to support and challenge new site

investment decisions and build programme.

•••••

Health and safety

Experience in the development of health,

safety and wellbeing frameworks and risk

management tools at large organisations.

••••••

Health, clinical and aged care

Leadership or governance experience

across the health and aged care sector.

•••••••

Digital and technology

Experience in the implementation of

digital transformation or new digital

product development in the health or

aged care sectors.

••

Human resources

Leadership experience in the development

and implementation of people and culture

programmes at large organisations.

••••••

Strategy

Experience of strategic oversight, including

the development and implementation of

strategic plans for organisations of similar

scale and complexity.

•••••••••

Greg Campbell

Dr David Kerr

Jo Appleyard

Warren Bell

George Savvides

Claire Higgins

Geoff Cumming

Anthony Leighs

Paula Jeffs

RYMAN HEALTHCARE

160

Statement of corporate governance (continued)
The board’s

responsibilities

The primary responsibilities of the board are to:

• ensure the company’s goals are clearly established and that strategies are in place for

achieving them

• establish policies for strengthening the performance of the company and ensure that

management is proactively seeking to build the business

• monitor the performance of management

• appoint the group chief executive and set the terms of the group chief executive’s

employment agreement

• decide on what steps are needed to protect the company’s financial position and its

ability to meet its debts and other obligations when they fall due and ensure that such

steps are taken

• ensure the company’s financial statements are true and fair and conform with the law

• ensure the company adheres to high standards of ethics and corporate behaviour

• ensure the company adheres to its health and safety obligations and commitments

• ensure that the company is adopting policies, practices and procedures that result in

the company meeting or exceeding societal and shareholders’ expectations with respect

to environmental, social and governance standards

• ensure the company has appropriate risk management/regulatory compliance policies

in place.

On appointment to the board by the shareholders, new directors sign a written agreement

that covers the terms of their appointment.

Every year, the board and its committees critically evaluate their own performance and

their own processes and procedures. Through this process, the board identifies any training

opportunities for individual directors to ensure they have relevant and up-to-date skills for

performing their role.

Under the Listing Rules, every director must stand for re-election on the later of 3 years

or the third annual meeting after their appointment. These directors may offer themselves

for re-election.

The Governance, Nominations and Remuneration Committee undertakes the process for

nominating directors on behalf of the board and makes appropriate recommendations to

the board.

Directors appointed by the board must retire at the next annual meeting following their

appointment. These directors may offer themselves for re-election.

ANNUAL REPORT 2022

161

Statement of corporate governance (continued)
Diversity

The board and management ensure that all eligible people get an equal opportunity to

demonstrate that they have the right skills and experience for a particular role, which forms

the basis of our diversity policy.

Ryman embraces the uniqueness in all of our people and welcomes diversity. We encourage all

of our employees to listen to each other and to our residents and their families and to work to

meet the needs of individual people.

Our approach to diversity is to continually develop a work environment that supports equality

and inclusion, regardless of difference.

The board sets measurable objectives for assessing performance against Ryman’s diversity

policy (including achieving gender diversity) and assesses progress annually. The board

ensures Ryman’s objectives are appropriate for promoting diversity and inclusion.

The gender diversity for our leadership roles at 31 March is as follows.

20222021

DirectorsMale66

Female33

99

Senior executive teamMale65

Female32

97

Ryman leadersMale224197

Female3 74349

598546

Independent

professional

advice

With the prior approval of the chair, each director has the right to seek independent legal

and other professional advice at the company’s expense about any aspect of the company’s

operations or undertakings to assist in fulfilling their duties and responsibilities as a director.

RYMAN HEALTHCARE

162

Statement of corporate governance (continued)
PRINCIPLE 3 – BOARD COMMITTEES

“The board should use committees where this will enhance its effectiveness in key areas,

while still retaining board responsibility.”

Board

committees

The board has five standing committees: Audit, Finance and Risk; People and Safety;

Clinical Governance; Development, Design and Construction; and Governance, Nominations

and Remuneration.

A separate Independent Directors’ Committee meets as needed.

Each committee operates under specific terms of reference approved by the board.

Any recommendations a committee makes are recommendations to the board.

The terms of reference for each committee are reviewed annually.

Audit,

Finance

and Risk

Committee

The objective of the Audit, Finance and Risk Committee (AFRC) (previously the Audit and

Financial Risk Committee) is to assist the board in discharging its responsibilities for financial

reporting, enterprise risk management and financial/secretarial compliance.

The committee makes recommendations to the board on appointing external auditors to

ensure that they are independent and to ensure that the company provides for a 5-yearly

rotation of the lead audit partner.

The committee provides a forum for effective communication between the board and

external auditors.

The committee’s responsibilities include to:

• review and oversee enterprise risk management, internal control and compliance systems

• review the appointment of the external auditor, the annual audit plan, audit findings

and address any recommendations from the audit

• review and oversee financial performance, forecasting, treasury management,

capital management and debt structure

• approve the release of all financial information.

The AFRC must consist of at least three directors who must wherever possible be independent

non-executive directors. The board chair must also not be the chair of the AFRC. The

current members are Claire Higgins (chair), Warren Bell, Geoff Cumming, Dr David Kerr,

George Savvides and Greg Campbell. Claire Higgins, Dr David Kerr, George Savvides and

Greg Campbell are all independent non-executive directors. Claire Higgins is a Fellow of CPA

Australia, and Warren Bell is a Fellow of Chartered Accountants Australia and New Zealand.

The committee generally invites the group chief executive, group chief financial officer and

external auditor to attend AFRC meetings as appropriate. The committee also meets and

receives regular reports from the external auditor without management present concerning

any matters that arise in connection with the performance of the auditor’s role.

The committee maintains direct lines of communication with the group chief executive

and group chief financial officer. Any director may attend.

ANNUAL REPORT 2022

163

Statement of corporate governance (continued)
Clinical

Governance

Committee

The Clinical Governance Committee supports and enhances the quality of the company’s

clinical performance and care, and exploration of new service provision.

The committee assists the board in discharging its oversight of clinical reporting and clinical

compliance and is focused on innovation in healthcare and ensuring alignment with emerging

best clinical practice.

The committee consists of three non-executive directors – George Savvides (chair),

Dr David Kerr and Jo Appleyard – as well as Tim Wilkinson, a professor at Otago Medical

School and a consulting geriatrician, and Dr Doug Wilson, an author and biotechnologist.

The committee also invite clinically-trained employees to attend as required.

People

and Safety

Committee

The People and Safety Committee assists the board in discharging its responsibilities

in overseeing and reviewing matters relating to organisational culture, health, safety and

wellbeing management and people and culture strategy and the impact of these activities

on employees, contractors, residents and visitors to Ryman.

The committee recognises the critical role people and safety forms as part of

Ryman’s day-to-day operations and wants to ensure a safety-first culture across

all business operations.

The members of the committee are Paula Jeffs (chair), Claire Higgins, Dr David Kerr,

Jo Appleyard, Geoff Cumming, Greg Campbell, Richard Umbers (Group Chief Executive),

as a director of all Ryman Group subsidiaries and David Bennett (Group Chief Financial Officer)

as a director of all Ryman Group subsidiaries.

The committee’s responsibilities include to:

• review and recommend health, safety and wellbeing strategies and provide oversight

of major projects or improvement plans

• review, monitor and make recommendations to the board on the organisation’s health

and safety risk management framework and policies, including assessments that

systems are fit for purpose and being effectively implemented, regularly reviewed

and continuously improved

• monitor compliance with health, safety and wellbeing policies and relevant applicable

law through oversight of major assurance functions conducted across the business and

ensuring that appropriate resources are available

• review and recommend people and culture strategies and provide oversight of major

projects or improvement plans to drive a positive culture and effective workforce

• review and recommend talent, succession and development plans, diversity and inclusion

plans and metrics, remuneration policy and targets, and employee engagement plans.

The committee maintains direct lines of communication with the chief executive – Australia,

chief operations officer, chief construction officer and chief people and safety officer.

RYMAN HEALTHCARE

164

Statement of corporate governance (continued)
Development,

Design and

Construction

Committee

The Development, Design and Construction Committee (previously the Development and

Construction Committee) reviews and enhances the quality of the company’s performance

in the development of integrated retirement villages. The committee has a focus on capital

management and recycling.

The committee assists the board in discharging its oversight of the company’s development,

design and construction activities and practices.

The committee consists of five non-executive directors: Anthony Leighs (chair), Jo Appleyard,

Warren Bell, Claire Higgins and Greg Campbell.

The committee’s responsibilities include to:

• oversee the company’s portfolio of village developments to ensure the annual and

longer-term business plans can be achieved

• monitor the stage-gate progression of projects from land acquisition recommendation to

construction commencement, including making recommendations to the board throughout

the process

• review risk and mitigation measures relevant to the development, design and construction

functions, including timeliness, quality and compliance issues

• review a range of profitability performance metrics for each development

• investigate innovative construction and design methods to improve resident and employee

experiences, improve efficiency and support the sustainability and climate change strategy

• review systems and procedures supporting the design, consent and building process.

The committee maintains direct lines of communication with the group chief executive,

group chief financial officer, chief construction officer and chief executive – Australia.

The committee’s responsibilities are to:

• ensure appropriate clinical information systems and external controls are in place

to achieve statutory compliance and quality care

• liaise with external clinical auditors, including reviewing the appointment of auditors

and audit findings

• liaise with internal clinical auditors and review audit findings

• review significant changes to clinical policies

• review significant complaints and investigations relating to care of residents

• review changes in clinical practice in aged care

• monitor the quality of care experienced by all Ryman residents.

The committee maintains direct lines of communication with the external clinical auditors,

group chief executive, chief operations officer, chief executive officer – Australia and internal

clinical auditor.

External clinical auditors are invited to attend a meeting each year and report to the

committee, including presenting a review of the internal clinical audit function.

ANNUAL REPORT 2022

165

Statement of corporate governance (continued)
Independent

Directors’

Committee

The Independent Directors’ Committee is convened as needed and consists of independent

non-executive directors who address significant conflicts of interest and any other matters

referred by the board.

Ryman has protocols that set out the procedures to be followed if there is a takeover offer.

These procedures are set out in the takeover response protocols that have been adopted

by the board.

Governance,

Nominations

and

Remuneration

Committee

The Governance, Nominations and Remuneration Committee (previously the Governance,

Remuneration and Nomination Committee) assists the board in establishing remuneration

policies and practices for the company in discharging the board’s responsibilities for

remuneration. The committee also undertakes the process for nominating directors on

behalf of the board and makes appropriate recommendations to the board.

Membership of the committee must comprise non-executive directors, a majority of

whom must be independent. The committee consists of four non-executive directors:

Geoff Cumming (chair), Dr David Kerr, George Savvides and Paula Jeffs.

Management attends committee meetings only at the invitation of the committee.

The committee’s objectives are to:

• assist the board in establishing remuneration policies and practices for the company

• assist in discharging the board’s responsibilities for reviewing the group chief executive’s

and directors’ remuneration

• advise and assist the group chief executive in setting remuneration for the senior

executive team

• regularly review and recommend changes to the composition of the board and identify

and recommend individuals for nomination as members of the board and its committees.

The directors’ remuneration is set out in the ‘Director’s disclosures’ section of this report.

Detail of the group chief executive’s remuneration is set out under Principle 5.

RYMAN HEALTHCARE

166

Statement of corporate governance (continued)
Attendance

at board and

committee

meetings

Director attendance at board and committee meetings is shown in the table below.

The table details the attendance at the meetings outlined in the board and committee

meeting plan for the year ended 31 March 2022 plus additional meetings held during the year.

Board meetings consist of a number of meetings held over multiple days.

Board

Audit,

Finance

and Risk

People and

Safety

Clinical

Governance

Development,

Design and

Construction

Governance,

Nominations and

Remuneration

Number of

meetings held

10345123

Greg Campbell

1

102410

Jo Appleyard104510

Warren Bell10312

Geoff Cumming10343 (chair)

Claire Higgins103 (chair)411

Paula Jeffs104 (chair)3

Dr David Kerr103452

Anthony Leighs1012 (chair)

George Savvides1035 (chair)3

The Independent Directors’ Committee did not meet during the year.

1 Greg Campbell replaced Dr David Kerr as chair of the board in January 2022.

Summary of

committee

memberships

CommitteeMembers at 31 March 2022Members at 31 March 2021

Audit, Finance and Risk

(previously Audit and

Financial Risk)

Claire Higgins (chair), Warren Bell,

Dr David Kerr, George Savvides,

Geoff Cumming, Greg Campbell

Claire Higgins (chair), Warren Bell

(deputy chair), Dr David Kerr,

George Savvides, Geoff Cumming,

Greg Campbell

People and Safety Paula Jeffs (chair), Claire Higgins,

Dr David Kerr, Jo Appleyard,

Geoff Cumming, Greg Campbell,

Richard Umbers (Group Chief

Executive), David Bennett

(Group Chief Financial Officer)

Paula Jeffs (chair), Claire Higgins,

Dr David Kerr, Jo Appleyard,

Geoff Cumming, Greg Campbell,

Gordon MacLeod (Group Chief

Executive), David Bennett

(Chief Financial Officer)

Clinical GovernanceGeorge Savvides (chair),

Dr David Kerr, Jo Appleyard,

Tim Wilkinson (external

consultant), Dr Doug Wilson

(external consultant)

George Savvides (chair),

Dr David Kerr, Jo Appleyard,

Tim Wilkinson (external

consultant), Dr Doug Wilson

(external consultant)

Development, Design and

Construction (previously

Development and

Construction)

Anthony Leighs (chair),

Jo Appleyard, Warren Bell,

Claire Higgins, Greg Campbell

Anthony Leighs (chair),

Jo Appleyard, Warren Bell,

Claire Higgins, Greg Campbell

Governance, Nominations

and Remuneration (previously

Governance, Remuneration

and Nomination)

Geoff Cumming (chair),

Dr David Kerr, George Savvides,

Paula Jeffs

Geoff Cumming (chair),

Dr David Kerr, George Savvides,

Paula Jeffs

ANNUAL REPORT 2022

167

Statement of corporate governance (continued)
PRINCIPLE 4 – REPORTING AND DISCLOSURE

“The board should demand integrity in financial and non-financial reporting, and in the timeliness

and balance of corporate disclosures.”

Reporting and

disclosure

The board focuses on providing accurate, adequate and timely information both to existing

shareholders and to the market generally. This enables all investors to make informed

decisions about the company.

As a company listed on the NZX Main Board, Ryman has an obligation to comply with the

disclosure requirements under the NZX Main Board Listing Rules. Ryman recognises that

these requirements aim to provide equal access for all investors or potential investors to

material price-sensitive information concerning issuers or their financial products. This in

turn promotes confidence in the market.

Ryman’s market disclosure policy outlines the obligations of Ryman and relevant Ryman

personnel in satisfying the disclosure requirements. It also covers other related matters

including external communications by Ryman.

This annual report is produced using the principles of Integrated Reporting <IR>. An integrated

report provides more information on the company’s business model and how we create value

over time. As a result, an annual report produced under the <IR> Framework will have a

broader narrative than an annual report that does not use the framework.

Ryman publishes its key governance and other relevant documents in the investor centre

of the company’s website at rymanhealthcare.co.nz/about-us/investors/governance.

All significant announcements made to the NZX and reports issued are also posted on the

company’s website.

RYMAN HEALTHCARE

168

Statement of corporate governance (continued)
PRINCIPLE 5 – REMUNERATION

“The remuneration of directors and executives should be transparent, fair and reasonable.”

Remuneration

The Governance, Nominations and Remuneration Committee makes recommendations

to the board on remuneration matters in keeping with the committee’s terms of reference.

The committee does not have the authority to make decisions on behalf of the board.

The committee is also responsible for making recommendations to the board on the

remuneration of the group chief executive.

The total director remuneration pool is approved by shareholders at the annual general

meeting (AGM) as required under the Listing Rules.

The board is responsible for the setting of individual directors’ fees in line with the approved

pool and the Listing Rules.

Details of the directors’ remuneration for the year are in the ‘Director’s disclosures’ section

of this report.

Ryman has in place a remuneration policy that outlines the key principles that influence

Ryman’s remuneration practices.

The remuneration of the group chief executive and senior executive team is determined by

the significance of their role and the industry. The total remuneration is made up of fixed

remuneration and short-term and medium-term cash-based incentives. The group chief

executive and senior executive team are also members of the senior leadership share scheme

(see note 26 of the financial statements).

The short-term and medium-term incentives are at-risk payments that reward performance.

They are designed to motivate and incentivise senior employees in the delivery of performance

over a 1-year and 3-year operating cycle. The amount payable is set over the performance

period. The payment of the short-term and medium-term incentive depends on achieving

certain results and outcomes. Performance over the 1-year and 3-year periods is measured

against stretch performance targets. The performance metrics differ with each role.

Every year, the committee reviews the levels and appropriateness of these incentives

and weighting.

There are no long-term incentives for the senior executive team that are subject to

performance risk.

The senior leadership share scheme provides certain employees with limited-recourse loans

on an interest-free basis to support the employees’ participation in the scheme.

For accounting purposes, these shares are treated as treasury stock when purchased on

market, due to the features of the scheme.

Shares subject to this scheme have a restricted period of 3 years from the date of purchase

to appropriately incentivise participants over a longer period. The loan is repayable if the

employee is no longer employed by Ryman.

ANNUAL REPORT 2022

169

Statement of corporate governance (continued)
Employees’

remuneration

The table below details the number of Ryman group employees who have earned over

$100,000 during the year ended 31 March 2022. The remuneration includes salary,

short-term incentives and employer’s contribution to KiwiSaver and superannuation.

Remuneration $Number of employees

2,760,000–2,770,0001

620,000–630,0001

600,000–610,0003

560,000–570,0001

530,000–540,0001

510,000–520,0001

450,000–460,0001

390,000–400,0001

370,000–380,0001

350,000–360,0001

340,000–350,0004

320,000–330,0002

310,000–320,0003

300,000–310,0002

280,000–290,0002

270,000–280,0004

260,000–270,0002

250,000–260,0002

240,000–250,0005

230,000–240,0004

220,000–230,00010

210,000–220,0005

200,000–210,00011

190,000–200,00010

180,000–190,00010

170,000–180,00013

160,000–170,00028

150,000–160,00036

140,000–150,00036

130,000–140,00045

120,000–130,00076

110,000–120,00076

100,000–110,000150

RYMAN HEALTHCARE

170

Statement of corporate governance (continued)
Group chief

executive

remuneration

Richard Umbers was appointed group chief executive effective 25 October 2021.

His remuneration for the period 25 October 2021 to 31 March 2022 is as follows:

20222021

$$

Salary498,462-

KiwiSaver14,954-

Subtotal513,416-

Short-term incentive--

Medium-term incentive --

Total remuneration

1

513,416-

Loan provided under the leadership share scheme

2

--

1 There were no other benefits (including long-term incentives) received in this financial year.

2 Richard Umbers is yet to participate in the leadership share scheme.

Gordon MacLeod was group chief executive until 22 October 2021.

His remuneration was as follows:

20222021

$$

Salary1,668,2161,080,284

KiwiSaver80,45432,408

Subtotal1 ,74 8 ,6 701,112,692

Short-term incentive1,013,583-

Medium-term incentive --

Total remuneration2,762,2531,112,692

Loan provided under the leadership share scheme-1,200,000

The at-risk short-term and medium-term incentives are payable on the achievement of certain

key performance indicators (KPIs). These KPIs are focused on the financial performance of

Ryman, specific operational targets and people-related expectations.

ANNUAL REPORT 2022

171

Statement of corporate governance (continued)
PRINCIPLE 7 – AUDITORS

“The board should ensure the quality and independence of the external audit process.”

PRINCIPLE 6 – RISK MANAGEMENT

“Directors should have a sound understanding of the material risks faced by the issuer and how to

manage them. The board should regularly verify that the issuer has appropriate processes that identify

and manage potential and material risks.”

Management

of risk and

internal

controls

External

auditor

The board is responsible for overseeing the company’s system of internal controls to manage

key risks and have overall responsibility for managing risk.

The company maintains a group risk register to identify and manage risk. Specific people and

safety, and clinical risk registers are separately maintained given the significance of these areas

to the business. The senior executive team is responsible for maintaining the risk registers.

Ryman operates an extensive internal accreditation programme that addresses issues such as

service delivery, health, safety and wellbeing, and administration. Internal audits are undertaken

regularly. The results of these audits and critical indicators are regularly reported to the board.

Through the AFRC, the board considers the recommendations and advice of external auditors

and ensures that those recommendations are investigated and, where considered necessary,

appropriate action is taken.

Through the board committees, health, safety and wellbeing is discussed regularly at board,

senior executive team, construction team and operational team meetings. Regular reporting

of key metrics is prepared to assist these teams in managing health, safety and wellbeing risks.

Ryman has a group tax charter that sets out the group tax strategy of Ryman and its subsidiaries.

The tax charter along with the tax risk management policy and other operational tax policies

form part of the group tax governance framework.

Ryman business activities include the construction and operation of retirement villages. These

activities are subject to the impact of climate change. The board has acknowledged that climate

change is a risk to Ryman activities and has accepted responsibility for managing and assessing

climate-related risks. In response to the recognition of climate change as a risk to the operations

of Ryman and in response to its legal obligations as an NZX issuer, Ryman has developed a

roadmap to support the implementation of climate risk-related processes across governance,

strategy, risk management, targets and metrics. The processes identified are consistent with the

climate-related disclosure (CRD) recommendations articulated by the XRB.

Through consultation with external and internal stakeholders, Ryman has identified key risks and

the impact of these risks. These risks and Ryman’s response are detailed in the materiality matrix

contained in this annual report.

The AFRC makes recommendations to the board on the appointment of the external auditor

as set out in its terms of reference. The committee also monitors the independence and

effectiveness of the external auditor and reviews and approves any non-audit services

performed by the external auditor.

RYMAN HEALTHCARE

172

Statement of corporate governance (continued)
PRINCIPLE 8 – SHAREHOLDER RIGHTS AND RELATIONS

“The board should respect the rights of shareholders and foster constructive relationships with

shareholders that encourage them to engage with the issuer.”

Information

for

shareholders

The company seeks to ensure that investors understand its activities by communicating

effectively with them and providing access to clear and balanced information.

The company website rymanhealthcare.co.nz provides an overview of the business and

information about Ryman. This information includes details of operational sites, latest news,

investor information, key corporate governance information and copies of significant NZX

announcements. The website also provides profiles of the directors and the senior executive team.

Previous annual reports, financial statements and results presentations are available on

the website.

Shareholders have the right to vote on major decisions of the company in line with the

requirements set out in the Companies Act 1993 and the Listing Rules.

Communicating

with

shareholders

Ryman has a dedicated investor relations manager and corporate affairs manager. These two

roles allow us to develop strong relationships and ensure our shareholders and bondholders

are kept informed.

Ryman’s investor centre sets out contact details for the investor relations manager and

corporate affairs manager for communications from shareholders.

We send the notice of the AGM to shareholders and publish it on the company website at least

20 working days before the meeting each year.

Voting by

shareholders

Voting on all resolutions at Ryman’s shareholder meetings is conducted by poll. This means

that Ryman shareholders enjoy one share, one vote (subject to any voting restrictions applying

under the Listing Rules).

The committee regularly meets with the external auditor to approve the terms of engagement,

audit partner rotation (at least every 5 years) and audit fee and to review and provide feedback

on the annual audit plan. Every year, a comprehensive review and formal assessment of the

independence and effectiveness of the external auditor is undertaken. The assessment uses

an external auditor evaluation tool, which is internationally recognised and endorsed by the

Independent Directors Council. The AFRC routinely meets with Ryman’s external auditor

Deloitte without management present.

Deloitte attends the company’s AGM.

The company continually monitors its internal control environment. Clinical auditors and

health, safety and wellbeing officers regularly test and assess controls and report their

findings to the Clinical Governance Committee and the People and Safety Committee.

ANNUAL REPORT 2022

173

General disclosures of interest
FOR THE YEAR ENDED 31 MARCH 2022

JO APPLEYARD

PartnerChapman Tripp

1

MemberUniversity of Canterbury Vice-Chancellor Employment Committee

Board memberCommunity Law Canterbury

TrusteeWai Wanaka

WARREN BELL

ChairHallenstein Glasson Holdings Limited group of companies

ChairSt George’s Hospital Inc.

DirectorMeadow Mushrooms group of companies

DirectorCyprus Enterprises Limited

DirectorSabina Limited

DirectorWarren Bell Limited

DirectorCHC Properties Limited

DirectorGlasson Trustee Limited

Director152 Hereford Limited

DirectorNew North Holdings Limited

DirectorWaiwetu Trustees Limited

DirectorHickman Family Trustees Limited

(part shareholder of Airport Business Park Christchurch Limited)

TrusteeEmerald Trust (part shareholder of Airport Business Park Christchurch Limited)

TrusteeWaiwetu Trust (part shareholder of Airport Business Park Christchurch Limited)

Bare trusteeRyman Healthcare Share Scheme ( jointly with Dr David Kerr)

2

Director/shareholderPoraka Limited

GREG CAMPBELL

DirectorChristchurch City Holdings Limited

3

Director

Terrequipe Limited

Director

Transdiesel Limited

Director/shareholder

Greg Campbell Limited

Director

Calder Stewart Family Holdings Limited and associated entities

Trustee

Maia Health Foundation

Director

Ravensdown Limited group of companies

4

Director

Development Christchurch Limited

4

GEOFFREY CUMMING

Chair/CEO/sole shareholderKarori Capital Limited

Chair/CEO/sole shareholderKarori Capital Canada Limited

Shareholder/lender/

joint manager

Various commercial property investment companies in the Caniwi Capital Partners

Limited group of entities

Advisory board member/

unit holder

Viewpoint Global Fund Trust

Advisory board member/

sponsor

Cumming Medical Research Fund, University of Calgary

DirectorAmira Medical Technologies Inc.

RYMAN HEALTHCARE

1 74

General disclosures of interest (continued)
FOR THE YEAR ENDED 31 MARCH 2022

CLAIRE HIGGINS

ChairREI Superannuation Fund Pty Ltd

ChairGMHBA Limited and subsidiaries

DirectorMargin Clear Pty Ltd

DirectorQE042 Pty Ltd

TrusteeHelen Macpherson Smith Trust

PAULA JEFFS

(None)

DR DAVID KERR

Bare trusteeRyman Healthcare Share Scheme ( jointly with Warren Bell)

2

DirectorForté Health Limited

TrusteeChristchurch City Mission

Director/shareholderD.W. Kerr Limited

ANTHONY LEIGHS

DirectorLeighs Construction Holdings Limited and associated entities

Director/shareholderAlisanca Holdings and associated entities

DirectorPortus Property Limited and associated entities

DirectorStar Scaffolding Limited

DirectorLabour Logistics Auckland Limited

DirectorChrist Church Cathedral Reinstatement Limited

4

GEORGE SAVVIDES

ChairSpecial Broadcasting Service (SBS) Australia

DirectorIAG Insurance Australia Group

Chair/shareholderTeamflow Asset Management Pty Ltd

Chair/shareholderTeamflow Pty Ltd

DirectorBuildXACT Software Limited

Chair/shareholder Lewis Street Nine Pty Ltd

ChairNext Science Limited

4

1 Jo has been a director since 2009, and since that time she has performed no professional services for the company in her

capacity as a partner at Chapman Tripp.

2 Greg Campbell has taken over the role of bare trustee of the Ryman Healthcare Leadership Share Scheme from Warren Bell.

3 Resigned post 31 March 2022.

4 Resigned during the year.

ANNUAL REPORT 2022

175

Directors’ disclosures
FOR THE YEAR ENDED 31 MARCH 2022

DIRECTORS’ REMUNERATION POOL

MEMBERSHIP OF COMMITTEES

Directors’ fees are reviewed every 2 years. Fees currently paid to Ryman directors for their

board and board committee responsibilities are paid out of a pool. The pool was set at the

amount approved by shareholders in 2021 ($1,500,000 based on a board of nine directors).

As permitted by Listing Rule 2.11.3, the pool can be increased by the board to enable any

additional non-executive director to be paid the average amount being paid to the other

non-executive directors (excluding the chair). This was not required in 2021. Australia-based

directors’ fees are paid in Australian dollars.

In 2021, the board adopted a fixed share trading plan so that each director must hold shares to

better align directors’ interests with those of the shareholders of Ryman. Under the plan, each

director will acquire shares in Ryman equivalent to 33.33 percent of their gross directors’ fees.

The shares are acquired by a broker on behalf of the directors through on-market purchases

during two fixed trading windows each year. The shares must be retained by the directors for

the term of their appointment, except in exceptional circumstances.

Shares acquired by directors under the plan are included in the disclosed security holdings

at 31 March 2022.

Director fees were aligned with the 2021 recommendations of Ernst & Young's Non-Executive

Director Fee Practices report commissioned by Ryman Healthcare and recommended to

the board by the Governance, Nominations and Remuneration Committee. Directors receive

fees for committee membership, and additional fees are paid to a director who acts as the

chair of a committee. During the year, George Savvides, Claire Higgins, Anthony Leighs,

Geoff Cumming and Paula Jeffs held committee chair positions. The board chair does not

receive fees for committee membership.

The approved fees are as follows.

Fees (per annum)From 1 August 2021Up to 1 August 2021

Board – chair263,000220,000

Board – deputy chair-18,000

Board – member110,000110,500

Committee – chair20,00018,000

Committee – member (excluding board chair)10,000-

Independent Directors’ Committee--

RYMAN HEALTHCARE

176

Directors’ disclosures (continued)
FOR THE YEAR ENDED 31 MARCH 2022

DIRECTORS’ REMUNERATION FOR THE YEAR ($)

DIRECTORS OF SUBSIDIARY COMPANIES

Greg Campbell, Dr David Kerr, Richard Umbers and David Bennett are directors of all

the company’s New Zealand subsidiaries. Claire Higgins, George Savvides, Paula Jeffs,

Richard Umbers, David Bennett and Cameron Holland are directors of Ryman Healthcare

(Australia) Pty Ltd and its subsidiaries. Martyn Osborn is a director of Ryman Healthcare

(Australia) Pty Ltd and Ryman Construction Pty Ltd. David Swann is a director of Ryman

Construction Pty Ltd. Greg Campbell, Dr David Kerr, Richard Umbers and David Bennett

are trustees of the Ryman Healthcare Charitable Trust. Warren Bell and Gordon MacLeod

resigned from their respective subsidiary directorships during the year. No fees are paid to

individuals in their capacity as directors of the subsidiaries.

SPECIFIC DISCLOSURES

In line with the company’s constitution and the Companies Act 1993, the company has

provided insurance for and indemnities to directors of the company and its subsidiaries.

Director

Board

fees

Audit,

Finance

and Risk

fees

Clinical

Governance

fees

Development,

Design and

Construction

fees

Governance,

Nominations,

and

Renumeration

fees

People

and

Safety

fees

Foreign

exchange

Total

directors’

fees

1

Greg Campbell

2

148,4184,167-4,167-4,167-160,919

Jo Appleyard110,167-6,6676,667-6,667-130,168

Warren Bell116,1676,667-6,667---129,501

Geoffrey Cumming110,1676,667--13,3336,6678,457145,291

Claire Higgins110,16719,333-6,667-6,6678,933151,767

Paula Jeffs110,167---6,66719,3338,980145,147

Dr David Kerr

3

211,0832,5002,500-2,5002,500-221,083

Anthony Leighs110,167--19,333---129,500

George Savvides110,1676,66719,333-6,667-8,934151,768

1,136,67046,00128,50043,5012 9,1 6 746,00135,304

1,365,144

1 Fee structure changed effective 1 August 2021, as noted above.

2 Greg Campbell was appointed chair of the board effective 1 January 2022.

3 Dr David Kerr resigned as chair of the board effective 1 January 2022.

The directors’ remuneration paid in the financial year ended 31 March 2022 is within the approved pool.

ANNUAL REPORT 2022

177

Directors’ disclosures (continued)
FOR THE YEAR ENDED 31 MARCH 2022

SECURITY HOLDINGS AT 31 MARCH 2022

Director

Ordinary

shares

RYM010

retail bonds

Jo Appleyard

1

86,885 -

Warren Bell 2,090 -

Greg Campbell

2

79,335 -

Geoffrey Cumming

3

49,040,716 -

Claire Higgins

4

19,011 -

Paula Jeffs 4,668 -

Dr David Kerr

5

388,193 -

Anthony Leighs

6

20,590 -

George Savvides

7

54,746 -

The table above includes shares acquired under the fixed share trading plan.

1 Held as trustees of The Appleyard and Larkin Family Trust.

2 Shares held by Gregory Shane Campbell and Nicole Anne Campbell.

3 Shares held by Karori Capital Limited.

4 Held as trustees of Adam Higgins Superannuation Fund Pty Ltd.

5 An ongoing disclosure notice was lodged on 25 May 2021 showing the transfer of legal holding of 358,000 shares from

DW & DJ Kerr and The DW Kerr Family Trust No. 2 to David William Kerr and Deborah Jane Floyd Kerr.

6 Shares held by Alisanca Holdings Limited.

7 Shares held by Teamflow Asset Management Pty Ltd.

RYMAN HEALTHCARE

178

SECURITY TRANSACTIONS DURING THE YEAR
DirectorNature of interest

Number of securities

acquired/(disposed of )Consideration ($)Date

Dr David KerrBeneficial (358,000) - 25 May 2021

Dr David KerrBeneficial 358,000 - 25 May 2021

Dr David KerrBeneficial 7,000 97,896 25 May 2021

Anthony LeighsBeneficial 10,000 131,600 26 May 2021

Greg CampbellBeneficial 22,600 297,308 26 May 2021

Claire HigginsBeneficial 2,870 3 7, 2 2 5 26 May 2021

Dr David KerrBeneficial 7,000 92,200 27 May 2021

Geoffrey CummingBeneficial 75,434 991,814 27 May 2021

Geoffrey CummingBeneficial 44,566 584,211 27 May 2021

Geoffrey CummingBeneficial 120,000 1,544,748 27 May 2021

Paula JeffsBeneficial 4,000 52,098 1 June 2021

Geoffrey CummingBeneficial 120,000 1,538,400 2 June 2021

Jo AppleyardBeneficial 7,550 99,487 13 July 2021

Dr David KerrBeneficial 15,000 194,275 23 November 2021

Dr David KerrBeneficial 1,193 14,536 6 December 2021

Greg CampbellBeneficial 635 7,73 7 6 December 2021

Geoffrey CummingBeneficial 716 8,724 6 December 2021

Paula JeffsBeneficial 668 8,139 6 December 2021

Warren Bell Beneficial 590 7,189 6 December 2021

Jo AppleyardBeneficial 635 7,73 7 6 December 2021

George SavvidesBeneficial 716 8,724 6 December 2021

Anthony LeighsBeneficial 590 7,189 6 December 2021

Claire HigginsBeneficial 716 8,724 6 December 2021

Greg CampbellBeneficial 8,100 98,650 10 December 2021

Dr David Kerr and Warren Bell, as joint custodians of the Ryman Healthcare Leadership Share Purchase Scheme,

acquired 1,065,259 shares during the year, disposed of 979,030 shares during the year and held 2,741,246 shares

in total at 31 March 2022 (see note 26 of the financial statements).

Directors’ disclosures (continued)

FOR THE YEAR ENDED 31 MARCH 2022

ANNUAL REPORT 2022

179

Shareholder information
TOP 20 SHAREHOLDERS AT 13 MAY 2022

Rank Investor nameNo. of shares% issued capital

1HSBC Nominees (New Zealand) Limited

1

63,549,761 12.71

2Karori Capital Limited 49,040,716 9.81

3BNP Paribas Nominees NZ Limited

1

44,634,772 8.93

4Hickman Family Trustees Limited

2

33,000,000 6.60

5Custodial Services Limited 30,370,270 6.07

6Citibank Nominees (NZ) Limited

1

27,862,632 5.57

7HSBC Nominees (New Zealand) Limited

1

27,086,065 5.42

8BNP Paribas Nominees NZ Limited

1

19,777,777 3.96

9JPMorgan Chase Bank

1

14,177,447 2.84

10Accident Compensation Corporation

1

11,654,909 2.33

11BNP Paribas Nominees NZ Limited Bpss40

1

10,991,024 2.20

12New Zealand Superannuation Fund Nominees Limited

1

10,446,491 2.09

13Tea Custodians Limited

1

10,327,099 2.07

14New Zealand Depository Nominee 7,001,784 1.40

15Forsyth Barr Custodians Limited 6,824,263 1.36

16National Nominees New Zealand Limited

1

6,385,291 1.28

17Premier Nominees Limited

1

5,654,748 1.13

18FNZ Custodians Limited 4,776,019 0.96

19Private Nominees Limited

1

4,240,992 0.85

20Public Trust

1

3,372,635 0.67

1 Held by New Zealand Central Securities Depository Limited as custodian.

2 Held as trustee of the Hickman Family Trust.

DISTRIBUTION OF SHAREHOLDERS AT 13 MAY 2022

Size of shareholdingNumber of shareholdersShares held

1–1,000 6,988 43.07% 3,453,241 0.69%

1,001–5,000 6,241 38.47% 16,014,192 3.20%

5,001–10,000 1,601 9.87% 12,008,107 2 .41%

10,001–50,000 1,184 7.30% 24,558,961 4.91%

50,001–100,000 116 0.71% 7,866,566 1.57%

Greater than 100,000 94 0.58% 436,098,933 87. 2 2 %

Total 16,224 100.00% 500,000,000 100.00%

RYMAN HEALTHCARE

180

Shareholder information (continued)
DISTRIBUTION OF BONDHOLDERS AT 13 MAY 2022

RYM010

Size of shareholdingNumber of bondholdersBonds held

1–1,000 - 0.00% - 0.00%

1,001–5,000 35 6.33% 175,000 0.12%

5,001–10,000 118 21.34% 1,138,000 0.76%

10,001–50,000 334 60.40% 9,092,000 6.06%

50,001–100,000 28 5.06% 2,261,000 1.51%

Greater than 100,000 38 6.87% 137,334,000 91.55%

Total 553 100.00% 150,000,000 100.00%

SUBSTANTIAL PRODUCT HOLDERS AT 31 MARCH 2022

ShareholderRelevant interest

Karori Capital Limited49,040,716 9.81%

Hickman Family Trustees Limited,

1

Kevin James Hickman and Joanna Hickman,

2

Warren Bell,

3


John Lindsay Holland

3

33,000,000 6.60%

ACATIS Investment KVG mbH on behalf of GANÉ Value Event Fonds

4

25,250,0005.05%

A total of 500,000,000 ordinary Ryman shares were on issue as at 31 March 2022 (the only voting products on issue).

1 Held as trustee of The Hickman Family Trust.

2 Joint holders of 100 percent of the shares in and directors of Hickman Family Trustees Limited and beneficiaries of

The Hickman Family Trust.

3 As independent directors of Hickman Family Trustees Limited and associated voting provisions attached to the shares

(alongside the other directors of Hickman Family Trustees Limited).

4 A substantial product holder notice was lodged on 1 October 2021 from the ACATIS Investment KVG mbH on behalf

of GANÉ Value Event Fonds.

ANNUAL REPORT 2022

181

RYMAN HEALTHCARE
182

We would like to thank
you, our team of

Rymanians. We are

immensely proud and

grateful for your incredible

efforts over the past

year. Your commitment

demonstrates what it

means to be a Rymanian,

and we send our sincere

thanks to each and

every one of you.

183

ANNUAL REPORT 2022

Aaminah Ahmed · Aanchal Bajaj · Aaron Allen · Aaron Brown · Aaron Bui · Aaron Edwards · Aaron
Enriquez · Aaron Essenberg · Aaron Eyles · Aaron Silk · Aaron Wairepo · Aarti Rawat · Aasim Zaveeri

· Abbe King · Abbey Mason · Abbey Bray · Abbey Santos · Abbey Williams · Abby Fernandez · Abby

Power · Abby Skipper · Abhi Abhishek · Abhishek Vashisht · Abigail Gacutan · Abigail Webb · Aby

Jomy · Ace Somosot · Achaal Prakash · Adam Allan · Adam Bird · Adam Harbour · Adam Joyce ·

Adam van Raalte · Adeesha Haljothi · Adele Lings · Adeline Plamenco · Adelle Scott · Adetoun

Oyekunle · Adheesha Perera · Adi Baleisomosomo · Adi Ratusai · Adi Secake · Adi Vakalalabure ·

Adrian Crowe · Adrian Lao · Adrianna Pavlekovic · Adrienne Marsh · Adrienne Sincock · Adrienne

Stewart · Adrienne Todd · Adrienne Wadham · Aez Pega · Afroz Sreekandh · Afsoun Nazari · Ag

Bloxham-Toi · Aga Gonzales · Aggie Butler · Agnes Cuanan · Agnes Lakner · Agnes Wallace ·

Aguinaya Ananayo · Agustine Affandi · Ahmed Naji · Aida Cachuela · Aik Eng · Aila Tan · Ailen Gaw

· Ailen Luste · Ailyn Estopace · Ailyn Muyano · Ailyn Reyes-Esmilio · Aima Polestico · Aimee Bell ·

Aimee Court · Aimee Gregory · Aimee Stratta · Aimee Verran · Aimee Wright · Ainslee Buchanan ·

Airun Kumar · Aiv Bagsican · Ajai Roy · Ajay Gautam · Ajay Philip · Ajdin Fejzic · Ajo Jose · Ajuna

Cherian · Akanisi Matanisiga · Akhil Viswambharan · Aki Yumoto · Akku Thomas · Aklima Akter ·

Akshat Tripathi · Al Lim · Alaenna John · Alan Jackson · Alan Wood · Alana Sanderson · Alana

Wallace · Alana Watson · Alanah Faga · Alastair Joyce · Albie Calope · Aldo Atmadja · Alefina

Baleisuva · Aleja Mendez Arango · Alena McCulloch · Alena McKenzie · Alesgo Ngu · Alesha Clark-

Gilmour · Alex Cagalitan · Alex Carter · Alex Cook · Alex Jackson · Alex Jurczenko · Alex Li · Alex

Lopez · Alex Mathew · Alex McNeillie · Alex Price · Alex Purcell · Alexa Alcantara Claudio · Alexa

Todd · Alexandra Perdrisat · Algine Ingking · Alias Kurian · Alice Gordon · Alice Johnstone · Alice

Jones · Alice McDuff · Alice Morrison · Alice Peram · Alice Vargas · Alicia Lane · Alicia Prima · Alie

Brinded · Alina Pariyar · Alisha Alex · Alisha Aliperio · Alisha Figgess · Alison Love · Alison Naylor ·

Alison Winstanley · Alison Wyllie · Alix Fabi · Aliya Bibi · Alka Thakur · Allan Brown · Allan Dempsey

· Allan Macala · Allana Caldwell · Alleah Munoz · Alleisha Briones · Allen Lee · Allen Zhang · Allison

Doak · Ally Harris · Alma Azarcon · Alma Cagalitan · Alma Ramirez · Alma Sicat · Almira Beniasan ·

Almira Bentadan · Alona Wandas · Alona Mateo · Alpha Atienza · Alpho George · Alphonsa George

· Alphy Thankachan · Alphy Thomas · Althea Santos · Alvin Campbell · Aly Procter · Alyana Delima

· Alysha Russell · Alyssa Budy · Alyssa Baxter · Alyssa Marion · Alyssa Saljay · Amal Sunil · Amali

Amarasinghe · Aman Balassi · Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur ·

Amanda Anastasopoulos · Amanda Brocklebank · Amanda Feltoe · Amanda Gilbert · Amanda

Goudie · Amanda He · Amanda Knight · Amanda Kruse · Amanda Murray · Amanda Whithair ·

Amanda Wootton · Amandeep Aulakh · Amandeep Kaur · Amandeep Kaur · Amandeep Sidhu ·

Amanjot Kaur · Amanpreet Kaur · Amanpreet Kaur · Amanpreet Kaur · Amanpreet Mahal · Amar

Kaur · Amaya Samarasinghe · Amber Aguilar · Amber Bottomley · Amber Lewis · Amber McKenzie-

Takau · Amber Qualischefski · Ambily Abraham · Ameek Singh · Amelia Ong · Amendra

Samantilake · Amika Thapa · Amina Dzakic · Amit Khanchi · Amit Patel · Amit Sapkota · Amita

Joseph · Amita Prasad · Amita Vyas · Amith Sabu · Ammy Kaur · Amol Adhokar · Amrit Kaur · Amrit

Kaur · Amrita Raj · Amrita Rattan · Amrutha Mathew · Amy Amtman · Amy Burgess · Amy Carpenter

· Amy Duncan · Amy Flood · Amy Hii · Amy Irwin · Amy Mian · Amy Morrison · Amy Muru · Amy Shen

· Amy Singleton · Amy Thornton · Amy Ward · Amy Wheeler · Amy Woon · Amy Yin · An Nguyen ·

Ana Catahan · Ana Fangupo · Ana Gluyas · Ana Hintay · Ana Leite · Ana Moala · Ana Padrelanan ·

Ana Savou · Ana Vukovic · Anabel Konigstorfer · Anabel Lindstrom · Anajepia Meimban · Analyn

Irorita · Anan Du · Anchitha George · Andre Battrick · Andre Calustre · Andre Kassal · Andrea

Adams · Andrea Ansell · Andrea Burgos · Andrea Butler · Andrea Caitum · Andrea De Wet · Andrea

Deo · Andrea Gaskell · Andrea Hills · Andrea Latoa · Andrea Manuel · Andrea Neil · Andrea

Ngamokopuna · Andrea Pangan · Andrea Smith · Andrea Tremain · Andrei Pirlea · Andresa Mendes

Teles · Andrew Browne · Andrew Caracoglia · Andrew Crerar · Andrew Gibson · Andrew Goldfinch

· Andrew Hilbert · Andrew Hill · Andrew Inch · Andrew Jones · Andrew McKenzie · Andrew Moulding

· Andrew Otto · Andrew Parker · Andrew Quezon · Andrew Roberts · Andrew Robins · Andrew

Searancke · Andryna Eberle · Andy Battersby · Andy Callaghan · Andy Clarke · Andy Heap · Andy

Martin · Andy Maylock · Andy Osborne · Andy Reid · Ane Pulou · Aneely Bhatt · Aneesh Kattikatt

George · Aneesha Aniyan · Ang Chamberlain · Ange Knibb · Angel Augustine · Angel Jose · Angel

Mendoza · Angel Montanez · Angela Aballog · Angela Barraclough · Angela David · Angela Ferguson

· Angela Fidler · Angela Hawkes · Angela Henry · Angela Johnson · Angela Kueh-Henry · Angela

MacKay · Angela McKenzie · Angela McLeod · Angela McMeekin · Angela O’Connor · Angela

Ravlich · Angela Simpson · Angela Singh · Angeli Suson · Angelica Araiza · Angelica Ona · Angelina

Adams · Angelique Roberts · Angelo Trabado · Anggia Puspa Kirana · Angie Angeles · Angie Cope

· Angus Newell · Ani Tuilau · Anika Smith · Anika Snell · Anish Anto · Anisha Chaudhary · Anisha

Thapa · Anit Dominic · Anita Bhusal Banjade · Anita Binns · Anita Chapman · Anita Dayal · Anita

Devi · Anita Devi · Anita Farmer · Anita Lowther · Anita Pau · Anita Setiaji · Anitha Paul · Aniva Hunkin

· Anja Thorne · Anjali Manoj · Anjali Mitra · Anjana Lama · Anjana Poojary · Anjani Chaudhary ·

Anjani Suresh · Anjelyn Pocession · Anjiline Singh · Anju Abraham · Anju Ashok · Anju Malakunnel

Isac · Anju Sajan · Anju Sebastian · Anjumol Saju · Ankita Joshi · Ann Beom · Ann Brady · Ann

Codina · Ann Fernando · Ann Furlong · Ann Joy · Ann Martin · Ann Mongcal · Ann Moorman · Ann

Nelson · Ann Olbinado · Ann Vo · Ann Wongchan · Anna Ao · Anna Benadie · Anna Binas-Lucinario

· Anna Brayshaw · Anna Casaje · Anna Coppens · Anna Crossan · Anna Curzon-Hobson · Anna

DeLorenzo · Anna Flanagan · Anna Groome · Anna Hendry · Anna Holland · Anna Jim · Anna

Johnson · Anna Lai · Anna Lumanglas · Anna Maharjan · Anna McCorkindale · Anna McLeod · Anna

Ouyang · Anna Pochron · Anna Scott · Anna Sianipar · Anna Smith · Anna Sriwulan · Anna Thomson

· Annabel Arcipe · Annabel Macdonald · Annabel Sharp · Annabelle Diamond · Annabelle Ewart ·

Annabelle March · Anna-lee Lyons · Annamay Toa · Anne Cameron · Anne Cantos · Anne Cooke ·

Anne Flint · Anne Hall · Anne Kenna · Anne Nihotte · Anne Nordstrom · Anne O’Donnell · Anne

Streatfeild · Anne Verano · Anneke Kuiti · Anne-Marie Hartley · Annette Adams · Annette Holdaway

· Annette Jeffares · Annette Lawrence · Annette Molloy · Annette Rains · Annie Dao · Annie

Armstrong · Annie Bright · Annie Eunson · Annie Glossop · Annie Tamang · Annie Walker · Annika

Lindquist · Ann-Marie Innes · Annu Gaur · Anoma Gunaratne · Anoop John · Anran Li · Ansh Prasad

· Anshal Hussain · Anshu Singh · Anshul Jairath · Ansu Anna Varkey · Ansu Babu · Anthea Johnson

· Anthony Baragwanath · Anthony Eaglestone · Anthony Mammone · Anto Sundaram · Antoinette

Morgan · Antonette Asuncion · Antonio Lavin Delgado · Anu Gill · Anu Jacob · Anu Joy · Anu Kumar

· Anu Kuruvilla · Anu Mathews · Anu Paul · Anu Samuel · Anu Sebastian · Anu Xavier · Anuja Kunwar

· Anuja Shrestha · Anuradha Shrestha · Anusha Peddina · Anusha Tamang · Anusha Vikram · Ao

Fuifui · Api Arpanpreet · Api Tuinasau · Apoorva Boora · Apple Uy · April Deraja · April Lacson · April

Ladia · April Mahuika · April Nattrass · April Nino · April Pinza · April Roberts · Arahia Wilson · Arati

Tamrakar · Archa Rajan · Archana Varghese · Archanau Devi · Archie Rawat · Aren Tonganibeia ·

Argay Clarin-Alvis · Arge Colado · Argie Forteza · Aria Wood · Ariana Guerin · Ariana Tarapi-Harris

· Ariane De La Pena · Aribo Timaai · Ariel Kwan · Arieta Faalau · Arishma Arti · Arjun George · Arlen

Evangelista · Arlene Corkin · Arlene Simadari · Arlet Anastasia · Armie Estevez · Armie Magcale ·

Arnel Cabanayan · Aroha Blythe · Aroha Te Huia Ngatuere · Arpana Andrades · Arpana Khadka ·

Arraminda Ariate · Arris Maximo · Arsha Gurung · Arthur Keane · Arthur Labiris · Arti Devi · Arti

Karan · Arti Lata · Arti Patel · Arti Prakash · Artika Lata · Artika Naidu · Aruna Prakash · Aruna Ram

· Aruna Reddy · Arvin Singh · Arvin Treebhowan · Asa Porter · Asfeen Khan · Ash Devi · Ash Kant ·

Ash Waszak · Ash Wensor · Asha Babu · Asha John · Asha Kiran · Asha Mariyarasa · Asha Thomas

· Asharif Rahman · Ashika Chand · Ashika Mandri · Ashika Singh · Ashim Singh · Ashish Mankotia ·

Ashka Patel · Ashleigh Griffiths · Ashleigh Kavanagh · Ashley Campbell · Ashley Dacyon · Ashley

Gray · Ashley Gutsell · Ashley Son · Ashley Willis · Ashmita Adhikari · Ashmita Gurung · Ashmita

Lata · Ashmita Roy · Ashnee Prakash · Ashupreet Kaur · Ashvin Mendonca · Ashween Singh ·

Ashwick Sharma · Ashwina Ashwina · Ashwina Seenevassenpillay · Ashwindar Kaur · Ashwini

Krishna · Ashwini Naicker · Asma Akram · Asmita Bhandari · Asmita Hirachan · Asmita Nepali ·

Asmita Rai · Asset Galeno · Astio Tunggonno · Astoria Litt · Aswathy Krishna · Aswathy

Padmanabhan · Aswathy Sreedas · Aswathy Thulaseedharansheela · Aswin Ajithkumar · Ata

Rerekura · Ateliana Ah Kuoi · Athena Tangonan · Athira Thilak · Athulya Jestin · Athulya Rakesh ·

Athulya Thankappan · Atin Suprihatin · Atish Suresh · Aurora Orogo · Ava Hu · Avhie Kagaoan · Avi

Singh · Avrill Burchell · Avrisha Singh · Awanui Tangiia · Awhina White · Axis Donato · Axl Funtila ·

Ayako Oyama · Ayesha Bashir · Ayesha Saeed · Aysha Ideris · Ayteya Lopez · Ayu Hardy · Ayumi

Maruyama · Ayumi Sato · Ayush Prasad · Ayusha Dheke · Azel Ramos · Azumi Kemmotsu-Watt · Ba

Sigola · Babal Kaur · Babita Baluri · Babita Kashyap · Bailee Jackson · Bailee Payne · Bailey

Anderson · Bailey Coombs · Bailey Trotter · Baisil Isaac · Balbir Ghuman · Baljeet Kaur · Baljinder

Kaur · Baljit Kaur · Balpreet Kaur · Bamber Postance · Bano Tasheem · Banu Banu · Barbara Barker

· Barbara Federico · Barbara Large · Barbara Russell · Barbara Turnbull · Barbie Bickerton · Barkha

Prakash · Barsha Timalsina · Bawan Kaur · Bayden Mellington · Bea Patang · Beata Buchajczyk ·

Beauty Chua · Bebien Montecillo · Beck Little · Beck Wilkins · Becky Gillanders · Becky McClelland

· Becky Moore · Becky Olliff · Bedi Thapa · Bee Weiss · Beena David · Beena Tamang · Belinda Bargh

· Belinda Greenwood · Belinda Hunt · Belinda Madriaga · Belinda Petitto · Bella Gray · Bella Jabat ·

Bella Lovison · Ben Bowles · Ben Chesler · Ben Dass Shrestha · Ben Garner · Ben Gonsalves · Ben

Jordan · Ben May · Ben Munro · Ben Musonye · Ben Sommerville · Ben Walshe · Ben Winters · Benita

Edwards · Benita Jessop · Benita Jonathan · Benita Kirkovits · Benita Prasad · Benjamin Cavanagh

· Benjilen Pablo · Benjula Timsina · Benni Hulme · Benson Mejorada · Bensy Philiph · Benzon De

Castro · Bernadette Forsdyke · Bernadette Lerios · Bernadine Faber · Bernard Cagalawan ·

Bernard Philpott · Bernie Pask · Bert Barola · Beryl Ryan · Beth Aseniero · Beth Capistrano · Beth

Fernandez · Beth Haryett · Beth Minsalan · Beth Po · Beth Reaney · Beth Smillie · Bethany Douglas ·

Bethany Edie · Betty Groves · Betty Lamb · Bev Dela Cruz · Bev Fockenga · Bev Newdick · Bev

Tembo · Bev Todd · Bev Toms · Bev Walker · Bevan Harris · Bex Croft · Bex Dean · Bex Nawalowalo

· Bex Neera · Beza Esclamado · Bharti Bedi · Bhavneet Kaur · Bheng Barrientos · Bhumi Jain · Bianca

de Agrella · Bianca Szabo · Bianca Van Doren · Bibin Christopher · Bibin Philip · Bibin Vijayan ·

Biddhya Gurung · Bidhya Magar · Bijo Mathew · Bikash Pathak · Bill Jin · Bill McCurdy · Billy Vickers

· Bimala Galaju · Bimbika Sirimane · Bina Patel · Bina Prajapati · Bina Pun · Binay Shrestha · Bindu

Paul · Bini Gurung · Binky Marsh · Binter Joseph · Binu Tiwari · Biyanka Maisuria · Blair Cullen · Blaire

Jang · Blake Amtman · Blanch Laroga · Blanche McLean · Blessie Lintag · Blessy Mathew · Blythe

Ward · Bobby Abhilash · Bobby Beck · Bobby Trolove · Bobin Pullikkattil Jose · Boris Barnett ·

Boritta Vorng · Braam Ellis · Brad Adlam · Brad Thomas · Brandi Ireton · Brando Bartolome ·

Brandon Paul · Breanna West · Brechell Dela Vega · Bree Gerritsen · Bree Farrow · Bree Herrick ·

Bree Jones · Bree Rayment · Brenda Dudson · Brenda Ferguson · Brenda Hobbs · Brenda

Schroeder · Brendon Marsh · Brent Lee · Brent Maru · Brent Morfett · Brent Sweeney · Brett

Johnson · Bri Insley · Brian Bark · Brian Irvine · Brian Robinson · Brian Tidey · Brian Ward · Brianna

McDonald · Brice Imanishimwe · Bridget Bocock · Bridget Free · Bridget Lyons · Bridgette des

Landes · Bridie Green · Brie Brian-Lumsden · Brieanna Hobbs · Briee Robinson · Brit Gilmore · Brita

Corbett · Brittany Francis · Brittany Jeffcott-Moore · Brittany Lovejoy · Brittany Wilson · Brodie

Hewitt · Brodie McPhail · Bronnie Carston · Bronte Lamond-Aird · Bronwyn Hancock · Bronwyn

Thomas · Brook Spedding · Brooke Arnold · Brooke Hughes · Brooke Muirsmeath · Brooke Roberts

· Brooke Tainui · Brooke Tyler · Brooke Upjohn · Bruce Andrews · Bruce Court-Patience · Bruce

Dawkins · Bruce Hodge · Bruce Nolan · Bruna Manduci · Bryan Bolong · Bryan Giray · Bryan

Manlangit · Bryant Fernandez · Bryce Rae · Brydie Baxter · Brydie Curtis · Buddhima Arachchige ·

Caelum Ewens · Caitlin Couling · Caitlin Jones · Caitlin Schultz · Caitlin Degering · Caitlin Foster ·

Caitlin McDonnell · Caitlin Taylor · Caitlin Thomas · Caleb Lepper · Caley McNeely · Callum

Chatfield · Callum Morrish · Cam Holland · Cam Palmer · Cam Sidhu Sidhu · Cameron Robertson ·

Cameron Scott · Camila Glaser · Camila Tawse-Smith · Camila West · Camilla Ryzner · Camille

Antonio · Camille Cajoles · Camille Santos · Candice Camingawan · Cara Bennett · Cara Floreza ·

Cardona Castro · Carina Paynter · Carina Toscano · Carl Arnst · Carl Dela Cruz · Carl McCullough ·

Carla Davies · Carla Dela Cruz · Carla Jones · Carla Lofredo · Carla Mantella · Carlo Damiani ·

Carmel Magbojos · Carmel Marino · Caro Swanston · Carol Duke · Carol Kay · Carol Luttrell · Carol

Mathias · Carol Nguyen · Carol Restrepo Ledesma · Carol Simpson · Carol Toohill · Carola Acevedo

· Carole Quickfall · Carolina Russi Serrato · Caroline Hart · Caroline Jones · Caroline Kean · Caroline

Manning · Caroline Martin Salas · Caroline Potgieter · Caroline Reyland · Caroline Senior · Caroline

Shanks · Caroline Skegg · Carolyn Delugar · Carolyn Faloon · Carolyn Greenaway · Carolyn Grogan-

Tinney · Carolyn Khan · Carolyn Lennox · Carolyn MacDonell · Carolynn Aicken · Carolynn Phillips ·

Carrie Duncan · Carroll King · Casey Cowley · Cassandra Osborne · Cassandra Wallis · Cassarndra

McNeil · Cassidy McMillan · Cassidy Woods · Cassie Chen · Cassie Scaife · Cassie Stephens ·

Cassie Ward · Cassim Nawaz · Cat Maessen · Cate Unsworth · Cath Concon · Cath Magbaton · Cath

Seguan · Catherine Bosch · Catherine Bunting · Catherine Cordwell · Catherine Haren · Catherine

Jalbuena · Catherine McKellar · Catherine Ramos · Cathrina Ababat · Cathy Byrne · Cathy

McDermott · Cathy Yang · Cathy Young · Cathy Zhou · Cece Moore · Cecelia Alford · Cecilia

Hansson · Cecilia Herrera · Cecilia Kerekes · Cecille Winspear · Cel Amante · Cel Padayogdog ·

Celeste Boonzaaier · Celeste Payne · Celeste Wallbank · Celia Anderson · Celia Doleman · Celly

Wilson · Celthea Yu · Cha Cabalagnan · Cha Diaz · Cha Juco · Chakri Siluveru · Cham Saragena ·

Chamara Hettiarachchige · Chan Manuel · Chandan Kaur · Chanel Porter-Reidy · Chanette

Teodosio · Chanpreet Kaur · Chantal Atngag · Chantal Guiguit · Chantal Kennedy · Chante Fourie ·

Chantel Pilcher · Chantelle Hand · Chantelle Hocking · Char Spencer · Charan Dhillon · Charie

Paytocan · Charise Meunier · Charisse Spence · Charith Ruwanpathirana · Charla Graham ·

Charlene Javier · Charlene Lardizabal · Charlene Tabigne · Charles Bushell · Charles Hall · Charles

Han · Charles Hannaford · Charles Serino · Charli Bootsma · Charlie Uy · Charlotte Body · Charlotte

Brown · Charlotte Bullock · Charlotte Hughes · Charlotte Key · Charlotte Senining · Charlotte

Turner · Charlyne Casil · Charm Laguardia · Charm Pontillano · Charmae Golosino · Charmagne

Castillo · Charmaine Infante · Charmaine Jeciel · Charmaine Lim-Capendit · Charmaine Smith ·

Charmaine Staines · Charmaine Tan · Charmaine Urbano · Charmaine Volschenk · Charmayne

Clarke · Charu Solanki · Chayle Argallon · Chazz Legaspi · Chee Chang Ho · Cheer Lin · Chelcei

Ninal · Chell Biato · Chelsea Gray · Chelsea Hill · Chelsea Richdale · Chelsea Sleep · Chelsea Woolf

· Chelsea Ziolo · Cherie Belcher · Cherie Brosnan · Cherie Reamico · Cherise Finnie · Cherry

Casama · Cherry Gallego · Cherry Lagare · Cherry Quiros · Cherry Ramel · Cherry Taleno · Cherryl

Bauzon · Cheryl Allan · Cheryl Buchanan · Cheryl Laguit · Cherylynn Stevenson · Chessie Yap ·

Cheyenne Gamblin · Cheyne Chalmers · Chhiring Lama · Chi Zhao · Chiara Mercer · Chikaina

Makatea · Chike Seguban · Chin Tutty · Chinchu Boban · Chinchu Charly · Chiquita Fleming · Chira

Ngamlerd · Chit Escalon · Chitra Devi · Chitt Fajardo · Chizuko Fabrin · Chloe Fitzgibbon · Chloe Gao

· Chloe Miller · Chloe Perez · Chloe Ruffles · Chloe Winn · Chris Ackerman · Chris Allen · Chris

Anderson · Chris Ashton · Chris Baet · Chris Beckett · Chris Busbridge · Chris Camm · Chris

Caselton · Chris Church · Chris Corriea · Chris Dombroski · Chris Downes · Chris Evans · Chris Hall

184

RYMAN HEALTHCARE

· Chris Harwood · Chris Henry · Chris James · Chris Jobe · Chris Keilty · Chris Kirk · Chris Lim · Chris
MacDonell · Chris Mathai · Chris Morell · Chris Owans · Chris Parker · Chris Saxon · Chris Sinclair ·

Chris Storer · Chris Strapp · Chris Sutton · Chris Timoti · Chris Tottenham · Chris Tunbridge · Chris

Tweedie · Chris Wright · Chrissy Atkins · Chrissy Macpherson · Chrissy Mathews · Chrissy Nkya ·

Chrissy Stanton · Chrissy Thompson · Chrissy Toa · Christelle Sazon · Christensen Barcelona ·

Christian Kiley · Christianna Yu · Christina Navarro · Christina Niutao · Christina Potgieter ·

Christina Reed · Christine Buck · Christine Clarke · Christine De Leon · Christine Dhariwal ·

Christine Elizalde · Christine Han · Christine Hawley · Christine Javier · Christine Kwiatkowski ·

Christine Labiton · Christine Langford · Christine Langley · Christine Laurente · Christine McCurdy

· Christine Miller · Christine Pauling · Christine Wang · Christo Paulraj · Christoph Fernandes ·

Christopher Singer · Christy Solina · Chu Kohlman · Chu Templa · Chua Chua · Chummy Madarieta

· Chunmei Li · Chyna Javier · Cici Miao · Cijo Augustine · Cilla T Stevenson · Cindy Cao · Cindy

Evangelista · Cindy Hou · Cindy Velasquez · Cindy Zhang · Citra Praditi · Claire Bate · Claire Burrell

· Claire Daunivavana · Claire Flanagan · Claire Harris · Claire She · Claire Vaughan · Claire Whitfield

· Clara Harrison · Clara Tan · Clarace Codyre · Clare Bower · Clare Burgess · Clare Glasspool · Clare

McKone · Clarissa Alojado · Clark Magtibay · Claudette Ndenzako · Claudia May · Claudia Reed ·

Claudia Rogers · Claudia Rueda De La Serna · Claudita Tayag · Clayton Jones · Cliff Lasmarias ·

Clint Deane · Clint Virgona · Clinton Palmer · Clod Uy · Coco Prak · Colin Alderson · Colin Caldwell ·

Colin Cameron · Colin Vose · Colleen Johnson · Colleen McCann · Colleen Watson · Collette

Backhouse · Collette Gordon · Comaneci Ong · Con Ciobanu · Con Van Niekerk · Conie Tiongson ·

Connell Bergin · Connie Fernandez · Connie Tagle · Connie Waine · Conor Fyall · Cooper Burns ·

Cora Jambalos · Cora Van der Heul · Coralea Potgieter · Coralie Vine · Corien Blom · Cornelia Chin

· Correen Steyn · Corrie Jarme · Corrine Belencion · Corrine Gillan · Corrinne Cooper · Cory Bryan

· Courtney Opie · Courtney Heberley · Courtney Skene · Courtney Trautvetter · Craig Atkinson ·

Craig Gibbons · Craig Hardy · Cree Fulford · Cris Viernes · Criselda Agbayani · Crish Landiza ·

Crishelle Robertson · Cristal Lozada · Cristel Carter · Cristina Alejandro · Cristina Corre · Cristina

Oliquiano · Cristina Plevko · Cristine Penuela · Cristy Carreon · Crystal Payne · Crystal Pomale ·

Crystal Walker · Csilla Feherne Kincses · Cushla Manaia · Cuzzy Iwai · Cym Seguan · Cynthia Bunag

· Cynthia Mercado · Cynthia Soriano · Cyril Balloso · Cyrus Vallecera · Czarina Ederango · Czarina

Pangilinan · Czhanna Dayo · Dae Yude · Dahlia Bontilao · Dailyn Meo · Dainah Magonde · Daisy Duka

· Daisy Lane · Daisy Wang · Dale Basinal · Dale Bell · Dale Donoghue · Dale Sadler · Daman Kaur ·

Daman Kaur · Damani Lata · Damith Amarathunga · Dan Domalanta · Dan Liu · Dan Pega · Dan Reid

· Dan Russo · Dan Vajc · Dana Levy-Sadlier · Danelle Franklin · Dani Bartle · Dani Bonoan · Dani Yu ·

Danica Little · Daniel Bakht-Khosh · Daniel Baldwin · Daniel Franklin · Daniel Halengo · Daniel Hanelt

· Daniel Knell · Daniel Pavletich · Daniela Diederichs · Danielle Jeffery · Danielle Kalkhoven · Danielle

Moran · Danielle Newton · Danielle Numan · Danielle Park · Danielle Steer · Danielle Tweed · Danni

Bond · Danni Wood · Dannie Bajkai · Danny Connery · Danny Roddick · Dara Prak · Darian Norgate

· Darille Huhu · Dario Parolin · Darlene Ross · Darnell Bonita · Darren Hicarte · Darrin Findlay · Darrryl

Neshausen · Darryl Smith · Darsana Ram Bindu · Darshan Patel · Daryl Page · Dashan Kaur · Dave

Clearwater · Dave Cooper · Dave Cronin · Dave Ellis · Dave Monk · Dave Murrell · Dave Pogson ·

Dave Robertson · Dave Sevilleno · Dave So · Dave Syle · Dave Wu · David Bennett · David Boston ·

David Cartwright · David Datoy · David de Veth · David Emblin · David Gibson · David Hall · David

Herrera-Rodriguez · David Kenny · David King · David Laing · David Ma · David Macdonald · David

Mahony · David Mills · David Oldham · David Oliver · David Ravenscroft · David Sepulveda · David

Stevens · David Swann · Davinder Kaur · Davinder Kaur · Davinna McDonald · Davu Deol · Dawn

Hunt · Dawn White · Daylinda Durango · Dayna Mckay · Dean Jackson · Deanna Glasson · Deb

Argent · Deb Butler · Deb Klein · Deb Ray · Deb Richardson · Deb Smith · Debbie Mindoro · Debbie

Ansett · Debbie Bontuyan · Debbie Bridger · Debbie Buchanan · Debbie Chapman · Debbie Dai ·

Debbie Dixon · Debbie Gemmell · Debbie Gray · Debbie Hartley · Debbie Hicks · Debbie Horne ·

Debbie Kennedy · Debbie Kilgour · Debbie Komarkowski · Debbie Lin · Debbie Ogden · Debbie

Quennell · Debbie Shotter · Debbie Wells · Debbie Williams · Debbie Zhou · Deborah Budden ·

Deborah Forde · Debra Berryman · Debra Lamartinie · Debra Stone · Debs Gordon · Declan

Rhodes · Dedeh Karyati · Dee Aery · Dee Broad · Dee Dilhani · Dee Geetanjali · Dee Jones · Dee

Mantell-Harding · Dee Matakece · Dee Nadan · Dee Reddy · Deep Kaur · Deep Kaur · Deepa

Bhandari G C · Deepa Lohala · Deepa Magar · Deepa Sigas · Deepa Sudhakaran · Deepak Chauhan

· Deepani Hewa Batagodage · Deepankshi Deepankshi · Deepi Kaur · Deepika Deepika · Deepika

Deepika · Deepika Wijesekara · Deeviya Patel · Dehan Henning · Deidre Flemming · Deidre

MacGregor · Deirdre Finlayson · Dekodda Tippett · Delia Espenido · Delia Wilkinson · Dell Smythe ·

Denicee Alongo · Denis Goodwin · Denise Carppe · Denise Chandler · Denise Cunniffe · Denise

Greenbank · Denise Higgs · Denise Hutchison · Denise Martin · Denise Payne · Denise Scott ·

Denise Thompson · Denisse Valdrez · Dennis De Leon · Dennis Frazer · Deo Arenajo · Derek Bird ·

Derek Gibbs · Derek Greening · Derek Holland · Derek Rodgers · Des Fielder · Desiree Vermeeren ·

Desirie Diwa · Desley Lawrence · Destinee Duthie · Dev Little · Devanshi Soni · Devi Arifah · Devi

Nagalingam · Devika Reddy · Devon Liddell · Devon Maurice · Dhanju Rana · Dhanya Ciril · Dhanya

Francis · Dhanya Lukose · Dhorey Gabinete · Dhruv Patel · Dhruvi Shah · Di George · Di Lister · Di

Mannix · Di McKenzie · Di Page · Di Sinclair · Di Tahi · Diana Brown · Diana Ettema · Diana Hanafin ·

Diana Keith · Diana Nicolescu · Diana Plesovs · Diana Sian · Diane Anderson · Diane Brown · Diane

Mondero · Diane Smiler · Diane Smith · Diane Taylor · Diane Vergara-Galang · Diane Wood · Dianhui

Huang · Dianna Alexander · Dianne Amolong · Dianne Austin · Dianne Casimiro · Dianne Dona ·

Dianne Durham · Dianne Melhuish · Dianne Rosado · Dianne Thompson · Diedri Bates · Diem Tran ·

Diksha Darlami · Diksha Mainh · Dilani Arachchilage · Dilpreet Kaur · Dilpreet Kaur · Dilshani

Mudiyanselage · Dina Garcia · Dindo Caitum · Dinika Godakumbura · Dinithi Medagedara · Dinna

Ermitano · Dipal Patelia · Disha Gandhi · Disha Kaur · Dishna Karunarathna · Divya Sebastian · Divya

Velunny · Dolly Alekar · Dolor Raposas · Don MacKay · Don Mathew · Dona Abeywickrama · Donah

Cagalawan · Donald Ferguson · Donald Pool · Donna Barnes · Donna Bradford · Donna Campbell ·

Donna Dael · Donna Dungey · Donna Flaws · Donna Garcia · Donna Gonzales · Donna Lepardo ·

Donna Lewis · Donna Munoz · Donna Rose · Donna Summerfield · Donna Tercenio · Donnelle Dean

· Dora Martinez-Velandia · Doreen Dacanay · Doreen Kumar · Doreen Lata · Doreen Narayan · Doris

Genovese · Dorji Yangzom · Dorothy Harris · Dorothy Kudinha · Dorothy Tavinor · Dot Luna · Dottie

Abuyabor · Doug Holt · Douglas Zhang · Dovie Villalobos · Dragan Mitrevski · Duncan Phillips ·

Duncan Underhill · Dustin Dominic · Dustin Tran · Dvenn Loibl · Dwi Wangsawidjaja · Dyan Rosquita

· Dylan Geldard · Dylan Sharma · Dylan Turner · Dylann Sweeney · Earl Te · Eda Galias · Eddie Deo ·

Eddie Kemp · Eddie Parker · Eddie Tandy · Eden Chapman · Eden Marshall · Edgar Condino · Edgar

Mamaril · Edgardo Blaya · Edi Igot · Edward Marshall · Edwina Hutchings · Edy Sayson · Effie

Emmanouel · Egho Lozada · Eileen Kielty · Eileen Welford · Eileen Wu · Eina Campos · Ekta Kaur ·

Ekta Sharma · Elaine Galbraith · Elaine Luay · Elaine Marsh · Ele Bibby · Eleanor Gaffley · Eleanor

Lee · Eleanor Santos · Eleen Kee · Elena Delector · Elena Kubesh · Elena Turnley · Eleni Heaven ·

Eleni Meimaris · Eleonor Moral · Eliana Kerrigan · Eliane Machado · Elina Rajie · Elina Yang · Elise

Clark · Elisel Valoria · Eliseo Lapus · Elishwa Toma · Eliza Smith · Elizabeth Bethell · Elizabeth

Caboverde · Elizabeth Davie · Elizabeth Dibanadane · Elizabeth Hunter · Elizabeth Mans · Elizabeth

Okanga · Elizabeth Peters · Elizabeth Ruffles · Elizabeth Waghorn · Elka Drozdowski · Ella Griffin ·

Ella Mravicich · Ella-Rose Henderson · Ellen Anastacio · Ellen Baguio · Ellen Cribb · Ellen

Encarnacion · Ellen Ganzon · Ellen Giles · Ellie Bovey-Brown · Ellie Siu · Ellie Welch · Ellie Wilson ·

Ellora Santos · Elly Nash · Elma Reoma · Elmer Carreon · Elodie Jullien · Eloisa Obnial · Eloise Baker

· Eloise Viscarra · Elona Walker · Elsie Pablo · Elsie Warriner · Elva Latonio · Elvia Fitriany · Elvira

Tangonan · Ely Masil · Emalyn Prosia · Emelie Taposok · Emelita Cagas · Emilia Ackerman · Emily

Andersen · Emily Burgess · Emily Chen · Emily Cruz · Emily Curd · Emily Dunbar · Emily Hayward ·

Emily Jepson · Emily Langdon · Emily Maoe · Emily Matthews · Emily Price · Emily Truong · Emily

Underwood · Emily White · Emily Xi · Emma Baker · Emma Begg · Emma Burnett · Emma Clark ·

Emma Coles · Emma Eason · Emma Ford · Emma Harper · Emma Hogan · Emma Holder · Emma

Jamie de Laborde · Emma Kielty · Emma Knott · Emma Lim-Yip · Emma McLeod · Emma Ngoc ·

Emma Nolan · Emma Raho · Emma Rankin · Emma Reardon · Emma Reece · Emma Ritchie · Emma

Saquiban · Emma Singh · Emma Tarunge-Wasi · Emma Tuipulotu · Emma Webb · Emman Galve ·

Emmy Dolotina · Entani Naidu · Eric Demo · Eric van Diggele · Eric Yu · Erica Bacasen · Erica

Butcher · Erick Abille · Ericka Sauquillo Adoyo · Erik Homena · Erin Lesley · Erin Munisamy · Erin

Pole · Erin Woodcraft · Erll Hulleza · Ernesto Espiritu · Eru Raroa · Erwin Blacer · Esau Knowles ·

Esmie Gonzaga · Este Barnard · Estela Garcia · Estela Guiao · Estella Jin · Estelle O’Neil · Estelle

Ramtano · Ester Da Rosa · Esther Cole · Esther Curtis · Esther Gupana · Esther Hukui · Esther Kingi

· Esther Lawangen · Esther Lin · Esther Simpson · Esther Zvenyika · Ethan McCarthy · Ethan

Prentice · Ethan Turner · Ethel Mondarte · Eti Aunese · Eugene Ortile · Eugenie May · Eunice Parreno

· Eunice Salenga · Eurita Balazo · Eva De Jong · Eva Mago · Eva Pan · Eva Rotich · Eva Xu · Eve

Espanta · Eve Lock · Eve Ojales · Evelinda Elan · Evelyn Liu · Evelyn Booth · Evelyn Cadzow · Evelyn

Calaunan · Evelyn Espina · Ezra Erueti · Fadhel Al Halwachi · Faeona Wallace · Fair Rupal · Faith

Sakalia · Fallon Eynon · Fana Raveora · Fang Zhou · Fara Naicake · Farah Abuyabor · Farida Shilpi ·

Fariha Nowshin · Farisha Begum · Farishta Samadi · Farry Hardianto · Farzana Begum · Farzana Bi ·

Faseela Thodi · Fatima Hima · Fay Furness · Fay Lilley · Fay Ramirez-de Jong · Fe Asinas · Fe Cuevas

· Fe Taganas · Fefiloi Tausi · Felicity King · Felis Pael · Felix Lacerna · Felmi Thomas · Fely Magpantay

· Fenton Prickett · Ferdi Roncal · Fermina Pasiona · Fern Elias · Feroza Bano · Figen Tunc · Fin Martin

· Finau Kafoa · Finbarr Doherty · Fincy Francis · Fiona Chen · Fiona Douglas · Fiona Dube · Fiona

Justine · Fiona Kingi · Fiona Le Gros · Fiona Noonan · Fiona Quinn · Fiona Rolland · Fiona Scotland ·

Fipe Lama · Fletcher Clarke · Fleur Smith · Flo Schrimpf · Flor Anasarias · Flora Torres · Florance

Nikeeta · Floren Guira · Florence Collis · Florence Esteban · Florence Mallari · Fonda Burt · Fortune

Onwukwe · Fraan Quirk · Fran Inoue · Fran Parkinson · Fran Spitzer · Fran Troncoso · Frances Bola ·

Frances Brown · Frances Haworth · Frances Le Grice · Frances Palmer · Frances Twaalfhoven ·

Frances West · Francesca Dela Cruz · Francesca Lockyer · Francie Cappleman · Francine

Palendeng · Francis Deferia · Francisca Soto · Frank Ryan · Frank Wang · Franz Sale · Fraser Hendry

· Fraser Mander · Fraser Sheat · Freda Chase · Freda Raptopoulos · Freda Van Schouten · Freddy

Akkara · Frelyn Acuzar · Fritha Ellis · Fritz Lozano · Frozan Azizi · Gabby Da Rosa · Gabby Hermen-

Free · Gabby Nunn · Gabriel D’Alberto · Gabriel Gimena · Gabrielle Lewis · Gabrielle Raife · Gaby

Maniloff · Gagan Dhaliwal · Gagan Hothi · Gagan Kaur · Gagan Kaur · Gagan Kaur · Gagan Kharoud

· Gagandeep Kaur · Gaganpreet Kaur · Gagneet Kaur · Gail Brown · Gail Calicdan · Gail Castro · Gail

Miller · Gail Te Au · Galina Shipina · Gamage Priyangika Sandamali · Garlett Ceniza · Garry Bott ·

Garry Dentice · Garry Singh · Gary Body · Gary Cox · Gary Robinson · Gary Sutcliffe · Gavin Lucas ·

Gay Benabaye · Gay Libatog · Gay Ordonio · Gayathri Kumar · Gaye Duff-Laing · Gayle Watt ·

Gayleen Watkins · Gaylene Downs · Gaylene Graham · Gaylene Hutcheson · Gedy Belicario · Geet

Sidhu · Geeta Mongam · Geetha Marupati · Gellie Dela Cruz · Gelyn Dalusag · Gem Evans · Gemeda

Wesho · Gemma Fernandez Duck · Gemma Hindley · Gemma Raumati · Gemma Tattley · Gen

Bautista · Gen Cabarles · Gen McEwan · Genalyn Arca · Gene Sanchez · Genelil Gonzales ·

Generose Jocson · Geneveve Van Dooren · Genevieve Schrijvers · Gennelle Davies · George

Crawford · George Mathew · George Sebastian · Georgekutty Joseph · Georgia Berry · Georgia

Butler · Georgia Kendall · Georgia Kirk · Georgia Ritchie · Georgia Sherlock · Georgia Smaill ·

Georgia Smith · Georgia Taylor · Georgie O’Dea · Georgina Spiers · Geraldine Kevill · Gerlie Navaja

· Ghela Domalanta · Gifty Anthrayose · Gihani Chathurika · Gil Fielding · Gil Ona · Gilbert Romero ·

Gilly Noon · Gilu Johnson · Gina Parkinson · Gina Salt · Gina Schenkel · Gina Villanueva · Gina Yan ·

Ginnie Ravell · Gino Magsino · Giovanna Falchi · Girley Pingol · Girlie Stevens · Giroma Labradores ·

Gisha Chandy · Glady Davis · Gladys Muwunganirwa · Gladys Datugan · Gladys Dayrit · Gladys

Gaspar · Glaiza Alwit · Glaiza Bernardo · Glaiza Saul · Glen Thomson · Glenda Aggarao · Glenn

Lubguban · Glenn McNickle · Glenn Scott · Glenn Taylor · Glenys Percy · Glenys Popenhagen ·

Glenys Stewart · Gloria Kavanagh · Gloria Kawadza · Gloria Wardle · Glyn Jenkins · Glynis Brenner

· Glynn Pegarro · Glynnis Mackay · Gogi Mudhar · Golda Ceniza · Gong Padayogdog · Gordon

Lambagan · Gorica Brasic · Govind Ghemre · GR Taala · Grace Aldridge · Grace Anacleto · Grace

Arbitrario · Grace Armstrong · Grace Blake · Grace Boyle · Grace Brunke · Grace Buchanan · Grace

Castro · Grace Fleming · Grace Gubatan · Grace Justus · Grace Kamuhangire · Grace Lubos ·

Grace MacIntyre · Grace Martinez · Grace Nathan · Grace Nieto · Grace Nochefranca · Grace

Samuel · Grace Tabut · Grace Tavara · Grace Tubo · Grace Wang · Grace Wei · Grace Wilson ·

Gracely Miyake · Gracie McLeod · Graeme Marriott · Graeme Thomson · Graeme Wilson · Grant

Costello · Grant King · Greece Tade · Greema Paul · Greeshma Kallanakkara Rajan · Greeshma

Susham · Greg Barclay · Greg Conquest · Greg Giles · Greg Pearce · Greg Small · Greg Whithair ·

Greta Kennedy · Gretch Tacuyan · Guilherme Reis · Gul Kaur · Guncha Maggu · Gunpreet Tiwana ·

Guri Mahel · Guri Singh · Gurjeet Kaur · Gurjit Kaur · Gurjit Kaur · Gurki Sandhu · Gurleen Kaur ·

Gurmeet Kaur · Gurmeet Kaur · Gurneet Kaur · Gurpreet Bhullar · Gurpreet Dhillon · Gurpreet Kaur

· Gurpreet Kaur · Gurpreet Kaur · Gurpreet Kaur-Gill · Gursharan Kaur · Gursharan Kaur · Gurwinder

Kaur · Guy Dryden · Guy Warburton · Gween Balistoy · Gwen Cajigas · Gwen Ward · Habiba Neniel ·

Hadrian Sultan · Hafsah Loukili · Haley Tran · Hamida Khan · Hamish Kennedy · Hamish Smith ·

Hanan Alshbrawi · Haneen Bsaiso · Hanh Pham · Hani Fatu · Hanna Huang · Hannah Angelucci ·

Hannah Apurillo · Hannah Barlow · Hannah Byas · Hannah Cantrick · Hannah Carter · Hannah

Casia · Hannah Diaz · Hannah Espanola · Hannah Garcia · Hannah Hamilton · Hannah MacLean ·

Hannah Manalaysay · Hannah Mercado · Hannah Oldroyd · Hannah Riches · Hannah Smith ·

Hannah Taylor · Hannes Cronje · Hans Joy Albano · Hans Koman · Hans Mohd Kassim · Happy

Nijjar · Hardeep Kaur · Harendra Sajwan · Harianne Canoy · Hariharan Ramakrishnan · Harish

Purohit · Harjeet Kaur · Harjinder Kaur · Harka Neopaney · Harkamal Minhas · Harleen Johal ·

Harman Kaur · Harman Kaur · Harmanpreet Deol · Harmonee Scott · Harmony Clark · Harneet

Kaur · Harparveen Kaur · Harper Connolly · Harpinder Kaur · Harpreet Kaur · Harpreet Kaur ·

Harpreet Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Kaur ·

Harpreet Khokhar · Harpreet Pabla · Harriet Hawksworth · Harriet Miller · Harry Capacite · Harry

Hemus · Harry Huynh · Harry Makhloga · Harry Snell · Harsh Kaur · Harshani Jayasinghe · Harveer

Kaur · Harwinder Kaur · Harylle Canoy · Hashini Ekanayake · Havana A’aifou · Haycie Orina · Haydee

Anson · Hayden Beaton · Hayden De Cleene · Hayley Behrns · Hayley Berriman · Hayley Gillespie ·

Hayley Hemsley · Hayley Kluytmans-Smith · Hayley Mackintosh · Hayley Milne · Hayley Mustapha ·

Hayley Sharp · Hazel Dodunski · Hazel Gonzales · Hazel Guillen · Hazel Magar · Heather Barnett ·

Heather Baron · Heather Jury · Heather Maynard · Heather Sharp · Heather Snodgrass · Heather

Turney · Heather Wallace · Heather Wilson · Heather Wooles · Hebbe Xia · Hedda Viray · Heena

Arora · Heena Kapoor · Heena Pardeshi · Heide Barkman · Heidi Atkins · Heidi Holm · Heidi O’Reilly

· Heila Louw · Helen Bailey · Helen Burnley · Helen Danielsen · Helen Edwards · Helen Farrell · Helen

Hall-King · Helen Hayes · Helen Higgins · Helen Highcazony · Helen Liu · Helen Maxwell · Helen

McKinnel · Helen Page · Helen Timra · Helen Van Der Meys · Helen Wehipeihana · Helen Weston ·

185

ANNUAL REPORT 2022

Helen Xu · Helena Barriga · Helena Dawson · Helena Van Zoggel · Hellen Grenfell · Hema Baldania ·
Hemal Patel · Henny Villaverde · Henry Arunjaroen · Henry Davis · Henry Stuart · Hepi Matapa ·

Herbert Zielinski · Hermie Nuqui · Hiep Do · Hieu Lam · Hilary Freeth · Hilary Van Zoelen · Hilary

Westley · Hilda Dimalibot · Hildah Muthui · Himanshu Juneja · Himshikha Paneri · Hina Veituna ·

Hine Kameta · Hinewa Mahanga · Hiromi Mizushima · Hit Patel · Hitesh Vaza · Hoana Brown · Hoani

Brown · Hollee McKay · Hollie Ruddick · Hollie Thomlinson · Holly Baxter · Holly Binnie · Holly Briggs

- Lyne · Holly Duff · Holly French · Holly Gillett · Holly Pham · Holly Pihema · Holly Ryan · Holly

Whitaker · Honey Arceo · Honey Duque · Honey Gill · Honey Honey · Honey John · Honey Neilson ·

Honey Pagtanac · Honeylane Bautista · Honor Braid · Hope McKelvey · Hope Robyns-Mackay ·

House Yuan · Hua Chen · Hubert Gacera · Hugo Gonzalez · Hui Ju Oh · Huiling Lu · Hulen Ke · Hunter

Lee · HyeJu Jeon · Hyma Gantyada · Iain Doody · Iain Jagger · Ian Bell · Ian Bezzubov · Ian Corry · Ian

Lee · Ian Mackay · Ian Whyte · Icon Dales-Lequido · Ida Waiwiri · Ili Lase · Iliui Filipo · Ilthon Tomo · Im

Konsila-Henderson · IndiaRose Cunningham · Indika Abeykoon · Indra Devi · Indra Senevirathne ·

Indu Baiju · Indu Gounder · Indy Farmer · Ine Wheeler · Inge Rickards · Ingrid Cagalawan · Ingrid

Hurst · Ingrid Ludovice · Ingrida Jones · Inigo Holmes · Inoka Jayaweera · Inosha Hettiarachchi ·

Iosefo Bahn · Irene Burt · Irene Celino · Irene Lee · Irene Li · Irene Morgan · Irene Rapa · Irene Yang ·

Iresha Perera · Iresha Jahinge · Irina Davis · Irish Pelegren · Iritana Tua · Isaac Bright · Isaac

Kavanagh-Stewart · Isabel Jimenez · Isabel Seville · Isabelita Ceniza · Isabelle Purdy · Ishan

Kolothodi · Ishara Subedi · Ishina Adhikari · Ishu Koirala · Isi Uata · Iskima Bhandari · Isla Gillies · Isla

Jean Tregonning · Isy Cassidy · Italia Taka · Ivan Nugraha · Ivane Parba · Ivy Carino · Ivy Chatterjee ·

Ivy Han · Ivy Liza · Izak Luther · Izel Martinez · Izzy Getty · Izzy Partridge · Jaala Attewel · Jabeline

Obra · Jac George · Jacinta Afamasaga · Jacinta Field · Jacinta Neilson · Jack Markham · Jackie

Diago · Jackie Hotter · Jackie Jenkins · Jackie Miller · Jackie O’Fee · Jackie Scanlon-James ·

Jackson Sumich · Jacky Adam · Jacky Basongit · Jaclyn Aitken · Jacob Cherian · Jacoeb

Uprichard · Jacque Manzano Leadbetter · Jacquelyn Cottam · Jacqui Clarke · Jacqui Forde ·

Jacqui Gillard · Jacqui Hurley · Jacquie Rui · Jade Bedel · Jade Dix · Jade Hemi · Jade Magno · Jade

Morrice · Jade Te Awhe · Jade Washbourn · Jaden Kim · Jadi Cubita · Jagath Esposo · Jagath

Wijetilleke · Jahleel Espineda · Jahn Katene · Jaime Awab · Jaime Clews · Jaime Redmond · Jaine

Hidalgo-Plaza · Jaison Johny · Jake Clansey · Jam Collado · Jam Rivera · Jamaika Mejorada ·

James Aoys · James Earls · James Inobaya · James Marshall · James Simpson · James Ward-

Johnson · James Webb · James Zeng · Jamie Murray-Macgregor · Jamie Quigg · Jamie Roberts ·

Jamie Rumbold · Jamie Sheary · Jamie Ung · Jamila Khaled · Jan Corbett · Jan Farac · Jan

Goodwin · Jan McKee · Jan Reyes · Jan Smith · Jan Strickland · Jan Thomson · Jan Tuuta · Jan

Villacorta · Jana Dinusova · Janaki Shrestha G. · Jane Baker · Jane Cribb · Jane Duncan · Jane Elle

· Jane Escalera · Jane Gordon · Jane Hickman · Jane Hockey · Jane Jordan · Jane Magan · Jane

Matorino · Jane McNeill · Jane O’Connell · Jane Paredes · Jane Patrick · Jane Pow · Jane Ram ·

Jane Smith · Jane Sun · Jane Tattley · Janeil Tan · Janel Castillano · Janelle Broughton · Janes

Castro · Janess Estillore · Janet Bucag · Janet Jesen · Janet Ngamaru · Janet Spaabaek · Janet

Stacey · Janeth Pascual · Janette Boyd · Janette Llesis · Janica Villaver · Janice Baker · Janice Liu

· Janice Munro · Janice Peralta · Janice Rodriguez · Janice Rothwell · Janice Ruste · Janice Stent ·

Janice Walsh · Janice Wright · Janine Aitken · Janine Amacio · Janine Lipsys · Janine Nathan ·

Janine Snape · Janine Waugh · Janine Wilde · Janis Bredenbeck · Jan-Marie Houliston · Jann

Heasley · Jann Tarrant · Janna Bowman · Jannel Escueta · Jannet Joseph · Janrell Relucio · Jared

Kemsley · Jas Bhotea · Jas Kaur · Jas Kaur · Jas Kaur · Jas Maxwell · Jas Taala · Jasleen Kaur ·

Jaslove Singh · Jasmeen Kaur · Jasmeet Kaur · Jasmeet Virk · Jasmin Cataquiz · Jasmin Raju ·

Jasmine Aulakh · Jasmine Evans · Jasmine Huang · Jasmine Kim · Jasmine Lee · Jasmine Mcilraith

· Jasmine Parker · Jasmine Shahbaz · Jasmine Song · Jasmine Ting · Jasmit Kaur · Jason Adam ·

Jason Browne · Jason Davey · Jason Higgins · Jason Kenna · Jason Mack · Jason Zhao · Jason

Zhao · Jasond Jamboy · Jaspal Singh · Jasper Ducusin · Jasper Wilson · Jaspinder Kaur · Jaspreet

Gill · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Singh

· Jasprit Kaur · Jass Kaur · Jass Kaur · Jass Kaur · Jass Kaur · Jass Kaur · Jass Reddy · Jasveer

Sidhu · Jasvir Kaur · Jaswinder Kaur · Jasz Kaur · Jay Kang · Jay Kirk · Jay Moore · Jay Pascua · Jay

Payot · Jay Saclo · Jay Sukhdarshan Singh · Jaya Mohan · Jaya Vandhana · Jayde Brown · Jayde

Kumsawng · Jayjay Jung · Jayn Baker · Jayne McIlroy · Jayne Money · Jaypee De Peralta · Jayson

Ehn · Jaz Fox · Jaz Sigley-Millar · Jaz Spicer · Jazz Harris-Urlich · Jazz Phillips · Jazz Rabbett · Jean

Cleaver-Paris · Jean Farrell · Jean Raga · Jean Ramos · Jean Rigor · Jean Villarin · Jeanafe

Abelarde · Jeanel Gutong · Jeanet Bagares · Jeanette Erestingcol · Jeanette Tebbutt · Jeanette

Wensor · Jeanie Gradwell · Jeanie Gamboa · Jeanie Salcedo · Jeanne Paterson · Jeannette

Subritzky · Jeannie Bautista · Jeannie Sales · Jeannie Wang · Jee Manipis · Jeema Lijo · Jeena Jose

· Jeena Oshana · Jeeva Vakkachan · Jeff De Los Reyes · Jeff Parkins · Jeff Ragragio · Jeff Salas ·

Jeff Suana · Jejay Sen · Jele Papellero · Jeli Howes · Jelica Ceballos · Jemma Lewin · Jen Asuncion

· Jen Ethugala · Jen Garcia · Jen Lemery · Jen Magrath · Jen McLean · Jen Nuevo · Jen Penfold · Jen

Rea · Jen Tufuga · Jenelyn Ragadi · Jenette Fursdon · Jenn Valavala · Jenna Aspeling · Jenna

Lester · Jenna Maire · Jenna Moore · Jenni Berkers · Jenni Harris · Jenni Simpson · Jenni Stevenson

· Jenni Thompson · Jennie Choi · Jennie South · Jennie Teodoro · Jennifer Ferrier · Jennifer

Gonzalo · Jennifer Grover · Jennifer Roberts · Jennifer Rodriguez · Jennifer Storer · Jennifer Wong

· Jenny Abalos · Jenny Achilles · Jenny Bongcog · Jenny Bower · Jenny Buhat · Jenny Campbell ·

Jenny Chen · Jenny Christmas · Jenny Cobden-Cox · Jenny Coleman · Jenny Cuffe · Jenny de

Peralta · Jenny Dominguez · Jenny Griffiths · Jenny Guanco · Jenny Halliday · Jenny Jackson ·

Jenny Kaur · Jenny Lane · Jenny Leader · Jenny Lopez · Jenny Magsilang · Jenny Parker · Jenny

Pasiol · Jenny Reyes · Jenny Ruttar · Jenny Thiele · Jenny Wilson · Jenny Zhang · Jens Kuriakose ·

Jerald Isleta · Jerald Sunto · Jeremy Alvez · Jeremy Moore · Jeremy Munday · Jeremy Wood · Jerin

Joy · Jerlene Cruz · Jermae Aguilon · Jermaine Masangkay · Jerome Wong Yit · Jerrom Lomocso ·

Jerry Barclay · Jervilou Santiago · Jesica Escueta · Jesilyn Delgado · Jesna Jose · Jess Anderson ·

Jess Benfell · Jess Bonustro · Jess Crook · Jess Dawes · Jess Hatfield · Jess Jewell · Jess Kim · Jess

Lewis · Jess Matthews · Jess Morris · Jess Nathan · Jess Snowball · Jess Steele · Jess Webb · Jessa

Dela Cruz · Jesse Grove-Gowans · Jesse Varney · Jessica Angelia · Jessica Csengo · Jessica

Gerken · Jessica Lewis · Jessica Martin · Jessica McArley · Jessica Rice · Jessica Taningco ·

Jessica Tonacao · Jessica Tran · Jessica Zhang · Jessica Zhou · Jessie Chu · Jessie McKay · Jessie

Tang · Jessy Arthur-Worsop · Jestin Johny · Jesty Nelson · Jeuenesse Martinez · Jewel Galang ·

Jewel Novera · Jharmane Catolico · Jhiede Tormis · Jhoanna Maithani · Jhonaliza Detera · Jhong

Solen · Jhuls Ocho · Jhunnelle Tabay · Jia Li · Jiaqi Zhao · Jiaying Yang · Jibin John · Jibita Maharjan

· Jie Yu Zeng · Jie Zhang · Jigisha Baraiya · Jiji Sevilla · Jijo Laurence · Jijo Paul · Jijo Varghese · Jiju

Joy · Jil Chua · Jill Clark · Jill Gregson · Jill Job · Jill Patel · Jill Turner · Jill White-Northcroft · Jillian

Cole · Jilsy Joy · Jim Beban · Jim David · Jim Frost · Jim Jose Vellakada · Jim Otimi · Jim Qian ·

Jimaima Naikatini · Jimmy Clemente · Jimmy Franks · Jimmy Sihombing · Jincy Thambi · Jing Cui

· Jing Estrella · Jing Fu · Jing Hu · Jing Meipieza · Jinghua Zhang · Jingjing Hou · Jini Joy · Jinit

Bhavsar · Jinky Munoz · Jinky Romero · Jinsa Joseph · Jinson Abraham · Jiny Johny · Jiratha

Khamsungnoen · Jisbin Siby · Jit Chhetri · Jiwon Park · Jiyeon Kim · Jo Anam · Jo Baker · Jo Bando

· Jo Base · Jo Bindon · Jo Blyth · Jo Cant · Jo Clare · Jo Dickson · Jo Dorado · Jo Duncan · Jo Franklin

· Jo Goode · Jo Hermogenes · Jo Hunt · Jo McKay · Jo Mooney · Jo Nelson · Jo Ratapu · Jo Rojo · Jo

Seed · Jo Turner · Jo Ward · Jo Willis · Joan Aguillo · Joan Lagman · Joan Lastimosa · Joan Rubio ·

Joan Wang · Joana Caramoan · Joanna Forbes · Joanna Gumangan · Joanna Little · Joanna

Symons · Joanna Taylor-Spedding · Joanne Bass · Jo-anne Buhler · Joanne Eaton · Joanne Ga-as

· Joanne Hart · Joanne McConchie · Joanne Robinson · Joanne Satchwell · Joanne Snalam ·

Joanne Steele · Joanne Wang · Joanne Wong · Joaquin Barillas · Joash Felipe · Joban Singh · Jobcy

John · Jobi Paul · Jocasta Jowett · Jocelyn Davidson · Jocelyn Hansen · Jocelyn Infante · Jocelyn

Lines · Jocelyn Prospero · Jodie Jenkins · Jodie Parker · Jodie Perocho · Jodie Robb · Jody

Brennan · Jody Coverdale · Jody Keating-Gorton · Jody Rerekura · Joe Manaena · Joe

Muttumpurath · Joe Nio-Aporo · Joe Rooney · Joe Sturrock · Joe Suedad · Joe Tierney · Joe Vas ·

Joe Won · Joeben Roxas · Joena Baculio · Joey Weaver · Johann Mabao · Johannes Bronkhorst ·

John Bernardo · John Beuth · John Buyung · John De Leon · John Entice · John Gavin · John

Graham · John Jenkins · John Jeong · John Katiyo · John Keighron · John Koen · John Maddaluno ·

John Malonzo · John Nayga · John Outten · John Reihana · John Reyes · John Taylor · John Uy ·

John Van Turnhout · John Viscovini · John Walker · John Waller · John Young · Johnny Seque ·

Johnny Zhu · Johno Robins · Johnson Alex · Johny Jory · Jojo Archer · Jojo Diquit · Jolden

Fernandes · Jolenie Zomil · Jolie Thuy · Jomith Jose · Jona Arganda · Jona Osmena · Jonah Lawry

· Jonald Laurico · Jonathan Ball · Jonathan Barber · Jonathan Barrett · Jonathan Cruz · Jonathan

Stewart · Jonathon Hean · Jone Seniceva · Jonelyn Valeroso · Joni-Lou Arcelo · Jonna Mangahas ·

Jonnel Tan · Jono Barnes · Jordan Braid-Eley · Jordan Dobson · Jordan Elvy · Jordan Mealings ·

Jordyn Keys · Joreena Mabini · Jorja Antunes · Jose Palathunkal · Jose Sebastian · Josep Marin

Lumbreras · Josephine Cunado · Josephine Slater · Josh Fitzsimmons · Josh Goodfellow · Josh

John · Josh Jones · Josh Meehan · Josh Orchard · Josh Rasolo · Josh Smith · Joshua Cole · Joshua

Elan · Joshua Smith · Josiane Bizoza · Josie McCrone · Josie Placino · Josmi Joseph · Josmin Jose

· Josna Joseph · Joti Chand · Joti Kumari · Joti Reena · Jouanna Tristeza · Jova Marquez · Jovana

Brasic · Jove Alocelja · Jovelyn Sison · Joy Abella · Joy Abellar-Sinha · Joy Ador · Joy Breward · Joy

Dolozon · Joy Gautam · Joy Mason · Joy Sy · Joy Tan · Joy Yang · Joyce Kydd · Joyce Roa · Joyce

Wang · Juanito Alforque · Juann Fabia · Jubin Sabu · Jude Fegi · Jude Guild · Jude Kerr · Jude Liddle

· Judette Froilan-Algodon · Judit Lukacsa · Judith Fernando · Judith Bell · Judith Ditablan · Judith

Rutledge · Judith Sturzaker · Judy Barron · Judy Binarao · Judy Campbell · Judy Christie · Judy

Lobb · Judy Lubanga · Judy McAuley · Judy Miguel · Judy Montero · Judy Patterson · Judy Petersen

· Juffin Koshy · Juhee An · Julia Charteris · Julia Evans · Julia Main · Julia Murphy · Juliana Serafim

da Silva Ribeiro · Juliana Stone · Julie Akinyele · Julie Camay · Julie Carlson · Julie Collings · Julie

Corkill · Julie Crayford · Julie Crofts · Julie Dehar · Julie Deticio · Julie East · Julie Gumban · Julie

Hoskin · Julie Leilua · Julie Madden · Julie Madden · Julie Mallia · Julie McGhie · Julie Morrish · Julie

Nelson · Julie Parker · Julie Rice-Gray · Julie Rodwell · Julie Rose Guinyang · Julie Russ · Julie Ryan

· Julie Schaab · Julie Seymour · Julie Simpron · Julie Sleep · Julie Thompson · Julie Toevai · Julie-

ann Beattie · Juliet Dixon · Juliet Findlay · Juliet Smith · Julio Rezende · Julius Macaraeg · Jully Cui ·

July Pili · Julyn Cancino · Jum George · Jun Lam · June Marshall · June Savage · Junior Tai · Junn

Alminaza · Juselle Dangate · Jussell Benedicto · Justin Reinecke · Justin Thankachan · Justine

Hilado · Justine Michel · Justine Taylor · Jylyn Javier · Jyoti Jyoti · Jyoti Bhanot · Jyoti Gurung · Jyoti

K C · Jyoti Kunwar · Jyoti Phuyal · Jyoti Shahi · Jyoti Sharma · Kabita Acharya · Kade O’Meara ·

Kaden Ko · Kae Tayong · Kael Fallu · Kaelan Healy · Kaitlin Ruscoe · Kaitlyn Do · Kaitlyn Rosevear ·

Kaito Hayashi · Kal Sherchan · Kalaivani Logeswaran · Kaleb Dunstan · Kaleshni Devi · Kali Nottle ·

Kalisi Savu · Kalpa Kumarasinghe · Kalpana Negi · Kalvi Selvaraj · Kam Kaur · Kamal Dhaliwal ·

Kamal Jajoria · Kamal Kaur · Kamal Pandher · Kamal Pathak · Kamala Phuyel · Kamalpreet Kaur ·

Kamalpreet Kaur · Kamini Prasad · Kanchan Dangol · Kanchi Peiris · Kane Harper · Kani Davis ·

Kaniata Halanukonuka · Kanika Arora · Kanta Mani · Kanti Karan · Kanwal Kaur · Kanwal Sandhu ·

Kanwal Singh · Kaori Matsunobu · Kara Montilla · Karamjeet Kaur · Karan Kaur · Kareen Galang ·

Karel Atilano · Karen Andrews · Karen Anne Strachan · Karen Bensemann · Karen Bloxham · Karen

Bolton · Karen Borland · Karen Castel · Karen Gage · Karen Ikimata · Karen Jackson · Karen

Jellyman · Karen Jenkins · Karen Kaefer · Karen Kelly · Karen Lake · Karen Layman · Karen Mabao ·

Karen Marquina · Karen McGinty · Karen Mecca · Karen Melo · Karen Merrilees · Karen O’Driscoll ·

Karen Rodger · Karen Sears · Karen Shaw · Karen Wellard · Karen Wellington · Karen Williams ·

Karen Young · Karena Miller · Karin McDonald · Karin Smits · Karina Landero · Karina Misterio ·

Karishma Naidu · Karl Drent · Karl Holloway · Karl Rosales · Karla Marrs · Karla Naude · Karm Kaur ·

Karm Kaur · Karuna Katwal · Karuna Maharaj · Karuna Singh · Karyl Saavedra · Karylle Dacanay ·

Karyn Marshall · Karyn Nobilo · Karyn Porter · Kase Woolley · Kasun Silva · Kat Hanson · Kat Porter

· Kata Samuelu · Katalina Aitaua · Katarina Biaukula · Katarina Cox-Winiata · Kate Anderson · Kate

Bowden · Kate Bruce · Kate Carr · Kate Cheng · Kate De Los Santos · Kate Ensor · Kate Lim · Kate

Milne · Kate Morgan · Kate O’Neill · Kate Ren · Kate Sharples · Kate Tran · Kate Whatford · Kate

Wood · Katelyn Stuart · Kath Abelligos · Kath Collett · Kath Daveis · Kath Dwyer · Kath Morgan · Kath

Owen · Kath Pegalan-Bataanon · Kath Simpson · Katherine Cade · Katherine Chen · Katherine

Olivar · Katherine Smith · Kathie Dimock · Kathleen Corcuera · Kathleen de Gracia · Kathlen

Gingoyon · Kathrin Schott · Kathrine Tan · Kathryn Francis · Kathryn Geopano · Kathryn Van de

Westerlo · Kathy Petersen · Katie Benson · Katie Greig · Katie Hutchinson · Katie Japor · Katie

Longden · Katie-Jane Knight · Katrin Marundan · Katrina Armstrong · Katrina Boyd · Katrina

Copland · Katrina Ede · Katrina Mann · Katrina McLean · Katrina Stevens · Katty Maya · Katy Fryer ·

Katy Hodder · Katy Van Nieuwenhuizen · Katz Melebo · Kavitha Sukumar · Kawther Kadhom · Kay

Fabrin · Kay Katene · Kay McKirdy · Kay Merekula · Kay Murdoch · Kaycee Borja · Kaycee Salmasan

· Kayden Clarke · Kaye Clyne · Kaye Francisco · Kaye Kaur · Kaye Stoddart · Kaye Wesley · Kayla

Gee · Kayla Myles · Kayla Richmond · Kaylee Du Preez · Kaylee Hird · Kaylee Stevenson · Kaylee

Tonga · Kaylene Brock · Kaylene Tipene · Kaylyn Merrall · Keefe Martinez · Keira McEwan · Keisi

Puafuti · Kellie Hura · Kelly Amemita · Kelly Barnes · Kelly Cooke · Kelly Findlay · Kelly Hatherell ·

Kelly Jansen · Kelly Jones · Kelly McDonald · Kelly Turner · Kelsey Griffin · Kelsey Wilson · Kelsie

Grantham · Kelvin Weston · Kemmarin Atkinson · Ken McKay · Ken Wongsomboon · Kendall James

· Kendall Johnson · Kendall Stobart · Kendra Parker · Kendyl Hudson - McDonald · Kennely Atilano

· Kenneth Alo · Kenneth Baldivinos · Kenneth Coade · Kenneth Penolbo · Kenny MacAskill · Kent

Chavez · Kenzie Genet · Keran Taylor · Keri Brickmann · Keri Ladbrook · Kerri Martin · Kerri Roberts

· Kerri Shirley · Kerri Smith · Kerry Gall · Kerry Hawkins · Kerstine Egot · Keryn Johnston-Dixon ·

Keryn Norris · Kev Moore · Kevin Selner Maniego · Kevin Bautista · Kevin Bowgett · Kevin Dela Cruz

· Kevin Durkin · Kevin Grimwood · Kevin Taylor · Kevin Tsai · Kharina Milan · Khaylen Schaup · Khina

Neupane · Khusbu Patel · Khush Arora · Khushboo Dhiman · Khushi Kiran · Kidst Mekonnen · Kie

Kassal · Kiely Buttell · Kiem Bayona · Kiera Bradford · Kiera Follows · Kieran Cox · Kieran Simpson ·

Kieti Kalava · Kika Fosita · Kim Baker · Kim Braniff · Kim Brougham · Kim Buere · Kim Chayag · Kim

Cunard · Kim Dawson · Kim Fisher · Kim Grundmann · Kim Hammersley · Kim Henry · Kim Housiaux

· Kim Hua · Kim Kavanagh · Kim Leighton · Kim Manansala · Kim Nanscawen · Kim Rivett · Kim Son ·

Kim Tran · Kim White · Kim Zipagan · Kimi Donaldson (Naruse) · Kin Wan · Kinley Wangdi · Kira

Wetere · Kiran Dhillon · Kiran Gudopp · Kiran Jawandha · Kiran Kaur · Kiran Kaur · Kiran Kiran · Kiran

Lata · Kiran Singh · Kirandeep Kaur · Kirandeep Kaur · Kirby Chunaco · Kiri Walsh · Kirk Lubos · Kirn

Brar · Kirsten Liggett · Kirsten Merrett · Kirsten Schubert · Kirstin Murdoch · Kirsty Newton · Kirsty

Winter · Kisa Faauli · Kisa Tanuvasa · Kishore Kurian · Klarissa Dacyon · Klarizza Piquero · Kolotita

Makalio · Komal Goundar · Komal Kaur · Komal Komal · Komal Patel · Koppel Sorono · Korinna Dela

Cruz · Koshala Waduwatta · Kreeti Kumar · Kripa Garad · Kris Perkins · Krishma Singh · Krishna

Krishna · Krishna Malcampo · Krishna Rajput · Kriss Apad · Krissy Hohepa · Krissy Talavera · Krista

Lee · Kristen Dela Cruz · Kristin Cadavis-Khiathani · Kristina Benkova · Kristine Baring · Kristine

186

RYMAN HEALTHCARE

Bello · Kristine Borres · Kristine Dalauidao · Kristine Fegi · Kristine House · Kristine Llave · Kristine
Pancho · Kristine Payot · Kristine Singh · Kristofer Toledo · Kristoff Bawayan · Krystal Manson ·

Krystyna Bostrovas · Kuart Jamero · Kuldeep Chauhan · Kuldeep Singh · Kuldip Singh · Kuljeet Kaur

· Kurt Hiller · Kurt Mepana · Kushma Gurung · Kusum Gurung · Kyamala Magar · Kyan Rumbold · Kyla

Ellis · Kyla Jeanjaquet · Kyle McIntyre · Kyle Thomson · Kylie Campbell · Kylie Dearing · Kylie Martin

· Kylie Maxwell · Kylie Thomas · Kym Le Riche · Kyoungmi Kim · Kyrene O’Donnell · Lacey Savage ·

Lachlan McIntosh · Lachmi Kanta · Ladine Hobson · Ladonna De Asis · Lady Canda · Lagi Fogavaa

· Laikha Mohamoud · Lailega Iosefa · Laiza Peters · Lal Sangi · Lami Taua · Lana Bogacheva · Lana

Boynton · Lana Fraser · Lana Tuipulotu · Lance Clendon · Lance Fletcher · Lance Gabionza · Lanei

Dimaano · Laney Brown · Laney Tomkins · Lanie Mabale · Lanna Schnetler · Lara Durand · Lara

Formentera · Lara Giles · Lara Nielson · Larissa Sedouch · Larry Montoya · Latchmi Murti · Lateesha

Douglas · Laura Attwood · Laura Blunsdon · Laura Carleton · Laura Carrington · Laura Clarke ·

Laura Jones · Laura Luague · Laura Manalaysay · Laura Menzies · Laura Moffett · Laura Mouat ·

Laura Reynolds · Laura Richmond · Laura Taylor · Laura Taylor · Laura Whicker · Laurel Gaskin ·

Laurellea Holmes · Lauren Baldock · Lauren Beaumont · Lauren Hubert · Lauren Marshall · Lauren

Odgers · Lauren Trowsdale · Lauren Wells · Laurence Alojado · Laurence Llenes · Laurindo De

Sousa · Lavanya Perumandi · Lavanya Shetty · Lavinia Kelly · Lavpreet Kaur · Lawale Baigern ·

Lawrence Manohara-Seelan · Lawrence Parina · Laya Mary Veliyil Shaji · Lazel Nieto Baungally · Le

Minh Bach · Le Phan · Lea Sullivan · Lea Valdez · Leah Bryan · Leah Evans · Leah Hill · Leah Mapa ·

Leah Ouano · Leah Soliva · Leah White · Leanda Bekker · Leanna Harding · Leanne Booth · Leanne

Des Landes · Leanne Fabish · Leanne King · Leanne Madsen · Leanne McFarlane · Leanne

Nukunuku · Leanne O’Meara · Leanne Paekau · Leanne Stewart · Leanne Watson · Leaoa Tolo ·

Leba Leqakowailutu · Lebron Suedad · Lee Evans Tadeo · Lee Gao · Lee Rodgers · Lee Wilson ·

LeeAnne Mahadeo · Leeba Babu · Leela Pathirannahelage · Leen Porathur · Leena Kumar ·

Lehanna Pio · Leigh Kench · Leigh Greyling · Leigh Kennedy · Leilane Alforo · Leis de Vernon · Leisa

Brown · Lekdhen Tshogyal · Len Diga · Len Ferrer · Len Medalla · Lena Gawler · Lena Te Miha · Lenin

Moncy · Leo Cochrane · Leo Dumagan · Leo Hahn · Leon Hewitt · Leon Joy · Leon van den Berg ·

Leonie Kebbell · Leonie Taylor · Lerio Corum · Leshani Gunawardana · Leshika Arachchige · Lesley

Crampton · Lesley Parfett · Lesley Pells · Leslie Ortega · Lester Salvosa · Lester Toms · Letitia

Corcoran · Leva Latu · Levi Roberts · Lewis Bradford · Lex More · Lexie Lei · Lez Pencz · Li Hayman

· Li Ma · Lia Pou · Liam Blackett · Lianne Woolford · Lianne Yoo · Libby Esguerra · Liby Joseph · Lidiya

Joseph · Lie Fiu · Ligaya Cobile · Ligi Johnson · Ligy John · Liji Jose · Lijo Ittoop · Likhwa Sigola · Lila

Patel · Lili Dong · Lili Talega · Lili Volpicelli · Lilian Ferreira · Liliana Romero · Lill Wawatai · Lilli Regan

· Lillian Lian · Lillie Harris · Lilly Va’a · Lilly-Belle James · Lily Aitken · Lily Elliott · Lily Forcadilla · Lily

Graciano · Lily Isleta · Lily Joyce · Lily McGivern · Lily Murphy · Lily Nicolescu · Lily Woodbury · Lily

Xiao Ying · Lima Ugapo · Lin Lim · Lin Tian · Lina Benedetti · Lina Tuimana · Lincy Cheriyan · Linda

Bridge · Linda Burnside · Linda Chungath Willys · Linda Churchill · Linda Gribben · Linda Havinga ·

Linda Hobrough · Linda Lockington · Linda Maharjan · Linda McGill · Linda Morey · Linda Odhiambo

· Linda Pettigrew · Linda Reid · Linda Richards · Linda Skelton · Linda Soloman · Linda Tyler · Linda

Vescherre · Linda Warren · Linda Yu · Lindsay Harrison · Lindsay Lewis · Lindsey O’Connor · Ling

Cheah · Lionel Kho · Lionel Pillay · Lisa Breeden · Lisa Cooper · Lisa Cowens · Lisa Crichton · Lisa

Gilligan · Lisa Grantham · Lisa Healey · Lisa Hinton · Lisa Humphrey · Lisa Laforgia · Lisa Marr · Lisa

Mazey · Lisa More · Lisa Neiman · Lisa Petana · Lisa Philps · Lisa Puklowski · Lisa Raika · Lisa

Robinson · Lisa Ross · Lisa Walton · Lisa Wang · Lisa Whitcombe · Lisa Wiltshire · Lisa Xu · Lisette

Mann · Lisi Fifita · Lita Naude · Litel Lacerna · Liting Hsu · Livi Ketewai · Liyana Bandara · Liyi Zhu ·

Liz Andoy · Liz Beresford · Liz Bradford · Liz Close · Liz Davidson · Liz De Villiers · Liz Dilger · Liz

Hampton · Liz Hickling · Liz Kwaimani · Liz Loughlin · Liz McRobbie · Liz Nancollis · Liz Penman · Liz

Schofield · Liz Thrush · Liz Wells · Liza Mierzejewski · Liza Siano · Liza Tso · Lize Blay · Lizell Umayam

· Lizeth Monzalo · Lizzie Pasa · Lizzie Tennent · Lizzie Viljoen · Lizzy McKenzie · Loa Tuiolemotu ·

Lochlan Wilson · Logan Fairbairn · Loida Malanyaon · Loida Zarandona · Lois Battersby · Lois

McKenzie · Lois Tooley · Loranne Bayford · Lordei Ledesma · Lorelle Cole · Loren De Chavia ·

Lorenza Macayba · Lorie Anderson · Lorie Bantugan · Lormie Talape · Lorna Alcasabas · Lorna

Carter · Lorna Dolores · Lorna Jenkin · Lorraine Barcibal · Lorraine Benjamin · Lorraine Dawson ·

Lorraine Fuller · Lorraine Hulse · Lorraine Knight · Lorraine Price · Lorraine Tippett · Lorraine White

· Lotis Baldozano · Lotis Caranguian · Loto Foaese-Aiolupo · Lou Anisy · Lou Cabuyadao · Lou

Camargo · Lou Moyle · Louis Matakino · Louis Wolmarans · Louisa Liang · Louisa Bradburg · Louisa

Morton · Louise Addis · Louise Brown · Louise Carr · Louise Challis · Louise Dawson · Louise James

· Louise Jean Bajao · Louise Nicholas · Lourde Riotoc · Lovaine Glariada · Love Singh · Lovely

Chauhan · Lovepreet Kaur · Lovepreet Kaur · Lovey Lovey · Loyda Miranda · Lua Tauaneai · Luca

Chiavola · Luca Fanti · Lucia Meyer · Lucie Chambers · Lucie Harrison · Lucille Catchete · Lucky

Schuster · Lucky Shakya · Lucresia Caitor · Lucretia Del Mundo · Lucy Ayers · Lucy Banaba · Lucy

Caldwell · Lucy Crawford · Lucy Fan · Lucy Kim · Lucy Lu · Lucy Mataki · Lucy McWilliams · Lucy

Nordstrom · Lucy Ryan · Lucy Uro · Lucy van Deursen · Lucy Ward-Johnson · Lucy Zengeni · Luis

De Los Santos · Luis Leh · Luis Lencioni · Luisa Feisst · Luisa Filimoehala · Luke Flynn-Mackenzie ·

Luke Hutchinson · Luke Patience · Luke Tapsell · Luna Touzel · Luna Wang · Lupe Finau · Lusia

Makihele · Lusiana Khan · Lusila Perez · Lydia Burgess · Lydia Gordon · Lydia Morintat · Lydia Renu

· Lydia Zheng · Lyds Nutter · Lyka Liban · Lylene Nuguid · Lyn Aso · Lyn Brown · Lyn Caylan · Lyn

Elton · Lyn Felizarta-Lee · Lyn King · Lyn Metran · Lyn Nguyen · Lyn Nickel · Lyn Zalavarria · Lynda

Dean · Lynda Ellington · Lynda Goston · Lynda Green · Lynda Hill · Lynda Petrie · Lynda Schuler ·

Lyndon Harper · Lyndsay Richards · Lyndy Direen · Lynette Darling · Lynette Neale · Lynette Pido ·

Lynette Polley · Lynley Ballantine · Lynley Gillies · Lynn Buist · Lynn Charlton · Lynn Feng · Lynn

Garner · Lynn Matthews · Lynn Rollo · Lynne Bretherton · Lynne Domigan · Lynne Egging · Lynne

Kane · Lynne Lepoidevin · Lynton Parkinson · Lynz Efalaimo · Lyree Sayers · Lyric Hoani · Lyssa

Foreman · Ma Kriezl Ramos · Ma Ley Diaz · Maaimoa Latu · Maan Singh · Mabel Mathews · Mable

Stewert · Mackenzie Jones · Mackenzie Wilson · Macy Moradei · Maddie Anthony · Maddie Layupan

· Maddy Huckel · Madeleine Dela Rosa · Madelyn Premacio · Madelynne Casison · Madhu Singh ·

Madi Rahman · Madison Wright · Mae Flores · Mae Resos · Mae Toreja · Maffy Coates · Maggie

Cornelio · Maggie Kam · Maggie Ma · Maggie Malone · Maggie Roberts · Maha Ramachandran ·

Mahal Gabionza · Mahi Rani · Mahija Jayasundara · Mai Nguyen · Maia Clare · Maia Scott-Wheeler ·

Maia Tagod · Maica Velasco · Maisy Hallet · Maitha Tan · Maitree Patel · Maitri Parikh · Mak Eketi ·

Makayla Ward · Makelesi Vula · Malav Patel · Malcolm Tolman · Malcolm Wilson · Maleesa Daniel ·

Malia Savelio · Malki Ruppage · Mallory Currier · Malo Tauaneai · Mamta Gusain · Mamta Kumar ·

Man Wai Fung · Manasa Mohan · Mandeep Gill · Mandeep Kaur · Mandi Ceelen · Mandi Smith ·

Mandy Clutterbuck · Mandy Errington · Mandy Grewal · Mandy Hemmingsen · Mandy Jiang ·

Mandy Parker · Mandy Tarquinio · Mandy Tipoki · Mandy Uren · Mangere Mairaro · Mani Mani ·

Manilyn Calda · Maninder Kaur · Manisha Rawat · Manisha Baniya · Manisha Gurung · Manisha Majhi

· Manisha Mane · Manisha Tiwari · Manjinder Kaur · Manju Benoy · Manju Bothara · Manju Shrestha

· Manjula Devi · Manmeet Kaur · Manni Singh · Manny Recamadas · Manny Tanzuaco · Manohari

Mendis · Manpreet Gill · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur ·

Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet Sekhon · Mantha

Thou · Manu Jimmy · Manu Sharma · Manu Sherchan · Manuela Jaramillo Gonzalez · Manwinder

Sangha · Mara Hernando · Marama Lomia · Marc Archbold · Marc Lyle · Marc Ytom · Marcela

Salazar · Marcelle Sherwood-Whall · Marcia Bernardo · Marcia Hawe-Akinwumi · Marcus Cullen ·

Marcy Dolar · Marecel Stevens · Maree Crozier · Maree Hughes · Maree Ockwell · Maree

Washbourne · Maree Whiting · Mareike Bohte · Mareli Carter · Marg Machee · Marg Vicente · Marg

Vince · Margaret Lethbridge · Margaret Osage · Margaret Rakai · Margarette Pepito · Margeaux

Harris · Margie Bell · Margie Mould · Margo Beale · Margot Boock · Margot Taylor · Mari Gomes-

Bradford · Mari Isnit · Mari Menchavez · Mari Piamonte · Mari Takahashi · Maria Abilay · Maria Achari

· Maria Aguilos · Maria Bautista · Maria Catu · Maria Cavan · Maria Cawdron · Maria Cuizon · Maria

Escandor · Maria Fe Pacible · Maria Flores · Maria Fodel · Maria Francisco · Maria Fuga · Maria

Gutierrez · Maria Inocencio · Maria Isnit · Maria James · Maria Jenkins · Maria Jordan · Maria Kurian

· Maria Lee · Maria Martinez · Maria Mathieson · Maria McNeilly · Maria Neill · Maria Nuval · Maria

Ralawa · Maria Ramos · Maria Reid · Maria Restrepo · Maria Rivera · Maria Salva · Maria Soares ·

Maria Torralba · Maria Viernes · Maria Walker · Maria Warriner · Marian De La Cruz · Mariane

Vicente · Marianel Miralles · Marianita Pelaez · Marianne Cobeldick · Marianne Hernandez ·

Marianne Vakalalabure · Marianne Ventura · Marianne White · Maricar Aquino · Maricar Blancaflor

· Maricar Santos · Maricel Angeles · Maricel Atienza · Marichille Bandales · Marichu Calpo · Marichu

Siao · Maricor Suarez · Maridel Balingit · Marie Aki · Marie Chandra · Marie Darling · Marie Domingue

· Marie Hodges · Marie Jenkins · Marie Molina · Marie Percy · Marie Rutherford · Mariel Marcos ·

Mariel Simblante · Marielle Daligdig · Marielle Palabasan · Marien Fabillar · Marievan Tan · Marife

Galvez · Marife Patterson · Marika Laflamme · Marilou Callo · Marina John · Marina Wildbore · Mario

Algodon · Mario Figura · Marion Paquit · Marion Ver Esguerra · Maris Taueki · Marisa Newman ·

Mariss Yamson · Marissa Hirawani · Marites Suaring · Marivic Sinio · Mariya Antony · Marizz Maneng

· Marj Diciano · Marj Guillemer · Marjan Aghakarimi · Marjo Engel · Marjorie Decena · Marjorie

Gomez · Marjorie Sojor · Mark Adams · Mark Attard · Mark Barber · Mark Bravo · Mark Buada · Mark

Cooley · Mark Dimaano · Mark Florendo · Mark Gela · Mark Gribble · Mark Harper · Mark Lacy · Mark

Nunn · Mark Padlan · Mark Rees · Mark Taylor · Mark Turton · Marlene Barbosa Da Silva · Marlys

Gollop · Marmyl Robson · Marnie Higgins · Marry Pareja · Marsha Cadman · Marta Manicia · Martha

Diprose · Martha Peka · Martin Angeles · Martin Greenfield · Martin Lau · Martin Westley · Martina

Himme · Martine Darrou · Martine Mathews · Martley Mitikulena · Martyn Osborn · Marvie Francisco

· Mary Aparicio · Mary Ann Domingo · Mary Ann Noquilla · Mary Ann Velarde · Mary Bayona · Mary

Boyce · Mary Camboliza · Mary Cho Aung · Mary Clare Craigen · Mary Compoc-Canoy · Mary

Cyriac · Mary Freeman · Mary Gipsy · Mary Gonzales · Mary Jacob · Mary Jean Basilio · Mary Jo

Giray · Mary Jo Matullano · Mary MacLeod · Mary Nicy · Mary Petersen · Mary Rayos · Mary Rongo

· Mary Shiju · Mary Sindhumary · Mary Vasaya · Mary Wagwag · Maryam Hosseini · Maryanne

Chester · Maryanne Gilmore · Mary-Anne Stone · Maryknoll Tacayan · Marylyn Narayan · Maryrose

Carina · Maryvonne Gray · Mason Ock · Matakeu Timms · Mathew Josipovic · Mathias Sackey · Mati

Mati · Matt Aldridge · Matt Bell · Matt Dowling · Matt Heys · Matt Hutchinson · Matt Orr · Matt Poskitt

· Matt Reddock · Matt Sheehan · Matt Southwick · Matthew Brown · Matthew Coates · Matthew

Gowdy · Matthew Leadbeater · Matthew Somosot · Matthew Todd · Mattie Rowlands · Maui Padilla

· Maumi Lavakeiaho · Mauree Parker · Maureen Geeves · Maureen Glentworth · Maureen Johnson ·

Maureen Pacilan · Maureen Puno · Maurice de Jesus · Maurice Schroeder · Max Bellamy · Max

Forthun · Max Wallace · Maxine Gordon · Maxine Gray · Maxine Hansen · May Bilalat · May Bonicatto

· May Carinan · May Checa · May De Los Santos · May Duong · May French · May Hemtanont · May

Magsino · May Raquepo · May Sino-Ag Sargento · May Techa · Maya Daniel · Maya Prasad · Maybel

Bumanglag · Maychelle Bechayda · Mayda Bromley · Maye Agdigos · Mayumi Kobayashi · Mayumi

Shinzaki · McKenzie Watson · Meagan Leqakowailutu · Meagan Spicer · Mealofa Faimalo · Meegan

Duncan · Meehee Kim · Meena Meenakshi · Meena Nathan · Meenu Bandara · Meenu Devasia ·

Meenu Mathew · Meenu Sheeja · Meg Atas · Meg Fraser · Megan Allen · Megan Coffey · Megan

Dempsey · Megan Green · Megan Grey · Megan Knight · Megan Rose · Megan Slater · Megha Pal ·

Meghan Blackwell-Hart · Meghana Thakkar · Mei Bitanga · Mei Yu · Meidy Maza · Meise Misa · Mejie

Macatimpag · Meke Unasa · Mel Allan · Mel Cousins · Mel Hart · Mel Mitchell · Mel Morgan · Mel

Redshaw · Mel Tolete · Mela Moceiwai · Melanie Reyes-Tagle · Melanie Asuncion · Melannie

Marasigan · Melchor Velandria · Mele Ekenasio · Mele Palelei · Mele Vaka · Mele Vi · Meleane Tauveli

· Meliame Nimmo · Melina Vasu · Melinda Opray · Melinda Reside · Melis Casimiro · Melissa Allan ·

Melissa Bell · Melissa Brewster · Melissa Caldwell · Melissa Clark · Melissa Cross · Melissa Downs ·

Melissa Escretor · Melissa Fluit · Melissa Gomintong · Melissa Kim · Melissa Knight · Melissa

Wayland · Melita Tivalu · Melkame Kebede · Mellissa Page · Melody Cajigas · Melvin Manglicmot ·

Melvyn Khatri · Mely Cruz · Memoree Wishart · Menaka Silva · Mengyao Luo · Menik De Silva ·

Menno Blom · Mercy Olores · Mere Caginiveisaqa · Mere Korotuku · Mere Mana · Mere Ravoka ·

Mere Tabataba · Meredith Fricker · Merewalesi Rogasagasa · Meri Janevska · Merin Babu · Merin

Sabu · Merin Thomas · Merina Pradhan · Merlin Daniel · Merlin Varghese · Merlyn Clarke · Merree

Harris · Merrin Jack · Merrit Shaju · Merryl Espanol · Meryll Totanes · Merz Maximo · Meserat

Mulegata Cherente · Mezzy Bi · Mhel Agpaoa · Mhel Bautista · Mi Chaw · Mi Mi Antonio · Mia Azogue

· Mia Bernard · Mia Gallao · Mia Herring · Mia Joseph · Mia Kang · Mia Maranan · Mia McKinley · Mia

Mihaila · Mia Sherwood-King · Mia Wallabh · Mia Wong Yit · Miao Tian · Michael Ablan · Michael

Aninon · Michael Apat · Michael Balazo · Michael Borostyan · Michael Cummings · Michael Esguerra

· Michael Lieu · Michael Malicse · Michael Mcdonald · Michael Mitchelson · Michael Morley · Michael

Sanders · Michael Spahn · Michael Stanton · Michael Turner · Michael VanDerZyden · Michaela

Benkova · Michaela Claridge · Michaela Forgus · Michaela Manu-Adams · Michaela Reyes · Michele

Borrack · Michelle Attard · Michelle Barnard · Michelle Bell · Michelle Berridge · Michelle Blanchard

· Michelle Canning · Michelle Cosslett · Michelle Cowan · Michelle Dew · Michelle Dewent · Michelle

Durrant · Michelle Forgus · Michelle Forman · Michelle Garland · Michelle Greig · Michelle Guthrie ·

Michelle Hetaraka · Michelle Houston · Michelle Howell · Michelle Legaspi · Michelle Lewis · Michelle

Lord-Roper · Michelle Mordaunt · Michelle Paco · Michelle Perkins · Michelle Pickworth · Michelle

Priest · Michelle Reponte · Michelle Robinson · Michelle Shaw · Michelle Sims · Michelle Smith ·

Michelle Sutherland · Michelle Tan · Michelle Tan · Michelle Ung · Michelle Vermeer · Michelle

Wright · Michelle Yang · Michy Mostoles · Mick Boyd · Midas Hill · Mifwany Freeman · Miho Tomoike

· Miita Kourabi · Mika Kato · Mika Nacionales · Mikaela Abraas · Mikaela Cunningham · Mikayla

Watson · Mikayla Miller · Mike Adair · Mike Arsenio · Mike Brophy · Mike Davidson · Mike Gebbie ·

Mike Munslow · Mike Narido · Mike Timajo · Mike Waldman · Mikey Payumo · Mikey Villafuerte · Miki

Nojima-Wylie · Mikie Bausin · Mila Biaukula · Mila Slavinskaya · Milan Rana · Mildred Gaspar · Mile

Grkoski · Milla Ymker-Williamson · Millie Edwards · Millie Fraser · Millie Shanahan · Millie Stratta ·

Milly Bergshoeff · Milly Oldfield · Milu Mathew · Mimi Mendoza · Min Cho · Min Huang · Min Kim · Min

Lee · Min Lee Phang · Min Wang · Mindy Duggan · Mini Poulose · Mint Antapanya · Minty Walia · Minu

George · Miracle Vave · Miranda Barnes · Miranda Bull · Mirasol Beattie · Miruna Karki · Misa

Patterson · Mitali Patel · Mitchell McCutcheon · Mitz Abucejo · Miyoung Kim · Miyuki Ferry · Mlete

Asfaw · Moana Fifita · Moana Martin · Moana Whakaruru · Mohini Nand · Mohini Narayan · Mohini

Olds · Molly Dunbar · Molly Elliott · Molly Steel · Molly Timmins · Momena Begum · Mona Mikhaeil ·

Mona Singh · Mona Zeng · Monette Angadol · Moni Choudhury · Monica Aringoy · Monica Cho ·

Monica Crossan · Monica Manao · Monica Monica · Monica Relucio · Monika Prasad · Monika Rani ·

Monika Yadav · Monima Thapa · Monique Awab · Monique Bahizi · Monique Kelly · Monique Leeson

· Monique Villalobos · Monique Voermanek · Monita Mala · Monty Singh · Monu Pradhan · Moon

Young Kim · Morag Davidson · Moreen Kaur · Morgan Barnes · Morgan Devere Beets · Morgan

Owen · Morgan Wood · Mouli Liyanaarachchi · Mounata Shrestha · Mounika Bathula · Mufida Nisha

· Munah Miller · Munaza Azmie · Murray Bain · Murray Mackessack · Murray Parkes · Murray West ·

187

ANNUAL REPORT 2022

Mykie Scott · Mylen Lingaolingao · Mylene Bugo · Mylene Riotoc · Myra Attwood · Myra Gotz · Myra
Tonks · Myrna Tulloch · Myrtle Brown · Myungju Chung · Nadee Talagala · Nadia Heggland · Nadia

Kuruvila · Nadia Te Awa · Nadia Warburton · Nadine Diack · Nadine Williams · Nafeeza Manga · Nafis

Monazam · Naincy Rastogi · Naini Babu · Naise Palusa · Naj Nahar · Najad Ali · Najete Labbouz ·

Najmoon Noorani · Nalanie Munasinghe · Nalukandathil Anilkumar · Nami Zaman · Namiko Uehara

· Namita Puri · Namita Shyam · Nancy Hayden · Nancy Kumaradhas · Nancy Strapp · Nancy Wilson

· Nandie Maung · Nandika Silva · Nandini Joshi · Nandini Ram · Nani Rokotuisuva · Nanise Bulicakau

· Nao Osato · Naoko Matsuo · Naomi Brady · Naomi Kaba · Naomi Silva · Naomi Tulaga · Naomi Vaea

· Narissa Dayap · Narmadha Dissanayake · Narumon Murray · Nashvin Natke · Nasriin Hagi

Mohamed · Natalei Down · Natalie Curtis · Natalie Finn · Natalie Kearns · Natalie Marya · Natalie

Randall · Nataliya Tretyakova · Natalya Latoa · Natalya Medlock · Natana Gisma · Natasha Carson

· Natasha Henderson · Natasha Rattray · Natasha Sydorenko · Nathalie Palad · Nathan Bremner ·

Nathan McPherson · Nathan Salanoa · Nathan Tahi · Nav Hehar · Nav Kaur · Nav Singh · Nav Singh ·

Navdeep Kaur · Navdeep Kaur · Navdeep Sooch · Naveen Allam · Naveen Pasunooti · Navjeet

Multani · Navjot Brar · Navjot Kaur · Navjot Kaur · Navneet Kaur · Navneet Navneet · Navneet Sidhu

· Navpreet Kaur · Naz McNaught · Neekayla McGimpsey · Neema Benny · Neeru Barot · Neethu

Maxin · Neethu Ramachandran Pillai · Neethu Xavier · Neha Malhotra · Neha Neha · Neha Sharma ·

Nehal Patel · Neil Blunden · Neil Davies · Neil Grinter · Neil Natarajan · Neil Sears · Neil Sunil · Neil

Swift · Neil Villaluz · Neil Watson · Nela Sepuloni · Nell Wineti · Nelson George · Nelson Pajarillage ·

Nemo Arriola · Nena Aglosolos · Nena Balbis · Neneth Alicamen · Neri Macolbacol · Nericha Van

Wyk · Nessa Ojales · Nessy Valoria · Nesum Selliah · Nett Taghoy · Nette Gabriel · Neville Dobson ·

Neville Parkinson · Ngaire Moreton · Niamh McGuigan · Nibin Antony · Nic Knight · Nicci Moeloa ·

Nick Bond · Nick Frische · Nick Hibberd · Nick Male · Nick McGarry-Burford · Nick Pearce · Nick

Wilson · Nicki Brown · Nicki Collingwood · Nicki Hawker · Nicki McLaren · Nicki Wilson · Nickie Tani ·

Nicky Anderson · Nicky Bercich · Nicky Crawford · Nicky Smith · Nicola Bowick · Nicola Fagan ·

Nicola Mitchell · Nicola Steel · Nicola Tarleton · Nicole Carroll · Nicole Chen · Nicole Currie · Nicole

Forster · Nicole Hurford · Nicole Toomey · Nicole Tretyakova · Nicole Yeatman · Nicy Abraham ·

Nidhi Patel · Nidhi Patel · Nidhi Patel · Nigel Bannan · Nigel Geonanga · Nigel Jallorina · Nigel Luff ·

Nigel Megaw · Nigel Orr · Nik Ekdahl · Nik Green · Nika Lafaele · Nikhil Arora · Nikhil Thilakan · Niki

Patel · Niki Rogerson · Niki Veeran · Nikita McIntosh-Zuppicich · Nikita Van Niekerk · Nikitha Madola

· Nikka Bermejo · Nikki Kaur · Nikki Bautista · Nikki Careford · Nikki Edwards · Nikki Flett · Nikki

Francisco · Nikki Hill · Nikki Johns · Nikki Kirner · Nikki Prado · Nikola Karlikova · Nikolai Balanski ·

Nila Boocock · Nila Jayasuriya · Nilda Pagba · Nileshni Devi · Nili Gyawali · Nilma Pettagam · Nilukshi

Perera · Nima Zangmo · Nimalka Rathnayaka · Nimi Jacob · Nimisha Bulsara · Nimisha Maharjan ·

Nimisha Shah · Nimmy Thomas · Nina Bulgakova · Nina Kluge · Nina Melocotones · Nina Reyes ·

Ninja Chahal · Nino De-Jesus · Ninu Augusthy · Nipu Malawalarachchi · Nira Gifkins · Nirali Patel ·

Nirmala Sharma · Niru Chouhan · Niru Wijesundara · Nisah Ismail · Nisha Ghimire Bashel · Nisha

Kaur · Nisha Maharjan · Nisha Mathew · Nisha Mohammed · Nisha Thapa · Nishal Narayan · Nita

Rataro · Nita Yu · Nithara Jose · Nithin Cheriyan · Nitish Thaman · Nittu Mathew · Nizar Virani · Noah

Valois · Nochelle Visitacion · Noel de los Reyes · Noel Giddens · Noeline Plowman · Noeline Watson

· Noema Leota · Noemie Flores · Nonie Alicamen · Nora Arango Bedoya · Nora Esplago · Nora

Tjandrawidjaja · Noreen Zamora · Norly Penalber · Norman Beattie · Nova Santiago · Nu Smith ·

Nuwan Rathanyake · Nye Vyas · Oakley Miller · Oceania Roberts · Odessa Abellana · Odette

Whitter · Ofa Lolohea · Ofa Vaipulu · Oksana Kotlyar · Olga Lorton · Olga Ross · Olive Balli · Oliver

Donaldson · Oliver Konigstorfer · Oliver Lanorio · Olivia Antonievich · Olivia Clover · Olivia Ferrer ·

Olivia Gilmore · Olivia Moorman · Olivia Pulley · Olivia Shin · Olivia Stacy · Olivia Tustin · Olivia Van

de Klundert · Ollie Parvin · Olwyn McGee · Om Prasad · Orada Wisatwongsa · Osien Andaya · Otep

Sacristan · Ovini Hewage · Owen Duncan · Oyahida Tumpa · Paban Karki · Paewai Tume · Paige Cull

· Paige Powell · Paige Tholen · Paki Fihaki · Palack Sharma · Palwinder Kaur · Pam Harliwich · Pam

Haskins · Pam Kaur · Pam Malang · Pam McCreedy · Pam Mino · Pam Mirk · Pamela Ginders ·

Pamela Gonzales · Pami Kariyapperuma · Panchami Thapa Koirala · Pandya Pandya · Pankti Modh

· Paolo Robles · Par Magar · Parampreet Kaur · Paras Kundra · Pardeep Brar · Pardeep Kaur · Parm

Kaur · Parminder Kaur · Parmjeet Kaur · Parmjit Kaur · Parmjit Kaur · Parth Patel · Parvathy Nair ·

Parvati Gandhi · Parveen Brar · Parveena Naicker · Parvinder Kaur · Parvinder Kaur · Parwati

Kriletich · Parwinder Kaur · Pascal Martinez · Pasepa Veilofia · Pat Belcher · Pat Mabunga · Pat

McKee · Pat More · Pat Patterson · Pat Sleeman · Pat Turner · Patch Perry · Patricia Dela Cruz ·

Patricia Hewitt · Patricia Nand · Patrick Fitzgerald · Patrick Ng · Patrick Recio · Patty Khunkaew ·

Paul Blackler · Paul Cameron · Paul Child · Paul Farrar · Paul Francis · Paul Korunic · Paul Lenette ·

Paul Maessen · Paul McGill · Paul McLeod · Paul Minards · Paul O’Carroll · Paul Ponce · Paul Ryan ·

Paul Scrimshaw · Paul Sutcliffe · Paul Sutton · Paul Sutton · Paul Tan · Paul To · Paul Tsang · Paul

Viernes · Paula Fa’aoso · Paula Kennard · Paula Moyles · Paula Tuimasi · Paulette Sheehan · Paulina

Woch · Pauline Liao · Pauline Linton · Pauline Moody · Pauline Murray · Pauline Nickson · Pauline

O’Brien · Pauline Robinson · Pauline Rousseaux · Pauline Waby · Paulini Singh · Pavithra Gunarathna

· Pawan Chand · Pawan Ghimire · Pawandeep Sandhu · Pawani Somarathna · Paz Chan · Paz

Checchecan · Peachy Wee · Pedro del Estal · Peggy Chao · Peggy Tonta · Pele Vaaga · Pelise Muiaa

· Peni Raroa · Penny Forrester · Penny Gallear · Penny Honey · Penny Oakes · Pepa Memea · Pepe

Toe · Percy Abian · Persis Chavan · Pete Allport · Pete Dayo · Peter Alloway · Peter Bellam · Peter

Erian · Peter Gertos · Peter Hollins · Peter Jonson · Peter Macintosh · Peter Shen · Peter Smith ·

Peter Swain · Peter Ware · Peter Whelan · Peti Griffiths · Petra Klingbeil · Petta Danny · Pha Taylor ·

Phil Haynes · Phil Price · Phil Quartly · Phil Yarrall · Philip Jackson-Cox · Philip Mealings · Philip

Spinks · Philippa White · Phill Larner · Phill Page · Phillipa A’Court · Phoebe Laureano · Phoebe Neho

· Phoebe Orola · Phoebe Premacio · Phoebe Tumata · Phoebie Wesche · Phoenix Ryan · Pieta

Valentine · Pieter Kruger · Pilar Merino Neyra · Pinal Parmar · Pine Konelio · Pinkal Patel · Pinki

Thapa · Pinky Ariar · Pip Nolan · Pip Smith · Pip Wayne · Piper Charteris · Pita Bhattarai · Piumi

Gallanga · Polly Hooper · Polly Matheson · Polly Maxwell · Poly Judicpa · Pooja Bist · Pooja Karan ·

Pooja Khaire · Pooja Trehan · Poojan Patel · Poonam Kumari · Poonam B K · Poonam Chauhan ·

Poonam Kumar · Poppy Griffin-King · Portia Chatadza · Prabath Meegoda Gamage · Prabh

Cheema · Prabh Kaur · Prabh Kaur · Prabhjot Sodhi · Pradip Khadka · Pragi Nithyananthan ·

Pragnesh Patel · Prakash Singh · Pramila Putuwar · Praneel Singh · Pranisha Shrestha · Prashant

Khaire · Prasita Prasannan · Pratiksha Wagle · Pratima Ghimire Adhikari · Pratima Singh · Prativa

Singh · Praveen Chirakkunnel · Pravin Singh · Precy Bond · Preema Jose · Preet Kaur · Preet Kaur ·

Preet Kaur · Preet Singh Bedi · Preet Thind · Preethi Meares · Preeti Nair · Preeti Preeti · Preferred

Names Last NamePrema Gavarriah · Premitha Silva · Premlata Shah · Pri Sharma · Pria Escalera ·

Prince Pagtanac · Princess Catostos · Princess Tabay · Priscilla Eru · Priscilla Francis · Priscilla

Mihaere · Pritee Gurung Lama Lopchan · Priti Devi · Priti Tayade · Pritika Devi · Priya Chand · Priya

Chellem · Priya Drummond · Priya Goundar · Priya Gurung · Priya Prakash · Priya Priya · Priya Raj ·

Priya Reddy · Priya Sharma · Priya Sharma · Priya Suresh · Priyanka Tandon · Priyanthi Perera ·

Priyashna Nand · Prox Tiwari · Prudy Macdonald · Puja Malla · Pujan Magar · Punam Kafle · Puneet

Bhardwaj · Pusham Pusham · Pushpa Balodi · Qin Xueqin · Qiong Bi · Quan Tran · Queen Samosa ·

Queenie Cabatingan · Queenie Liu · Queenie Ly · Quentin Howell · Quinn van Vierzen · Rabina Silwal

· Rabyn Reveche · Rach Wates · Rachael Boyd · Rachael Crow · Rachael Hearn · Rachael Mason ·

Rachael Pates · Rachael Seyb · Rachael Shaw · Rachael Tuhi · Rachael Van Aalst · Rachael Walker

· Racheal Trinidad · Rachel Alford · Rachel Andrews · Rachel Bakker · Rachel Borthwick · Rachel

Cadzow · Rachel Clark · Rachel Garrard · Rachel Lalor · Rachel Lim · Rachel Llido · Rachel Pointon

· Rachel Ratcliffe · Rachel Seumanutafa · Rachel Simons · Rachel Wangui · Rachel Williams ·

Rachelle Javier · Rachelle Jones · Rachelle Summerfield · Radhika Lingam · Radhika Reddy ·

Radika Sami · Raewyn Bishop · Raewyn Oppert · Raewyn Redfern · Raewyn Sides · Raewyn Slade ·

Raewyn Taylor · Raewyn Wright · Raf Lachica · Rafelle Tantia · Rafi Arrafi · Raghad Asmaro ·

Raghani Chandra · Rahul Choudhary · Rahul Parel · Rahul Rahul · Rahul Suresh · Raissa Manicad ·

Raissa Morales · Raj Grewal · Raj Kaur · Raj Kaur · Raj Kaur · Raj Kumar · Raj Lata · Raj Radhakrishnan

· Raja Lakshmy Antonrefod · Raja Thirumugam · Rajan Kumar · Rajani Acharya · Rajbeer Kaur ·

Rajbir Kaur · Rajee Srikanthan · Raji Naguleswaran · Rajiv Patel · Rajneel Shankar · Rajni Punia · Raju

Lama · Raju Pudasaini · Rajveer Brar · Rajwinder Kaur · Raken Abiteti · Rakesh Patel · Ralph Molina

· Ralph Wang · Ram Amancio · Ram Martir · Rama Niroula · Raman Gill · Raman Kaur · Raman Kaur

· Raman Kumar · Ramandeep Kaur · Ramandeep Kaur · Ramandeep Kaur · Ramandeep Kaur ·

Ramandeep Kaur · Ramandeep Kour · Ramanpreet Syal · Ramhari Basnet · Rami Kamel · Ramil

Francisco · Ramon Supit · Ramya Bellam · Randeep Kaur Parihar · Randy Wineti · Rane Largo ·

Rangi Hill · Rani Devanand · Ranjana GC · Ranjana Gurung · Ranjit Kaur · Ranshan Nanayakkara ·

Raoul Bravo · Raphael Rausch · Raquel Bibal · Raquel Rapp · Rasanjana Kumarasinghe · Rashmi

Gurung · Rashmika Senevirathne · Rasleen Sidhu · Ravandeep Dhaliwal · Ravanjit Sidhu · Raveena

Sharma · Raveesha Suriyapperuma · Raven Bitancor · Raven McMillan · Ravi Singh · Ravs Kaur ·

Rawinia Renata · Ray Fairbairn · Ray Guiao · Raya Aganon · Raylene Rangi · Raziya Nisha · Razyl

Canlas · Rea Pagkaliwangan · Rebecca Bullock · Rebecca Burgess · Rebecca Croudace · Rebecca

Denmark · Rebecca Fielding · Rebecca Keen · Rebecca Kenny · Rebecca Little · Rebecca Lomax ·

Rebecca Marquis · Rebecca McKinstry · Rebecca McMillan · Rebecca Mushet · Rebecca Sabu ·

Rebecca Schumacher · Rebecca Tuipala · Rebecca Waine · Rechelle Gonzales · Red Mati · Reema

Devi · Reema Kaur · Reema Mathew · Reena Abaya · Reena Chandar · Reena Kumar · Reena Waiba

· Reet Gumber · Reet Mann · Reet Ritu · Reeta Singh · Regina Gounder · Regine Macarubbo ·

Rehana Sharif · Rei Paranihi · Reina Saludares · Reis Lectura · Rejena Galimba · Rejena Lazar ·

Rejina Khadka · Rekha Ramanath · Rekha Rekha · Remya Rajagopal · Remya Sudeep · Rena Allen ·

Rene Knight · Renee Green · Renee Green · Renee Hanmore · Renee Hayes · Renee Julian · Renee

Lowe · Renee Mahe · Renee Perreau · Renee Peters · Renee Ring · Renee Schreuder · Renee

Tauwhare · Renee Young · Renei Thaggard · Renish Raju · Renisha Senchyury · Renuka Gounder ·

Renuka Kant · Reshma John · Reshma Mala · Reshma Mathew · Reshma Vandhana · Reshmi Lata ·

Reshmi Narayan · Reshmi Rao · Rester Delarmente · Revlin Ratishma · Reydun Kihi · Reyn Dilag ·

Reys Gengoyon · Rezina Pradhan · Rhea Mesia · Rhianna Litherland · Rhianne Overell · Rhoi Maza ·

Rhona Licanda · Rhona Miranda · Rhonda Colvin · Rhondda Carter · Rhyarna Batchelor · Rhys

Hodgins · Ria Jamin · Ria Verma · Riana van Niekerk · Riarawa Tematau · Ric Bonacua · Ric Diaz ·

Ricardo Onate · Ricardo Pureza · Richa Ale · Richa Kumar · Richard Chisholm · Richard Crump ·

Richard Dackers · Richard Greathead · Richard Rivera · Richard Sherrell · Richard Stoop · Richard

Umbers · Riche Campaniel · Richell Sabsal · Richelle Villanueva · Rick Davies · Rick Moller · Ricky

Bruining · Ricky Ciobanu · Ricky Wang · Riddhi Chaudhary · Rie Moulton · Riffy Jahan-Khan · Riji

Johny · Riju Rajnashi · Rika Kawakami · Riki Dobbs · Rikita Kunwar · Riley Acutt · Rimmi Kaur · Rina

Maharjan · Rindi Harmse · Rino Selvaraja · Rinu Mathew · Rio Lagahit · Risa Ellis · Rishad Hussain ·

Rishi Mangalat Kokkodan · Rita Antonisamy · Rita Chand · Rita Connolly · Rita Duffy · Ritchell Kho ·

Ritchie Ponce · Riya Darshani Ram · Riya George · Riya Mahna · Rizwana Batool · Rizza Moron · Rob

Carter · Rob Madden · Rob Maier · Rob Miller · Rob Shone · Rob Tanner · Rob Treanor · Robbie

Muller · Robby Mendoza · Robert Cradock · Roberta Baxendale · Robyn Elder · Robyn Kerr · Robyn

McCracken · Robyn McNeil · Robyn Nicholson-Pepe · Robyn Sullivan · Robyn Thompson · Robyn

Tutton · Rochelle Chau-Lacerna · Rochelle Apps · Rochelle Bibal · Rochelle Cohen · Rochelle

Concha · Rochelle Cooper · Rochelle McIntyre · Rocky Atendido · Rod Quan · Rodela Caldea ·

Rodney Lewis · Roger Cabuquin · Roger Nuttall · Rohan Sharma · Rohina Nick · Rohini Devi · Rohini

Gurung · Rohini Lal · Rohini Lata · Rohini Lata · Roj Diola · Roji Maharjan · Roji Timilsina · Roma

Tarranza · Romina Carangalan-Rosales · Romisha Timsina · Romy Wimalaratne · Ron Anand · Ron

Emilio · Ron Ente · Ron Lim · Ronald Babe · Ronald De Jesus · Ronaliza Labang · Ronalyn Alolor ·

Ronalyn Corpuz · Ronan Payinda · Roni Lamsen-Castillano · Roni Mathew · Roni Mathew · Ronita

Devi · Ronita Prakash · Ronita Prasad · Ronna Torregosa · Ronny Liew · Roop Bhullar · Roopa Roopa

· Roopa Shetty · Roopal Patel · Rory Harris · Rory Edwards · Ros Glennie · Ros Hayhoe · Rosa

Dalgleish · Rosa Hye-Won · Rosa Pendijito · Rosa Tipa · Rosanna Beveridge · Rosanne Gee · Rosaria

Manjala · Rose Antioquia · Rose Avery · Rose Baby · Rose Coulson · Rose Jenkins · Rose Kaur · Rose

Lawlor · Rose Noval · Rose Tabasan · Rose Taylor · Rose Tom · Roseanne Crockett · Rosebelle

Presilda · Rosecilla Saulon · Roselee Mudalige · Roseleen Khan · Roseline Sharma · Roselle Camatis

· Roselle Plata · Roselle Rensulat · Rosemary Deane · Roshan Punnose · Roshan Sharma · Roshila

Cherman · Roshini De Silva · Roshmen Ali · Roshni Hicks · Roshni Lata · Roshni Raja · Roshni Reddy

· Rosie Butler · Rosie Malone · Rosie Williams · Rosina Bano · Roslyn Prentice · Ross Bulling · Ross

Howes · Ross Sutherland · Rosy Khokhar · Roula Yianakis · Rowan Moustaid · Rowena Battad ·

Rowena Corpuz · Rowena Daan · Rowena McClutchie · Rowena Newport · Rowena Wood · Rowie

Jabiguero · Roxanne Balidio · Roxanne Gapuzan · Roxanne Mores · Roxanne Rosquita · Roxanne

Shaw · Roy Staite · Rozmin Rasheed · Rubbi Kaur · Ruben Kumar · Rubie Banas · Rubina Jamal ·

Ruby Galviz · Ruby Johny · Ruby Kanwar · Ruby Kaur · Ruby Natt · Ruby Shrestha · Ruchi Thakur ·

Ruel Infante · Ruel Alcaria · Rufaida Khaled · Rufaro Ndoro · Rui Liu · Rukshan Gopallawa · Ruling

Huang · Rupa Sherma · Rupi Kaur · Rupinder Kaur · Rupinder Kaur · Rupinder Kaur · Russell Keast ·

Russell Reazon · Ruth Makin · Ruth Murray · Ruth Waterhouse · Ruthy Rabo · Ruthy Van Heerden ·

Rutvik Patel · Ruwan Colombage · Ry Llanes · Ryan Bensberg · Ryan Evans · Ryan Jarvis · Ryan

Junaid · Ryan Knofflock · Ryan McLaren · Ryan Patron · Ryan Tri Duc · Ryan Verbo · Ryan Winks ·

Rylee Trembeth · Rylee Wagteveld · Rymel Polittude · Saakshi Sunnaina · Saane Toniafa · Sabarine

Asif · Sabby Barara · Sabita Bhattarai · Sabitri Gajurel · Sabrina Cheema · Sabrina De Souza ·

Sachin Parmar · Sade Scott · Sadhana Devi · Sadhana Wati · Sadika Shrestha · Sageera Rawat ·

Saggita Devi · Saifun Nisha · Saijy Lijo · Saj Karki · Sajana Khadka · Sajana Shabin · Sajeeve

Rajasuriya · Sajid SK · Sake Kovuri · Sakul Viliyatharayil · Sala Tagata · Sala Waqanituinayau · Salani

Penisula · Sale Guranjit · Saleem Richards · Salie Alcartado · Sally Crawford · Sally Haslam · Sally

Hayashi · Sally Sampson · Sally Thornton · Sally Uolo · Sally Veng · Sally Waldek · Sallyann

Galodamu · Salochana Naidu · Saloma Faaaoga · Salote Mocevakaca · Salote Tuivakano · Sam

Adhikari · Sam Bagrie · Sam Case · Sam Cassidy · Sam Dove · Sam Gardner · Sam Greaves · Sam

Harvey · Sam Hay · Sam Hibbs · Sam Huang · Sam Huang · Sam Hudson · Sam Kingsbury · Sam

Leahy · Sam Magno · Sam Mahapure · Sam Manson · Sam Nelson · Sam Nicholls · Sam Pewhairangi-

Stok · Sam Powell · Sam Price · Sam Rakai · Sam Rintoul · Sam Rusden · Sam Shirkey · Sam Singh ·

Sam Singh · Sam Thomlinson · Sam Tobias · Sam Twyman · Sam van den Heever · Sam Weston ·

Sam Woolford · Samantha McPherson · Samantha Morris · Sami Gulliver · Sami Maharjan ·

Samikshya Dhakal · Samira Khan · Samista Subedi · Samita Magar · Samjhana Rocka · Sammi

Zhang · Samuel Julian · Sanam Adhikari · Sandeep Johal · Sandeep Kaur · Sandeep Kaur · Sandeep

Kaur · Sandeep Kaur · Sandeep Kaur · Sandeep Kaur · Sandeep Kumar · Sandeep Sidhu · Sandeep

Waraich · Sandi Keen · Sandie Campbell · Sandie Eddy · Sandika Ghimire Gautam · Sandra Batten

· Sandra Berridge · Sandra Champion · Sandra Chapman · Sandra Duckworth · Sandra Hartley ·

Sandra Hendriks · Sandra McGlade · Sandra Officer · Sandra Rogers · Sandra Siakifilo · Sandra

Stacey · Sandy Kaur · Sandy Kaur · Sandy Kaur · Sandy Kurukularatne · Sandy Paterson · Sandy

188

RYMAN HEALTHCARE

Patterson · Sandy Pihema · Sandy Wilde · Sangeeta Lata · Sangya Thapa · Sanita Kumar Bai ·
Sanjay Rivera · Sanjay Ruke · Sanjita Gurung · Sanjita Ratnam · Sanjita Rayamajhi Karki · Sanju

Skaria · Sanjuni Thapa · Sanna McGavin · Sanumol Antony · Sanura Kuruwita · Sany Sany

Kalappurakkal · Sapana Bayambu · Sapana KC · Sapna Mer · Sapna Walia · Sara Bray · Sara Croul ·

Sara Fearnley · Sara Ghale · Sara Hodgson · Sara Kuruvila · Sara Lukic · Sara McCunnie · Sara Rosa

· Sara Vahua · Sarah McCardle · Sarah Andrews · Sarah Arps · Sarah Direen · Sarah Emett · Sarah

Greig · Sarah Guo · Sarah Henderson · Sarah Higgins · Sarah Jamieson · Sarah Keane · Sarah Laiz ·

Sarah Lomax · Sarah Lovelady · Sarah Maxwell · Sarah McKeon · Sarah Meakin · Sarah Motion ·

Sarah Munoz · Sarah Owen · Sarah Reat · Sarah Reid · Sarah Taylor · Sarah Tomas · Sarah Vivian ·

Sarah Walsh · Sarah-Jane Hamblin · Saras Govender · Sarath Kundathil · Saravjeet Kaur · Sarda

Gounder · Sarika Prasad · Sarina Hubber · Sarina Shrestha · Sarit Devi Lal · Sarit Epshteyn · Sarita

Kumar · Sarita Prasad · Saritha Kaithavalappil · Saritha Mathew · Saroj Chauhan · Sarojni Kumar ·

Sarojni Sarojni · Sarpreet Kaur · Sasha Laiz · Sasha Nefiodov · Sashi Hutchins · Sashi Lata · Sashi

Prasad · Sasi Chakrapani · Saskia Hannink · Satbir Kaur · Sathya Shanmugasundaram · Savannah

Agnew · Savannah Kemp · Savannah Lu · Savi Kumar · Savita Kumari · Savita Reddy · Savitri Naidu

· Savitri Naidu · Scott Bremner · Scott Crawford · Scott Duckford · Scott Lewis · Scott Newey · Scott

Perry · Scott Schofield · Scott Thompson · Sean Crosby · Sean De Guzman · Sean Jenkins · Sean

Morgan · Sean Ortuoste · Sechelle Smith · Seekku Silva · Seema Parmar · Seena Sudharman ·

Seena Varghese · Seetha Mwashomah · Seirosa Fakaofo · Sejalben Patani · Selina Philibossian ·

Selly Tumigolung · Senijiale Fuakilau · Seniya Sebastian · Senolita Vea · Sequoia Aitken · Sereana

White · Serena Young · Serene Liutogia · Serene Ng Brown · Sergio Cordeiro Junior · Sha Sun ·

Shabana Jawaid · Shabnam Ali · Shaira Canete · Shairin Begum · Shaleeni Goundan · Shalesni

Kumari · Shalika Wijethilaka · Shalini Shah · Shaly Lazer · Shameena Abdurahiman · Shamini

Priyatharsan · Shamshad Begum · Shamsun Partap · Shanaye Anderson · Shane Fairbairn · Shane

Gumley · Shane Ormshaw · Shane Rawlins · Shane Vargas · Shanelle Pretorius · Shanjita Chand ·

Shanlee Barnes-Webber · Shanna Li’o · Shanno Chand · Shannon McClutchie · Shannon Walsh ·

Shannon Whitmore · Shantam Lone · Shanthi Fernando · Shanthy Gopal · Shanti Prasad ·

Shaqueena Kerr · Sharalyn Pomare · Sharan Brar · Sharandeep Kaur · Sharanjit Kaur · Shareen Devi

· Sharifa Hamidu · Sharil Narayan · Sharl Absin · Sharleen Gounder · Sharleen Warren · Sharlene

Garcia · Sharmila Lal · Sharmila Sharma · Sharni Mitchell · Sharol Sunny · Sharon An · Sharon

Armstrong · Sharon Balsom · Sharon Chapman · Sharon Denniston · Sharon Grogan · Sharon

Hamlyn · Sharon Henderson · Sharon Maich · Sharon Mathew · Sharon McDonald · Sharon Ritchie ·

Sharon Saju · Sharon Tainui · Sharon Wilton · Sharon Wu · Sharron Neale · Sharyn Elliott · Sharyn

Basham · Sharyn Hunt · Sharyn Kennedy · Sharyn Pisani · Sharyn Ward · Sharyn Weightman · Shaun

Steele · Shaveen Fernando · Shay Singh · Shay Spark · Shayal Lata · Shayal Naidu · Shayal Raju ·

Shayal Shiwani · Shayna Begum · Shazneen Bi · She Briones · Shee Hawe · Sheema Bhujel ·

Sheemal Shiwani · Sheena Benitez · Sheena David · Sheena Theobald · Sheena Villa · Sheethal

Joseph · Sheevey Quezon · Sheffy Jose · Sheila Bascara · Sheila Gamboa · Sheila Nelgas · Sheila

Opena · Shekhar Katwal · Shelby Bercich · Shell Child · Shellden Kruyff · Shelley Austin · Shelley

Ferguson · Shelley Harris · Shelly Carroll · Shelly Castillo · Shelly Kaur · Shelly Mani · Shelly

Snodgrass · Shelomy Dollaga · Shemery Sevilleno · Shenal Shivasani · Sheng Puguon · Shequille

Stewart · Sheral Dayal · Sherine Megula · Sherlyn Alquetra · Sheron Kaur · Sheron Perera · Sherree

Wilson · Sherry Cruz · Sherry Janagal · Sherry Verma · Sherryl Sy · Sherwin Li · Shery Mercado ·

Sheryl Aguarilles · Sheryl Cosep · Sheryl Keen · Sheryl Madlangbayan · Sheryl Morris · Sheryl

Soriano · Shey Landiza · Shiela Abiada · Shiela Cabauatan · Shiela Llameg · Shiela Nebalga · Shija

Koirala · Shikha Shikha · Shikha Singh · Shikha Vala · Shikha Verma · Shilpa Mathew · Shinaai

Schroeder · Shiny Varghese · Shirjana Neupane · Shirley Bakulich · Shirley Bucua · Shirley Goodall

· Shirley Jiang · Shirley Krishna · Shirley Lagavakatini · Shirley Pan · Shirline Lubanga · Shivam

Awasthi · Shivangika Ashok · Shivani Gounder · Shivani Patel · Shivani Puri · Shivani Shivani ·

Shiwani Acharya Tiwari · Shobna Kumar · Shom Lata · Shon Frater · Shona Bayliss · Shona Newman

· Shoncey O’Brien · Shraddha Maharjan · Shreta Chand · Shrijana Dahal · Shuba Selvaraj · Shubham

Rana · Shukri Mohamed · Shun Lu · Shunyi Zhang · Shuvayi Mbewe · Shweta Bawlekar · Shweta

Devi · Shweta Nand · Shweta Raheja · Shy Thomas · Shyani Weerawansa · Shyji Sebastian · Shyna

Boock · Shyrene Bechoo · Sia Anand · Sia Palusa · Siam Siam · Sianne Pinto · Sibi Antony · Siby

Mathew · Sidharth Saini · Sieska Verdonk · Siga Parker · Sigas Bose · Sigfred Lagajino · Sigin

Pullemkunnel · Sikva Javaid · Siliva Samuelu · Silvana Marascia · Silvy Thomas · Simeon Brink ·

Simerjit Kaur · Simi John · Simin Alipour · Simoa Ale · Simon Mitchell · Simon Emett · Simon Hooker

· Simon Jantke · Simon Judd · Simon Judge · Simon Lee · Simon Morley-John · Simon Richards ·

Simona Cernic · Simone Blandford · Simone Taylor · Simone Venanzi · Simran Kaur · Simran Kaur ·

Simran Kaur Sra · Simran Singh · Simran Verma · Sina Afamasaga · Sini Gibu Joseph · Sini Jose ·

Sioban Gray · Siobhan O’Connor · Sione Tonga · Sipa Kiko · Sirisuda Charoensak · Sisi Tawake · Sisy

Tamala · Sita Mainali · Siteri Kama · Siteri Nava · Siu Tapaevalu · Skye Davis · Snap Venturanza ·

Snezhana Bubnova · Snower Singh · Sobin Stephen · Sofia Ditta · Sofia Ryan (Faagutu) · Sofia

Sartori · Sofin Mohammed · Sohaib Kabir · Somkhit Lightbourne · Sona Basnet · Sona Varghese ·

Sonam Dhir · Sonia Bonaobra · Sonia Cuasito · Sonia Joseph · Sonia McMartin · Sonia Peter · Sonia

Sharma · Sonia Vincent · Sonika Kissun · Sonika Sharma · Sonika Singh · Soniya Alex · Soniya Magar

· Sonya Brown · Sonya Dunlop · Sonya Overy · Sookie Magallones · Sophia Jarvis · Sophia Kevill ·

Sophia Le Grice · Sophia Niblock · Sophia Schaumkel · Sophia Shan · Sophia Zhang · Sophie

Barnes · Sophie Bates · Sophie Beechey · Sophie Campbell-Patston · Sophie Devi · Sophie Gillham

· Sophie Griffths · Sophie Harvey · Sophie Howell · Sophie Iceton · Sophie Koroniadis · Sosma

Adhikari · Soumia Jose · Soumya Antony · Soumya Charlie · Sova Nairoroi · Sowmya

Balasubramanian · Sree Somasekharan · Sreypov Ing · Srishti Yelagani · Sriyani Sriyani · Stacey

Hancock · Stacey Magee · Stan Bickerton · Starra Wood · Steen Neal · Stef Monje · Steffen Muir ·

Stella Boyte · Stella Wong Mok · Steph Cawte · Steph Croy · Steph Griffin · Steph Villarin · Steph

Young · Stephanie Hore · Stephanie Broadhurst · Stephanie Chen · Stephanie Song · Stephen Best

· Stephen Browning · Stephen Cartwright · Stephen Denvers · Stephen Dickson · Stephen Fitchett

· Stephen Hammond · Stephen Thompson · Stephen Wordsworth · Stephy Jose · Stephy Joy ·

Steve Burns · Steve Clark · Steve Cotter · Steve Hayes · Steve Herries · Steve Jennings · Steve

Kleehammer · Steve Lewthwaite · Steve Porter · Steve Wakeman · Steve West · Steven Maxwell ·

Stevie Gideon-Scurrah · Stevie Johnson-Roberts · Stevie Taiwhati · Stewart Connolly · Stu

Oostdam · Stuart McPherson · Stuart Williams · Su Kyong Kim · Su Rai · Subhnam Khan · Suchada

Jarupongpimarn · Sue Adamson · Sue Banks · Sue Claxton · Sue Duckworth · Sue Fox · Sue Frew ·

Sue Gemmell · Sue Hammond · Sue Horan · Sue Hurcomb · Sue Kaur · Sue Kim · Sue Knight · Sue

Lee · Sue Liang · Sue Massie · Sue Miller · Sue O’Brien · Sue O’Malley · Sue Serau · Sue Stace · Sue

Stalls · Sue Su · Sue Su · Sue Tan · Sue Taylor · Sue Wells · Sue Wickham · Sugith Lonappan · Sujana

John · Sujata Patel · Sujee Shrestha · Suji Subash · Sujitha Pallissery · Sukh Rai · Sukhbir Kaur ·

Sukhleen Kaur · Sukhmani Khatri · Sukhmeet Kaur · Sukriti Jain · Sulfiya Abdulrahiman · Su-Lize

Page · Sultan Salauddin · Suman Lata · Sumi Gurung · Sumi Neupane · Sumitha Raju Pottayil ·

Sumitra Shrestha · Sumnima Poudel · Sun Bhandari · Suna Rijal · Sunil Magar · Sunita Ghimire ·

Sunita Nepali · Sunita Sami · Sunny Choi · Sunny Sandeep · Sunny Singh · Sunny Singh · Sunshine

Ramirez · Supriya Shrestha · Suren Deshar · Suresh Fernando · Susan Cristina · Susan Bacod ·

Susan Baird · Susan Braybrook · Susan Brister · Susan Crarer · Susan Crozier · Susan Hughes ·

Susan Jane · Susan MacLean · Susan Rae · Susan Sainsbury · Susan Somerfield · Susan Spittal ·

Susanne Boehm · Sushila Devi · Sushma Bajracharya · Susi Alefosio · Susie Alayne · Susie

Magalhaes · Susie Thomas · Susinder Rajendran · Susmita Chhetri · Susmita GC · Suzan Dougherty

· Suzanna Allan · Suzanne Austen · Suzanne Cook · Suzanne Elliott · Suzanne Gain · Suzanne Mason

· Suzanne Wells · Suzette Nuyda · Suzette Otacan · Suzleen Lata · Suzy Gibbs · Svetlana Ivanova ·

Swastika Kumar · Swathy Dev · Swati Prakash · Sweta Borkar · Sydney Burchell · Sylvia Consadine

· Syvelle Baricuatro · Tabby Foster · Tae Tekarawa · Tagi Yabakirua · Taha Al-Zaher · Tahmina

Rahman · Taina Tuipulotu · Takumi Obara · Tala Taulupoo · Tala Vea · Talai Ati · Tali Ruatu ·

Talwinder Kaur · Tam Gurung · Tamara Bradford · Tamara Nkhuwa · Tamara Price · Tami Trow ·

Tamsin Eldridge · Tanae Jansen · Tangi Ohuka · Tania Boyd · Tania Carlson · Tania Hapi · Tania

Johnston · Tania Lilley · Tania Lister · Tania Palomino Vargas · Tania Richards · Tania Walker ·

Taniko Rangihau · Tanja Kroch · Tannia Tannia · Tanu Kaur · Tanya Dwimarsita · Tanya Grieve ·

Tanya Lombardi · Tanya Mandeya · Tanya McGurk · Tanya Swart · Tanya Waters · Tara Berkett ·

Tara Budhathoki · Tara Jacobsen - Kedzlie · Tarn Gardner · Tarn Ketpichai · Tarnz Jordan · Tarnz

Morrison · Tarnz Nuku · Tarryn Carson · Tarun Kumar · Taryn Eagle · Taryn Jonasen · Tash

Richardson · Tatenda Jack · Tatto Amran · Tau Faatoto Malaga · Tau Kalepo · Tayla Ball · Tayla Beck

· Tayla Markwick · Tayla Penfold · Taylor Allison · Taylor Lawson-Smith · Taylor Murphy-Peters ·

Tayyaba Latif · Tazia Nisha · Tazmin Houghton · Te Kopa Reedy · Te Manuka · Te Rangi White ·

Teeau Kabiri · Teenu Skaria · Tehanie Azcona · Tehsin Mansuri · Tejal Patel · Tek Namoori · Telma

Tom · Tenia Kapera · Tenille Pickett · Teota Aiwa · Tererei Koura · Teresa Churchill · Teresa

Jurkiewicz · Teresa Mazzola · Teressa Matthews · Terri McKenzie · Terri Taylor · Terry Bacon · Terry

Daniels · Terry Geoghegan · Tesa Leano · Teshi Khatiwoda · Tesma Chittettu Tom · Tess Canoy ·

Tess Danganan · Tess Desai · Tess Mallari · Tessa Burry · Tessa Edwards · Thalia Taurere · Thamara

Fernando · Thanz Lachica · Tharaka Premachandra · Tharuksha Soysa · Thavy Mey · Thea Dickson

· Thea Robiso · Theja Kudahetti · Thejani Sasanthika · Thelma Escobar · Thelma Littlejohn · Theo

van de Klundert · Theodore Hernandez · Theresa Zamora-Coates · Theresa Ada · Theresa

Hattingh · Theresa Hooper · Theresa Maniulit · Theresa Rayner · Theresa Robiso · Theresa Te

Whata · Theresa Tuilata · Theresa Turner · Thesa Dizon · Thomas Picard · Thomas Wanke · Thu

Nguyen · Thushari Withanage · Tiau Itaaka · Tiegan Maru · Tiffa Jumao-As · Tiffanie Chen · Tiffany

Grant · Tim Goodwin · Tim Lewis · Tim Reihana · Tim Saubuli · Tim Vaughan · Tin Liclican-Coloma ·

Tin Novilla · Tin Tagle · Tina Aston · Tina Belsham · Tina Cundy · Tina Fenton · Tina Healy · Tina

Mateo · Tina McNally · Tina Schwenke · Tina Strahl · Tina Thomson · Ting Chen · Tintin Naharoh ·

Tin-Tin Ladisla · Tintu Thomas · Tisa Gopal · Tish Prosser · Tita Diamante · Tittu Thomas · Tiyanie

Arachchige · Toa Sa Utaiaana · Toby Cartwright · Toby Cooke · Todd Clayton · Todd Parker · Tofi

Lefeau · Toji Nihinsa · Toka Toawea · Tom Bright · Tom Brownrigg · Tom Farrell · Tom Goldsmith ·

Tom Karamalis · Tom Mantle- Chadfield · Tom Necklen · Tom Sun · Tom Zaugg · Tomi Bidois ·

Tomirose Dela Cruz · Tong Go · Toni Acciarito · Toni Cochrane · Toni Pasco · Toni Rankin · Toni Ryan

· Toni Snell · Tonia Shakhova · Tony Burke · Tony Cassidy · Tony Clyne · Tony Killip · Tony Santiago ·

Tony Thomas · Tony Villanueva · Tony Weber · Tony Zinsli · Tori Miles · Tory Lennon Hamilton · Toto

Ajawas · Toyomi Furuta · Tracey Burtenshaw · Tracey Campen · Tracey Clapp · Tracey Doody ·

Tracey Dunn · Tracey Herron · Tracey Irvine · Tracey Leuty · Tracey Lord · Tracey McCauley ·

Tracey McCullough · Tracey Moncur · Tracey Vertigan · Tracey Voumard · Tracey Williams · Tracy

Blackadder · Tracy Elliott · Tracy Kemp · Tracy Lui · Tracy Mahoney · Tracy McCartney · Tracy

McLeod · Tracy Munford · Tracy Quill · Tracy Thomson · Tracy Webster · Tracy Wickman · Tram

Lam · Trang Le · Trav Maaka · Travis Cocks · Trent Keen · Tressa Thomas · Trevor Davies · Tricia

Ditablan · Trini Humphrey · Trippee Velasco · Trish Coker · Trish De Jong · Trish Malone · Trish

Murray · Trish Reid · Trish Tallott · Trish W Warren · Trisha Valdrez · Tristan Rodway · Tristan

Youngblood · Troy Le Comte · Troy Mason · Troy Noronha · Troy Pedder · Trudi Martin · Trudi

McNamara · Trudy Royfee · Trudy Shepard · Trudy Stark · Trystan Su · Tsitsi Marimi · Tua Brown ·

Tua’a Simone · Tui Duffull · Tulip Atinae · Ubbie Kooma · Udara Wickramaratne · Ula Taufao · Ulric

Bawayan · Ultric Du Plooy · Ulysses Estrellada · Uma Chinnaiyan · Uma Kumar · Uma Tamang ·

Umang Baldaniya · Una Liavaa · Unnti Madaan · Upekha Fernando · Upul Welgama · Urvashi Joshi ·

Urvashi Puri · Usha Pratheepan · Uwe Braun · Uzma Zaveeri · Vaisakh Bijukumar · Val Abarquez · Val

Calvert · Val Spalding · Vandan Rishi · Vandana Kazal · Vandana Narayan · Vandana Pillay · Vanessa

Camba · Vanessa Capistrano · Vanessa Claridge · Vanessa Hallett-Free · Vanessa Jeng · Vanessa

Jinayon · Vanessa Maher · Vanessa Manihera · Vanessa Manozo · Vanessa Ranger · Vanessa Welch

· Vaneza Narsico · Vannida Kheng · Vara Nailawe · Varice Mangente · Varns Tuapawa · Varun Dayal

· Varun Surendranath · Vasga Naidu · Vash Ella · Vasu Sharma · Veda Kantayapalam · Vee Morris ·

Veena Prabha · Veer Kaur · Veerpal Kaur · Venice Sayson · Venus Conag-Ochea · Vera Butler · Vera

Go · Vera Karauia · Vera Tia · Verna Jacobs Douglas · Verna Mepana · Veronica Basinang · Veronica

Freire · Veronica Tellis · Vick Zhou · Vicki Engu · Vicki Leggett · Vicki McLennan · Vicki Minehan ·

Vicki Mokalei · Vicki Payne · Vicki Taylor · Vicki Webb · Vicky Boswell · Vicky Lilley · Vicky Padillo ·

Vicky Sel-Ayen · Vicky Tunnell · Vicky Veeran · Vicky Weekley · Vicky Zhang · Victor Tan · Victoria

Brevoort · Victoria Dalpatan · Victoria De Luna · Victoria Nand · Victoria Nuzzi · Victoria Oun ·

Viduni Gunarathne · Vidya Ashok · Vidya Wati · Vijay Gounder · Vijay Khadka · Vijay Lachmi · Vijaya

Sathasivam · Vikas Sharma · Vikashni Prasad · Vikki Searle · Vilma Cahis · Vilma Valerio · Vimal

Kaur · Vimesha Ramanayake · Vimla Wati · Vincent Ngawini · Vincy Varkey · Vinil Wilson · Vinita

Nand · Vinita Vishalni · Vinny Naikau · Vintika Vinashni · Vipi Vasu · Vir Villacorta Jr. · Virginia

Makore · Vishal Modi · Vishal Kishor · Vishal Patel · Vishal Vaghela · Vishnu Somasundranpillai ·

Vitash Sharma · Viv Nixon-Mead · Viv Sayson · Vivian Phillips · Vivian Du · Wallace Chen · Walter

Aban · Wan Yaemkul · Wanfei Cao · Wani Lalwani · Wanida Boonyarak · Wara Prakobtiang · Watinee

Srathongboon · Wayne Blazey · Wayne Booth · Wayne Lockhart · Wayne Murray · Wayne Turnbull ·

Weena Aglugub · Weena Evora · Wemerson Barbosa Nunes · Wen Wang · Wendy Arluck · Wendy

Bourke · Wendy Burns · Wendy Chinh · Wendy Gacayan · Wendy Gordon · Wendy Hamilton · Wendy

Harris · Wendy Hern · Wendy Jiang · Wendy Johnstone · Wendy Kaka · Wendy Kappler · Wendy

Kennedy · Wendy Laurie · Wendy MacDonald · Wendy Miller · Wendy Stanton · Wendy Turton ·

Wendy Wei · Wenna Barrido · Wesi Singh · Whela King · Whetu Haua-Bartlett · Whitney Howman ·

Wiian Bundalian · Wil Borres · Wilhelmina Bloem · Will Craine · Will Drennan · Will Locking · William

Geck · William See · Wilna Junio · Wilsy Wilson · Win Win Kyi · Won Hills · Wrizu Shakya · Wyndham

Tapsell · Xavier Loretz · Xylia Arnel · Yamuna De Silva · Yan Luo · Yan Zhang · Yancey Valoria · Yani

Encarnacion · Yanjana Limbu · Yanne Vicente · Yanti Forsyth · Yanti Sriyanti · Yaowapa Somjitsakul

· Yasasmi Basnayake · Yash Maduwanthi · Yashna Prasad · Yashni Gounder · Yasmin Hughes ·

Yasoda Dewan · Yemo Ghale · Yeshi Khatiwoda · Yeshia Govender · Yeshni Rai · Yhan Borja · Yin

Huang · Yin Yin Huang · Ying Chen · Ying Jiao · Ying Lam · Ynys Cadogan · Yok Wongsa · Yolanda

Acebedo · Yolanda Grobler · Yoli Zabala · Yordanka Kirkova · Youmi Lee · YounJung Jeong · Yra

Diez · Yuka Minai · Yuki Kanno · Yuki Maeda · Yukie Nakano · Yulia Lucas · Yunisha Nakarmi · Yvanne

Evangelista · Yvette Liu · Yvette Pearl · Yvonne Bourassa · Yvonne Bresser · Yvonne Carter · Yvonne

Go · Yvonne Jiang · Yvonne Manson · Yvonne Murray · Yvonne Na · Yvonne Robinson · Zahra Salot

· Zai Gonzales · Zakk Haddon · Zamira Ensor · Zara Nichol · Zarah Masote · Zarah Villanueva ·

Zayyan Jahan · Zed Tahirovic · Zee Khan · Zehavit Darlington · Zhiella Venezuela · Zhu Zhu · Zingara

McDougall · Zoe Attrill-Palmer · Zoe Canete · Zoe Hunter · Zoe King · Zoe Noble · Zoe Stephens ·

Zoe Zhang · Zoreen Nisha · Zubaida Khan · Zuzka Erdossyova · Zyra Casul

189

ANNUAL REPORT 2022

Village locations
WHANGĀREI


Jane Mander

AUCKLAND

Tāmaki-makau-rau


Bert Sutcliffe


Bruce McLaren


Edmund Hillary


Evelyn Page


Grace Joel


Karaka


Keith Park


Kohimarama


Logan Campbell


Miriam Corban


Murray Halberg


Possum Bourne


Takapuna


William Sanders

WELLINGTON

2

WAIKANAE

PALMERSTON NORTH

WHANGANUI

NEW PLYMOUTH

HAVELOCK

NORTH

NAPIER

GISBORNE

TAURANGA

HAMILTON

CAMBRIDGE

WHANGĀREI

AUCKLAND

111

2

11

4

1

HAMILTON

Kirikiriroa


Hilda Ross


Linda Jones

CAMBRIDGE

Kemureti


Cambridge

TAURANGA


Bob Owens

GISBORNE

Tūranga-nui-a-Kiwa


Kiri Te Kanawa

NEW PLYMOUTH

Ngāmotu


Jean Sandel

NAPIER

Ahuriri


Princess Alexandra

HAVELOCK NORTH

Karanema


James Wattie

WHANGANUI


Jane Winstone

PALMERSTON NORTH

Te Papaioea


Julia Wallace

WAIKANAE


Charles Fleming

WELLINGTON

Te Whanganui a-Tara


Bob Scott


Karori


Malvina Major


Newtown


Rita Angus


Shona McFarlane

NEW ZEALAND NORTH ISLAND

Aotearoa Te Ika-a-māui

1

1

1

1

1

1

1

1

1

RYMAN HEALTHCARE

190

INVERCARGILL
DUNEDIN

RANGIORA

CHRISTCHURCH

NELSON

2

1

1

7

1

NELSON

Whakatū


Ernest Rutherford

RANGIORA


Charles Upham

CHRISTCHURCH

Ōtautahi


Anthony Wilding


Diana Isaac


Essie Summers


Kevin Hickman


Margaret Stoddart


Ngaio Marsh


Northwood


Park Terrace


Woodcote

RYMAN VILLAGE

UNDER CONSTRUCTION

COUNCIL APPROVAL

PROPOSED VILLAGE

ROLLESTON

Tauwharekākaho


Rolleston

DUNEDIN

Ōtepoti


Frances Hodgkins


Yvette Williams

INVERCARGILL

Waihōpai


Rowena Jackson

NEW ZEALAND SOUTH ISLAND

Aotearoa Te Waipounamu

ROLLESTON

1

11

191

AUSTRALIA VICTORIA
MELBOURNE


Coburg North


Essendon


Highett


John Flynn


Kealba


Mulgrave


Nellie Melba


Raelene Boyle


Ringwood East


Weary Dunlop

BELLARINE PENINSULA


Charles Brownlow


Deborah Cheetham

MORNINGTON PENINSULA


Mt Eliza


Mt Martha

RYMAN VILLAGE

UNDER CONSTRUCTION

COUNCIL APPROVAL

PROPOSED VILLAGE

In the spirit of reconciliation Ryman Healthcare acknowledges the

Traditional Custodians of country throughout Australia and their

connections to land, sea and community. We pay our respect to their

Elders past and present and extend that respect to all Aboriginal and

Torres Strait Islander peoples today.

CHARLES

BROWNLOW

MT MARTHA

RAELENE BOYLE

KEALBA

1

DEBORAH

CHEETHAM

WEARY DUNLOP

NELLIE MELBA

COBURG NORTHJOHN FLYNN

ESSENDON

MULGRAVE

1

1

1

1

11

1

HIGHETT

1

RINGWOOD EAST

1

1

1

1

MT ELIZA

1

RYMAN HEALTHCARE

192

Directory
REGISTERED OFFICE

Airport Business Park

92 Russley Road, Christchurch

PO Box 771, Christchurch 8042

New Zealand

SHARE REGISTRAR

Link Market Services

PO Box 91976, Auckland 1142

New Zealand

P: +64 9 375 5998

E: enquiries@linkmarketservices.co.nz

MELBOURNE OFFICE

Suite 10.03, Level 10

420 St Kilda Road

Melbourne

PO Box 33119

Melbourne VIC 3004

Australia

New Zealand

0800 588 222

rymanhealthcare.co.nz

Australia

1800 922 988

rymanhealthcare.com.au

For more information on any of Ryman Healthcare’s retirement villages:

AUCKLAND OFFICE

93 Ascot Avenue, Remuera

Auckland 1050

New Zealand

WELLINGTON OFFICE

10B Waterloo Quay

Wellington 6011

New Zealand

ANNUAL REPORT 2022

193

rymanhealthcare.co.nz
rymanhealthcare.com.au

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.